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SUMMARY
A series of studies which have utilised the euglycaemic hyperinsulinaemic 
clamp to measure insulin sensitivity is described. The methods for measuring insulin 
sensitivity have been evaluated and conclusions drawn about reproducibility and 
inherent limitations of the technique. The euglycaemic clamp has been used to 
examine the effects of angiotensin II and antihypertensive drugs on insulin sensitivity 
in normal subjects, patients with essential hypertension and patients with impaired 
glucose tolerance or non-insulin dependent diabetes mellitus (NIDDM). Each 
individual study was approved by the local Research and Ethical Committee and 
informed consent was obtained from each subject before participation in a study.
(i) Evaluation of the euglycaemic hyperinsulinaemic clamp technique.
It was recognised that despite widespread use of the euglycaemic clamp in 
clinical research, key aspects of the technique remained to be validated.
(a) The intra- and inter- subject variability in insulin sensitivity and the time 
for insulin mediated glucose disposal to reach steady state were evaluated in 18 
healthy male subjects and 6 patients with essential hypertension who attended two 
study days when a euglycaemic hyperinsulinaemic clamp was performed.
M easurem ents o f insulin  sensitiv ity  derived from the euglycaem ic 
hyperinsulinaemic clamp were expressed as whole body glucose uptake (M), and the 
insulin sensitivity index (SJp). M values at 120 mins were significantly less than at 180 
mins in both the healthy subjects and in the hypertensive patients indicating a 
progressive increase in glucose utilisation over the 180 minutes. The intra subject 
coefficient of variation (c.v.) of M at 120 mins and 180 mins was 8% and 6% for 
healthy subjects and 14% and 5% for patients with essential hypertension respectively. 
The inter subject c.v. of M at 120 mins and 180 mins was 22% and 21% for healthy 
subjects and 43% and 38% for patients with essential hypertension. The intra subject
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c.v. of the insulin stimulus was 10% in both groups. The intra subject c.v. of the SIp 
was 21% for healthy subjects and 16% for patients with essential hypertension.
Thus, it was demonstrated that the clamp is highly reproducible within subjects 
but the inter subject variability is wide. Clamps of 120 min duration underestimate M 
by up to 10% and are not as reproducible in patients with essential hypertension. The 
S[p is poorly reproducible; my data suggest that the M value is a better index for 
comparison of possible changes in insulin sensitivity.
(b) The need to arterialise venous blood with a heated hand box was evaluated 
in 6 healthy subjects. Each subject attended 2 study days when a euglycaemic 
hyperinsulinaemic clamp was performed and "arterialised" (AV; heated hand vein) 
and mixed venous blood (MV; antecubital fossa) were collected simultaneously for 
the measurement of plasma glucose and oxygen saturations
It was demonstrated that AV blood was effectively arterialised achieving 
oxygen saturations of 95±2%, and that plasma glucose concentrations were less 
variable when compared with MV samples.
(c) The haemodynamic and metabolic effects of hand warming were evaluated 
in 6 healthy male subjects who attended 2 study days when a euglycaemic 
hyperinsulinaemic clamp was performed. On the first day AV blood was used to 
adjust the glucose infusion rate required to maintain euglycaemia; on the second study 
day MV blood was used. The results demonstrate that there was a significant trend for 
M values to be higher when arterialised blood was used when compared with mixed 
venous blood. My results suggest that hand warming may induce a blood pressure 
lowering effect that is associated with a confounding increase in the derived 
measurement of insulin sensitivity.
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(ii) Evaluation of the effects of lacidipine on insulin sensitivity.
The acute and chronic (2 weeks) effects of the dihydropyridine calcium 
antagonist, lacidipine (4 mg daily), on insulin mediated metabolic responses was 
evaluated in a double-blind placebo-controlled crossover study in 12 healthy subjects 
and 6 patients with essential hypertension. Each subject attended 4 study days when 
insulin sensitivity was evaluated using the euglycaemic hyperinsulinaemic clamp.
In the healthy subjects, reflex tachycardia was observed after lacidipine 
administration but neither first dose nor 2 weeks of lacidipine treatment altered insulin 
sensitivity when compared with placebo. A significant decrease in fasting triglyceride 
concentrations was observed after 2 weeks lacidipine treatment. 95% confidence 
intervals excluded a 15% change in whole body glucose uptake.
In the hypertensive patients, lacidipine treatment was associated with reflex 
tachycardia and a trend towards decreased blood pressure but there was no significant 
effect on whole body insulin sensitivity.
(iii) Evaluation of manipulation of the renin-angiotensin system on insulin 
mediated metabolic responses
(a) The effects of 4 weeks treatment with the ACE inhibitor trandolapril on 
insulin sensitivity was evaluated in a double-blind, placebo-controlled, crossover study 
in 12 "multiple risk factor" patients with impaired glucose tolerance or NIDDM, and 
essential hypertension. Each subject attended 3 study days (once after a single blind 
placebo run-in, and after each crossover) when insulin sensitivity was evaluated using 
the euglycaemic hyperinsulinaemic clamp. The hypothesis under test was that ACE 
inhibition would increase insulin sensitivity via a vasodilatory mechanism and 
angiotensin II "sparing" effect.
Despite evidence of 70% ACE inhibition and significant blood pressure 
lowering effects of trandolapril, there was no evidence that trandolapril altered insulin
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sensitivity when compared with placebo. Confidence intervals excluded a 12% 
increase in insulin sensitivity associated with ACE inhibition.
(b) To test the hypothesis that acute adm inistration of the potent 
vasoconstrictor angiotensin II would decrease insulin sensitivity, twelve healthy male 
volunteers completed a double-blind, placebo-controlled crossover to evaluate the 
effects of a sub-pressor (lng/kg/min) and a weakly-pressor (5 ng/kg/min) infusion of 
angiotensin II on insulin mediated metabolic responses. Each subject attended three 
study mornings when whole body insulin sensitivity measured using the euglycaemic 
hyperinsulinaemic clamp.
The higher dose of All produced a significant rise in blood pressure and 
plasma angiotensin II concentrations were increased to within the pathophysiological 
range; 11+5,27+9 and 125±28 pg/ml after placebo, low and high dose angiotensin II 
respectively. The corresponding values for insulin sensitivity were 10.5±2.0,10.5±2.2 
and 10.9±3.4 mg/glucose/kg/min (NS; 95% confidence interval -1.9,1.1 for placebo 
vs. pressor angiotensin II). Thus, acute administration of angiotensin II with or 
without a pressor response and producing plasma angiotensin II concentrations within 
the pathophysiological range, has no effect on insulin stimulated glucose disposal in 
healthy subjects.
(c) As there is evidence that the renin-angiotensin system may be involved in 
the metabolic as well as the cardiovascular features of diabetes, the effects of 
angiotensin II on insulin-dependent pathways of metabolism were evaluated in 
patients with NIDDM. In a randomised, double-blind, placebo-controlled, crossover 
study 11 patients with (diet-controlled) NIDDM attended on 3 study days to evaluate 
the effects of a 3-hour infusion of subpressor (lng/kg/min) and pressor (5 ng/kg/min) 
doses of angiotensin II on whole-body insulin sensitivity using the euglycaemic 
hyperinsulinaemic clamp.
Plasma angiotensin II levels were 8 ± 4, 28 ± 9 and 162 ± 45 pg/ml after 
placebo, low dose and high dose infusions of angiotensin II. The l^igher dose of 
angiotensin II was associated with significant increases in blood pressure and plasma
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aldosterone. Whole-body insulin sensitivity was 4.3 ± 2.3 mg glucose/kg/min after 
placebo, and 5.5 ± 2.3 and 4.9 ± 2.4 mg glucose/kg/min following low and high dose 
angiotensin II respectively (p<0.05, ANOVA). Angiotensin II had no effect on 
hyperinsulinaemia-induced reductions in serum potassium and triglycerides.
In summary, contrary to general expectation, acute infusion of angiotensin II, 
with or without an increase in blood pressure, increases insulin sensitivity in 
normotensive patients with NIDDM.
The dissociation of metabolic and blood pressure effects of angiotensin II 
suggests that haemodynamic alterations and redistribution of cardiac output might not 
be the sole (or principal) underlying mechanism in patients with diabetes.
(iv) Determinants of insulin sensitivity
Having validated the euglycaemic hyperinsulinaemic clamp and characterised 
insulin sensitivity in 75 individual hypertensive, diabetic, diabetic hypertensive 
patients or healthy subjects, an attempt was made to identify which demographic, 
metabolic or biochemical factors account for the large inter subject variability in 
insulin sensitivity observed.
Demographic and morphometric data were collected for each subject and a 
standard 75 gram oral glucose tolerance test (OGTT) was performed at screening 
when blood samples were collected for serum insulin and plasma glucose profiles at 
baseline and at 30 minute intervals until 120 minutes. On at least one occasion, each 
individual underwent a euglycaemic hyperinsulinaemic clamp was performed using 
arterialised blood samples to derive the calculation of insulin sensitivity.
The relationship between all variables was investigated at two levels. Firstly, 
for individual variables by correlation analysis, and secondly for multiple variables by 
multiple stepwise linear regression analysis. Thus, insulin sensitivity was the 
dependent variable and the independent variables were modelled separately and in all 
combinations with each other to find the best fit.
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For the group as a whole, age, body mass index, diastolic blood pressure, 
fasting insulin and fasting glucose concentrations were the best correlates of insulin 
sensitivity. In the 30 patients with impaired glucose tolerance or NIDDM, the waist 
hip ratio and body mass index were individually the best predictors of insulin 
sensitivity and insulin and glucose concentrations during an OGTT poor predictors.
CONCLUSIONS
This work has validated the euglycaemic hyperinsulinaemic clamp as a safe, 
reproducible method of evaluating insulin-stimulated metabolic responses, but has 
highlighted some inherent limitations of the technique; for example, the wide 
inter-subject variability in insulin sensitivity and the potential confounding metabolic 
and haemodynamic effects of hand-warming. The technique therefore lends itself to 
studies in which subjects act as their own control. Thus, in a series of double-blind, 
placebo-controlled crossover studies, treatment with the calcium antagonist lacidipine, 
and the ACE inhibitor, trandolapril, have been shown to have neutral effects on insulin 
sensitivity in man. Acute administration of sub-pressor and weakly pressor angiotensin 
II in healthy man had no effect on whole body glucose uptake; in contrast, in a group 
of patients with NIDDM, the same experimental protocol was associated with an 
increase in whole body insulin sensitivity suggesting a dissociation of haemodynamic 
and metabolic effects. In a regression analysis metabolic and haemodynamic data 
have been used to explore the most important determinants of insulin sensitivity in
i
man.
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CHAPTER 1 
GENERAL INTRODUCTION
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1.1 INSULIN RESISTANCE: METABOLIC ABNORMALITIES AND
CARDIOVASCULAR DISEASE
Altered sensitivity to the biological actions of a hormone is a well recognised 
phenomenon in clinical medicine; for instance, resistance of peripheral tissues to 
thyroid hormone or refractoriness of end-organs to gonadotrophins. The pancreatic 
hormone insulin, through its integrated actions on carbohydrate, protein and lipid 
metabolism, plays a pivotal role in maintaining glucose homeostasis. Loss of 
sensitivity to the hormonal effects of insulin, i.e. insulin resistance, affects mainly 
liver, muscle and adipose tissues and stands out because of its uniquely high 
prevalence in a variety of physiological and pathological conditions [table 1.1]. In 
some cases, loss of tissue sensitivity can be viewed as a physiological adaptation to an 
environmental challenge; for example, the insulin resistance that develops after any 
stressful insult (trauma, surgery, infection) clearly serves the function of sparing 
glucose substrate from both oxidation and storage at the expense of fat sources of 
energy. When the stress subsides, the insulin sensitivity returns to normal. In other 
cases, insulin sensitivity subserves a general homeostatic regulation of tissue growth 
and substrate utilisation. For example, the insulin resistance associated with pregnancy 
or puberty may reflect the need for more insulin to sustain accelerated tissue growth 
without the associated danger of hypoglycaemia. These physiological examples of 
insulin resistance can often be explained by increased secretion of hormones with 
insulin antagonist properties (catecholamines, cortisol, growth hormone, sex steroids). 
In many cases, however, the biochemical mechanisms and pathophysiological 
implications of insulin resistance have not been clearly established (Moller and Flier,
1991), and the insulin resistance can not always be explained by an adaptive response. 
Thus, the insulin resistance found in diabetic or hypertensive individuals does not 
appear to serve any protective function. Indeed there is growing consensus that the 
insulin resistance associated with such conditions may be a marker of disease or even
25
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play a pathophysiological role in the development of the disease.
A reduction in insulin-mediated glucose disposal leads to a compensatory 
hypersecretion of insulin; fasting and post-prandial plasma insulin and triglyceride 
concentrations increase, usually with a reduction in high-density-lipoprotein (HDL) 
cholesterol. If the pancreatic response is insufficient or defective, insulin resistance 
may precipitate glucose intolerance. Thus, in non-insulin dependent diabetes mellitus 
(NIDDM), the combination of reduced insulin action and impaired insulin secretion 
gives rise to hyperglycaemia (DeFronzo et al, 1992). By comparison, many obese, 
non-diabetic subjects are more insulin resistant but avoid overt diabetes - at least in 
the short term - by virtue of an adequate 6-cell reserve.
Thus, considerable in terest has recently  focussed on putative 
pathophysiological roles of insulin resistance in the aetiology of various endocrine 
and cardiovascular disorders, including NIDDM (Reaven, 1988a), ovarian 
hyperandrogenism (Barbieri et al, 1988), hypertension (Daly and Landsberg, 1991) 
and in the genesis of atheroma (Stout, 1989). While it is fairly clear that insulin 
resistance is of primary importance in the development of NIDDM (DeFronzo et al,
1992), and some rare hereditary syndromes (Moller & Flier, 1991), the pathogenetic 
significance of insulin resistance (short of diabetes) and individual disorders [table 
1.1] remains in doubt. What seems likely, however, is that insulin resistance 
contributes to some of the clinical, biochemical and metabolic features that often 
complicate these conditions; for example, glucose intolerance in pregnancy and 
hypertriglyceridaemia in obesity and diabetes (Reaven, 1988a).
This chapter explores three areas pertinent to the association of insulin 
resistance and essential hypertension. Firstly, the epidemiological and experimental 
data suggesting a putative role of insulin resistance and consequent hyperinsulinaemia 
in the genesis of hypertensive and atherosclerotic cardiovascular disease is reviewed.
27
Secondly, a description and critique of the presently available techniques for 
measuring insulin sensitivity in vivo will be discussed. To enable the insulin sensitivity 
of individuals or populations to be defined, and to allow the evaluation of any strategy 
which may ameliorate insulin resistance, it is essential that investigators have a very 
precise and reproducible technique to quantify the body’s response to insulin.
Thirdly, the studies evaluating differential drug effects on insulin sensitivity 
and new pharmacological approaches to metabolism will be reviewed. One 
explanation for the association between insulin resistance and essential hypertension is 
that some of the commonly used drugs in hypertensive patients (thiazides and 
beta-blockers) may worsen insulin sensitivity.
1.1.1. A CLINICAL TRIAD: OBESITY, NON-INSULIN DEPENDENT
DIABETES MELLHUS AND ESSENTIAL HYPERTENSION.
Simple clinical observation suggests that NIDDM, obesity and essential 
hypertension often occur together in the same patients. The extent to which they are 
associated has been clarified by several large epidemiological studies; for example, 
analysis of data from the 2930 individuals in the San Antonio Heart Study (Mitchell et 
al, 1990) suggests that, by the fifth decade, 85% of diabetics are hypertensive and 
obese and 80% of obese subjects have abnormal glucose tolerance and are 
hypertensive. Conversely, of the 287 patients (9.8%) who were hypertensive, three 
quarters were obese and half had either impaired glucose tolerance or NIDDM 
(Ferrannini et al, 1990) [figure 1.1]. The Framingham Heart Study confirmed that 
diabetic persons have an increased prevalence of hypertension, with as many as 50% 
having some degree of elevated blood pressure, and that the incidence of both diabetes 
and hypertension increases progressively with the degree of obesity (Kannel and 
McGhee, 1979). A high prevalence of hypertension was also noted in the United 
Kingdom Hypertension and Diabetes Study, with 46% of female patients and 35% of
28
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Figure 1.1. Patients in the San Antonio Heart Study with associated metabolic disorders. 
Of 2930 subjects in this study, 287 hypertensive patients were screened. Definitions are 
as follows: Obese = BMI > 27kg/m2, IGT = impaired glucose tolerance, NIDDM = non 
insulin dependent diabetes mellitus (hatched area), HTG = hypertriglyceridaemia (>2.9 
mmol/L), HCH = hypercholesterolaemia (> 6.48 mmol/L). Modified from Ferrannini et 
al, 1990.
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males being affected (Hypertension in Diabetes Study Group, 1993). Finally, a study 
which screened over one million individuals (Stamler et al, 1978), estimated that 
hypertension was twice as prevalent in young overweight subjects and 50% more 
common in older obese individuals than in normal weight controls. Thus a wealth of 
epidemiological data confirm a striking degree of overlap between essential 
hypertension, obesity and NIDDM. Although the incidence of all three conditions 
increases with age, it has been established that the association between essential 
hypertension and NIDDM is independent of age, obesity and renal function (Teuscher 
et al, 1989; Kannel et al, 1991). When the two conditions coexist, hypertension 
predates the diagnosis of diabetes eight times more commonly than the reverse 
sequence (Lundgren et al, 1988).
Such clinical observations have prompted investigators to explore the 
pathophysiological mechanisms underlying these relationships. A primary abnormality 
in NIDDM is insulin resistance, and this is also a characteristic feature of obesity: over 
the last two decades substantial data has emerged indicating that resistance to the 
glucoregulatory effects of insulin with consequent hyperinsulinaemia are also features 
of essential hypertension. These metabolic abnormalities have therefore resulted in 
new perspectives in the investigation and treatment of hypertension.
1.1.2. INSULIN ACTION, HYPERINSULINAEMIA AND ESSENTIAL
H Y PER TEN SIO N
The two major target tissues in insulin action are muscle and liver. Although 
the insulin-receptor interaction elicits a complex array of biochemical responses, by 
convention "insulin resistance" refers only to the effects of insulin on hepatic glucose 
production and peripheral glucose disposal (both oxidative and non-oxidative). 
Elevated basal free fatty acid levels and failure of insulin to suppress free fatty acid 
production reflect insulin resistance to lipid metabolism (Chen et al, 1987), which is
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often secondary to impaired glucose oxidation. Thus, pathways of glucose, lipid and 
amino acid metabolism are closely inter-linked; resistance to glucose usually implies 
resistance to lipid and amino acid metabolism as well - but other effects of insulin, for 
instance on salt and water balance, may be spared in classic insulin resistant states. For 
example, it is still unclear whether insulin resistance extends to potassium disposal.
The concept of insulin resistance is not new; in 1936, Himsworth proposed that 
patients with diabetes mellitus were either "insulin-sensitive when the cause of the 
disease is deficiency of insulin", o r " insulin insensitive when the cause of the disease 
is not lack of insulin, but the restriction, to a greater or lesser degree, of an unknown 
sensitising factor" (Himsworth, 1936). Thus, loss of tissue sensitivity to the actions of 
insulin leads to a compensatory hyperinsulinaemia which is a characteristic feature of 
both NIDDM and obesity.
Evidence that essential hypertension is associated with metabolic abnormalities 
first emerged in 1966 when Welbom and colleagues reported higher plasma insulin 
concentrations in hypertensive compared with normotensive subjects (Welbom et al, 
1966). This initial evidence, based on only 19 patients, many of whom were on 
treatment, went largely unnoticed, but has more recently been substantiated by data 
from several large scale studies in which oral glucose tolerance tests have been 
performed in patients with essential hypertension. Thus, in a study of over 2000 
individuals, Modan reported higher post-prandial insulin levels in both treated and 
untreated hypertensive patients than normotensive controls (Modan et al, 1985), a 
relationship which was independent of both glucose tolerance and obesity. A similar 
study by Asch in 1437 North Americans reported significantly higher post load insulin 
concentrations in hypertensive individuals, but the significance was lost when 
stratified for glucose intolerance and obesity (Asch et al, 1991). Berglund reported 
elevated fasting insulin concentrations and significantly higher blood glucose 
concentrations 60 minutes after a 100 g oral glucose tolerance test in 106 untreated
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hypertensive patients as compared to 41 controls (Berglund et al, 1976). Parillo 
similarly reported higher serum glucose levels and serum insulin levels 60 to 180 
minutes after a glucose tolerance test in hypertensives as compared to controls (Parillo 
et al, 1988). In a more physiological study, Singer reported that subjects with essential 
hypertension showed a higher insulin response after feeding despite similar changes in 
glucose levels when compared with normal subjects (Singer et al, 1985).
It is important to note, however, that not all hypertensive patients are 
hyperinsulinaemic and that many patients with hyperinsulinaemia and insulin 
resistance do not have hypertension. Ethnic differences may explain these 
discrepancies; for example, the Pima Indians in the United States, in whom insulin 
resistance and hyperinsulinaemia are common, do not have a high prevalence of 
hypertension (Saad et al, 1991). Mbanya reported similar insulin levels in hypertensive 
and normotensive subjects, and although obese subjects were hyperinsulinaemic, there 
was no significant correlation between hypertension and hyperinsulinaemia; in fact 
there was a tendency for a negative correlation between plasma insulin concentrations 
and blood pressure (Mbanya et al, 1988). Moreover, in a recently reported study from 
Mauritius, a positive relationship between insulin and blood pressure was wholly 
accounted for by obesity and age, and showed marked inter-ethnic variation (Dowse et 
al, 1993). Thus, there appear to be racial differences in the association of 
hyperinsulinaemia and blood pressure.
Another explanation for these discrepant results may be problems with 
conventional one-site radioimmunoassays for insulin used in these studies. Insulin is 
normally produced by processing of proinsulin in the fi-cell yielding C-peptide and 
two, 2-amino acid fragments (figure 1.2). Conventional radioimmunoassays for insulin 
lack specificity for the hormone, and different kits show significant but variable 
cross-reactivity with proinsulin and its split products: insulin levels may therefore be 
variably overestimated (Heding, 1977). For example, Temple and colleagues, using 
two-site sensitive and specific immunoradiometric assays for insulin, intact proinsulin
32
Proinsulin
/   ^  \
trypsin-like enzyme
32-33 split proinsulin 65-66 split pro-insulin
\ carboxypeptidase-like enzyme i
i *
Des - 31,32 split proinsulin Des - 64,65 -proinsulin
\  C-peptide /
Insulin
Figure 1.2: The insulin processing cascade. Pro-insulin is split in the beta-cell to yield 
insulin, C-peptide and two amino acid fragments.
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and 32,33 split proinsulin, have shown that newly-diagnosed patients with NIDDM are 
hypoinsulinaemic and hyperproinsulinaemic (Temple et al, 1989; Temple et al, 1990). 
However, Reaven and Polonsky, using a specific proinsulin enzyme-linked 
immunosorbant assay and by subtracting from total immunoreactive insulin levels to 
give an estimate of "true" insulin levels, showed that the overestimation of insulin 
levels was modest in a similar group of patients (Reaven et al, 1993). Preliminary data 
(in abstract form) using a specific insulin assay to m easure fasting insulin 
concentrations in a large Caucasian population suggest that, after adjustment for 
confounding factors (including weight and age), specific insulin levels but not those 
measured by a conventional radioimmunoassay are, indeed, related to blood pressure 
(Grootenhuis et al, 1993).
The variable association of insulin levels and blood pressure, the variable 
overestimation of insulin levels by conventional assays, and the lack of an obvious 
pressor effect of insulin, raise the possibility that proinsulin (and its split products) 
may have independent vascular and haemodynamic effects. Proinsulin has only 1% of 
the activity of insulin in stimulating glucose disposal in humans, but split-products 
have higher biological activities and are thought to bind to insulin receptors. 
Proinsulin has a longer elimination half-life than insulin and is converted to 
split-products, but not insulin, in the circulation (Galloway et al, 1992). Indirect 
evidence implicating proinsulin as an aetiological factor in human vascular disease has 
come from a clinical trial in which proinsulin was compared to insulin in the treatment 
of insulin-dependent diabetes mellitus (Spradlin et al, 1990). The trial was abandoned 
on safety grounds owing to an increase of myocardial infarctions in the proinsulin 
treated group, and as a result, proinsulin now has very limited availability for human 
study. Data on the relationships among proinsulin, insulin and insulin resistance in 
patients with essential hypertension and appropriately matched controls are still 
awaited.
Conflicting evidence from epidemiological studies may also have arisen
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because they have used glucose tolerance test data which give only indirect 
information about insulin sensitivity, as the resultant insulin and glucose values are the 
product of secretion, distribution and elimination, and may be affected by various 
pathophysiological processes [see section 1.2.1]. The euglycaemic hyperinsulinaemic 
clamp technique, the minimal model technique of Bergman, and the insulin 
suppression test [see sections 1.2.2. to 1.2.5.] are more direct methods of assessing 
insulin dependent metabolic pathways. Using these techniques, steady state metabolic 
studies have been performed on hypertensive patients and it is now clear that the 
elevated insulin levels are a compensatory response to a peripheral defect in 
insulin-stimulated glucose uptake (Ferrannini et al, 1987; Pollare et al, 1990) [figure 
1.3], that this defect persists even after blood pressure has been lowered with 
antihypertensive medication (Swislocki et al, 1989), and that the coexistence of either 
obesity or diabetes results in a further impairment in insulin-stimulated glucose 
disposal.
The metabolic abnormalities of essential hypertension are not restricted to 
carbohydrate metabolism. An abnormal lipoprotein profile associated with essential 
hypertension has been identified, namely an increase in triglycerides and a reduction 
in HDL-cholesterol (Shieh et al, 1987; MacMahon et al, 1985). Reaven has coined the 
term "syndrome X" to describe the combination of essential hypertension, 
dyslipidaemia, hyperinsulinaemia and insulin resistance (Reaven, 1988a). There are 
also data suggesting that elevated levels of fibrinogen (Kannel et al, 1987) and 
plasminogen activator inhibitor (PAI-1) (Landkin et al, 1990) are also features of the 
hypertensive state.
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Figure 1.3.: Relationship between tissue sensitivity to insulin (glucose disposal rate as 
measured by glucose clamp technique) and systolic blood pressure in 143 
normal-weight patients with essential hypertension (•) and 54 normotensive control 
patients (□). p < 0.001; r = -0.42. Modified from Pollare et al, 1989.
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1.1.3. HYPERINSULINAEMIA IN ESSENTIAL HYPERTENSION: CAUSE 
OR CONSEQUENCE OF HIGH BLOOD PRESSURE, OR 
EPIPHENOMENON
It remains unclear whether the defect in glucose uptake and hyperinsulinaemia 
described in hypertensives is an epiphenomenon, a consequence of the hypertensive 
process itself, or whether it may precede and thus possibly promote the development 
of hypertension.
(D Insulin sensitivity in primary and secondary hypertension.
M arigliano studied 36 patients with essential hypertension, 12 with 
renovascular hypertension, and 69 normotensive controls. He concluded that the 
essential hypertensives had significantly higher fasting insulin concentrations than 
those patients with renovascular disease or the controls (Marigliano et al, 1990). 
Shamiss evaluated insulin sensitivity in 5 patients with essential hypertension, 5 
patients with renovascular hypertension, 5 patients with primary hyperaldosteronism 
and normotensive controls using the euglycaemic hyperinsulinaemic clamp (Shamiss 
et al, 1992). He concluded that the essential hypertensives had significantly lower 
insulin sensitivity than patients with secondary forms of hypertension. These data 
suggest, therefore, that insulin resistance is only found with essential hypertension and 
not in secondary forms of high blood pressure.
(ii) Longitudinal relationship between insulin resistance and essential hypertension.
The association between insulin resistance and essential hypertension appears 
to be long term, and to predate the development of clinically important high blood 
pressure. For example, further analysis of data from the San Antonio Heart Study 
suggests that changes in glucose tolerance and insulin concentrations coexist with
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subclinical elevations in blood pressure in healthy subjects, eight years before the 
onset of essential hypertension (Haffner et al, 1992). Similarly, Zavaroni and 
colleagues subdivided workers in a factory into those who had relative 
hyperinsulinaemia and those with normal insulin concentrations (Zavaroni et al, 1992). 
The hyperinsulinaemic subjects had higher mean blood pressures without being 
hypertensive and also had increased levels of triglyceride and decreased HDL 
cholesterol concentrations than those with normal insulin levels. More recently, Ferrari 
and colleagues prospectively investigated insulin sensitivity, plasma insulin and 
glucose concentrations in 70 normotensive children of essential hypertensives as 
compared with 78 age and weight matched controls of normotensive families (Ferrari 
et al, 1991a). They concluded that the young normotensives with one hypertensive 
parent were apparently in excellent health, but were hyperinsulinaemic and had 
significantly reduced insulin mediated glucose disposal as compared with controls. In 
a similar study, Beatty and colleagues (1993) matched 15 normotensive subjects who 
had at least one hypertensive parent with 15 controls. Despite having similar blood 
pressures, the insulin mediated glucose disposal of the offspring with hypertensive 
parents as measured by the euglycaemic hyperinsulinaemic clamp was significantly 
lower than controls. The Bogalusa Heart Study has also shown that children 
demonstrate a relationship between blood pressure and metabolic changes at a 
relatively young age (Jiang et al, 1993). Finally in a Finnish study, Salomaa and 
colleagues reported that subjects with impaired glucose tolerance in 1968 had an 
increased risk of becoming hypertensive nearly 20 years later when compared with 
normoglycaemic subjects (Salomaa et al, 1991). Thus, the available clinical evidence 
suggests that a familial trait for essential hypertension would appear to co-exist with 
defects in carbohydrate metabolism, and that the metabolic abnormalities and 
hyperinsulinaemia may precede the development of hypertension. These metabolic 
abnormalities would not appear to be present in secondary forms of hypertension.
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(iii) Animal Evidence.
Insulin resistance and hypertension are associated in some rodent models of 
high blood pressure. Reaven has documented the presence of in-vivo dyslipidaemia 
and hyperinsulinaemia, and reduced in-vitro insulin-mediated glucose uptake by 
adipocytes in two animal models of genetic hypertension; the spontaneously 
hypertensive rat (SHR) (Reaven et al, 1989a), and the Dahl salt-sensitive rat (Reaven 
et al, 1991a). In the SHR the development of insulin resistance precedes the 
development of the hypertension (Reaven & Chang, 1991b). In addition, the normal 
Sprague-Dawley rat, an animal with no genetic predisposition to hypertension, 
develops insulin resistance and hypertension when fed a fructose-enriched diet 
(Hwang et al, 1987). Reaven’s group have also demonstrated in this model that the 
hypertension is attenuated by correcting the insulin resistance by physical training or 
by the administration of somatostatin (Reaven et al, 1989b). In contrast, rats made 
hypertensive by renal artery clipping do not become insulin  resistan t or 
hyperinsulinaemic (Buchanan et al, 1991). In an elegant series of experiments, 
Burstyn studied the in-vivo uptake of a glucose tracer in three animal models of 
hypertension; the SHR, the DOCA-salt animal and the 2-kidney, 1-clip model of 
renovascular hypertension and their controls (Burstyn et al, 1992). He concluded that 
the SHR’s were hyperinsulinaemic and had reduced clearance of the glucose tracer 
compared with controls. In the two non-genetic models of hypertension, however, 
there were no differences between hypertensives and controls.
In another species, insulin resistance has been evaluated in a model of obesity 
hypertension developed by Rocchini. By feeding dogs cooked beef fat, he 
demonstrated that weight gain was directly associated with an increase in blood 
pressure and insulin levels (Rocchini et al, 1989).
In summary, it appears that insulin resistance and hyperinsulinaemia are
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associated principally with essential hypertension in humans and equivalent animal 
models, and that the metabolic abnormalities predate the development of hypertension. 
This raises the possibility that hyperinsulinaemia contributes to the development of 
high blood pressure, and also suggests that an underlying genetic abnormality may 
predispose to both pathophysiological disorders. In this context it is of interest that 
increased red blood cell sodium/lithium counter transport is also associated with 
insulin resistance and other metabolic abnormalities in hypertension, such as 
triglyceride and uric acid levels (Hunt et al, 1991; Mattiasson et al, 1992; Canessa et 
al, 1980). This ion transport activity is a good marker of genetically determined 
essential hypertension, and reinforces the notion that inherited factors may determine 
insulin sensitivity in these subjects. However, other evidence suggests that 
environmental influences in very early development may also play a role. For 
example, Barker and colleagues have shown that low birth weight accurately predicts 
long term development of high blood pressure, coronary heart disease, NIDDM and a 
number of adverse metabolic factors including increased fibrinogen levels and insulin 
resistance in later life (Barker et al, 1993a). It has been proposed that foetal 
under-nutrition might be a common predisposing factor to these abnormalities, and the 
same group have proposed that abnormal pancreatic development might be a possible 
contributory cause to the abnormal insulin response (Barker et al, 1993b).
1.1.4. MECHANISMS AND CONSEQUENCES OF INSULIN RESISTANCE
IN HUMAN DISEASE
Classically the term insulin resistance refers to a reduction in insulin stimulated 
glucose uptake [section 1.1.2]; the im plication of this defin ition is that 
pathophysiological characteristics of insulin resistant states may differ if a selective 
resistance to insulin occurs. The high insulin levels needed to compensate for the 
defect in carbohydrate metabolism may cause increased effects in other pathways. 
Indeed, experimental evidence suggests that the insulin resistance of obesity, aging
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and NIDDM show differential effects on other insulin mediated metabolic processes; 
for example, obesity is also associated with a reduction in glucose oxidation and 
potassium uptake (Bonadonna et al, 1990). In contrast, the insulin resistance of 
essential hypertension appears to be selective for glucose uptake. Using clamp 
studies, Ferrannini has suggested a ’’tissue specific" (predominantly located in skeletal 
muscle), and "pathway-specific" (impairment of insulin-stimulated glycogen 
synthesis, but unaffected lipid, protein and electrolyte metabolism) form of insulin 
resistance (Ferrannini et al, 1987), although these specific observations have not been 
independently confirmed. A number of possible mechanisms which may account for 
the insulin resistance observed in essential hypertension have been proposed.
(i) Altered regional blood flow.
Julius has argued that reduced delivery of glucose to skeletal muscle as a 
consequence of altered regional haemodynamics contributes to the insulin resistance 
of essential hypertension (Julius et al, 1991). Data which report an increase in insulin 
sensitivity after administration of antihypertensive drugs with a predominant 
vasodilatory action may support this hypothesis (Pollare et al, 1989a) [see sections 
1.3.2 and 5.1.1) as may recent studies with angiotensin II (Buchanan et al, 1993; 
Townsend & DiPette 1993) [see chapter 6].
Altered vascular effects of insulin may also contribute to the suggested change 
in regional blood flow, and consequent alteration in delivery of glucose to target 
tissues in essential hypertension. Insulin has been shown to have vasodilator properties 
(at least in pharmacological doses) by some (Creager et al, 1985) but not all (Natali et 
al, 1991) workers. It opposes the direct vasoconstrictor actions of noradrenaline and 
angiotensin II in vitro (Yagi et al, 1988). Findings in humans are, however, 
conflicting: although Sakai and colleagues found that intra-arterial infusion of insulin 
attenuated the decrease in forearm blood flow caused by phenylephrine and
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angiotensin II (Sakai et al, 1993), Naehring reported no effect in studies using a 
similar protocol with noradrenaline (Nearhing et al, 1993), while Lembo and 
colleagues have shown that insulin attenuates the vasoconstriction caused by reflex 
forearm sympathetic activation (Lembo et al, 1993). Insulin-mediated vasodilatation is 
decreased during euglycaemic hyperinsulinaemia in patients with either obesity or 
NIDDM, causing post-prandial blood flow to skeletal muscle to decrease and a 
corresponding reduction in net tissue glucose uptake (Baron et al, 1990; Baron et al, 
1991a). In contrast, skeletal muscle blood flow during hyperinsulinaemia in 
hypertensive subjects has been reported to be no different from that in control subjects 
(Capaldo et al, 1991); however, data are conflicting as another study found that 
attenuation of insulin-stimulated blood flow was correlated with insulin resistance and 
blood pressure in healthy subjects (Baron et al, 1993). Most data which have 
addressed this point have been accrued from normal or obese subjects and further 
studies in patients with essential hypertension are required.
(ii) Altered tissue cellular characteristics.
Differences in glucose transport between skeletal muscle fibre types may be an 
important determinant of in vivo insulin action (James et al, 1986). For example, 
Lillioja and colleagues (1987) found that obesity was associated with capillary 
rarefaction and that capillary density was positively correlated with insulin mediated 
glucose disposal in a population of lean and obese non-diabetic men. In hypertensive 
patients it has also been suggested that there is a quantitative difference in the 
composition of muscle fibres as compared to controls; there are less type I (red) 
oxidative highly vascularised fibres which are more sensitive to the actions of insulin, 
than type lib non-oxidative fibres which are less sensitive (Johlin-Dannfelt et al, 
1979). Therefore both capillary density and insulin sensitivity may be determined by 
fibre composition. In addition, muscle fibre composition could determine insulin
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sensitivity as a function of GLUT 4 transporter expression. This is because, in rats, 
muscles containing greater numbers of type I fibres express more GLUT 4 glucose 
transporters and display a greater capacity for insulin-mediated glucose uptake 
(Richardson et al, 1991; Hardin et al, 1993).
(iii) Cell signalling, glucose uptake and metabolic disposal of substrate.
The defect in glucose uptake in hypertensive animals appears to be unrelated to 
insulin receptor number, binding or tyrosine kinase activity (Reaven et al, 1989a). The 
major mechanism by which insulin activates glucose transport is via a rapid and 
dose-dependent recruitment of glucose transporter proteins from a large intracellular 
pool. In search of a post-receptor defect in insulin action, attention has focussed on 
this family of facilitative glucose transporters in the plasma membrane, particularly 
GLUT-4 which is primarily located in fat and skeletal muscle. For example, in a recent 
comprehensive study which examined the insulin sensitivity in athletes, Ebeling and 
colleagues (1993) concluded that the cellular mechanisms that explained the enhanced 
insulin sensitivity observed were an increase in GLUT-4 content and an increase in 
glycogen synthase activity. There is some evidence, using immuno-blotting and 
measurement of the corresponding mRNA, that reduced levels of GLUT 4 occur in 
skeletal and adipose tissue of patients with NIDDM and/or obesity (Dohm et al, 1991). 
However, in another study using human skeletal muscle biopsies, no difference could 
be found in the plasma membrane content of immunoreactive GLUT 4 between 
patients with NIDDM and normal subjects (Lund et al, 1993). Direct observations of 
glucose transporters or insulin receptors have not been reported in essential 
hypertension.
The studies of Ferrannini suggest that the abnormality in insulin-stimulated 
glucose uptake is restricted to non-oxidative pathways of glucose metabolism, suggest 
a defect in glycogen synthesis (Ferrannini et al, 1987). There is evidence in man that
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alterations in glycogen synthase activity directly account for changes in insulin 
dependent glucose incorporation into glycogen (Bogardus et al, 1987). There are no 
studies which have measured glycogen synthase activity specifically in essential 
hypertension.
The role of glucocorticoids in the genesis of insulin resistance in essential 
hypertension may also be worth considering. Action of hormones at the type II 
corticosteroid receptor has a hyperglycaemic effect which may precipitate diabetes. A 
genetic variation linked with this (glucocorticoid) receptor locus has been reported to 
be associated with the insulin resistance of obesity (Weaver et al, 1992), and it is of 
interest that the same polymorphism, in a different study, was found to be increased in 
frequency in subjects with a high likelihood of developing hypertension (Watt et al, 
1992). More recently, it has been shown that administration of pharmacological doses 
of glucocorticoid to pregnant rats results in development of hypertension in their 
offspring (Benediktsson et al, 1993): this has been ascribed to an imprinting effect of 
the steroid, and preliminary evidence suggests that this rise in blood pressure is 
associated with hyperinsulinaemia. Thus, there is some evidence that altered steroid 
hormone action, either in utero or in adult life, can lead to insulin resistance and 
hypertension.
(iv) Amvlin.
Amylin is a recently described pancreatic peptide which is co-secreted with 
insulin (Cooper et al, 1988). Preliminary evidence suggests that amylin opposes a 
number of the cellular actions of insulin, and it has been suggested that increased 
amylin levels may contribute to the increased insulin resistance seen in subjects with 
NIDDM (Amiel, 1993). However, there is no information on the levels of amylin or 
the effects of this peptide in hypertensive patients or in animal models of hypertension 
and there remains doubt about the exact physiological role of the peptide.
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In summary, the primary mechanisms underlying the reduced insulin 
sensitivity in essential hypertension remain unclear. Although there are a number of 
attractive hypotheses which may account for the abnormality, further careful 
physiological studies in hypertensive patients are required.
1.1.5. CLINICAL IMPLICATIONS OF HYPERINSULINAEMIA AND
INSULIN RESISTANCE IN HYPERTENSION
No satisfactory single hypothesis has been proposed for the mechanism by 
which insulin resistance and the compensatory high plasm insulin levels (or other 
B-cell products) might produce a rise in blood pressure. Any plausible explanation 
needs to take into account the lack of hypertension in patients with insulin/proinsulin 
secreting tumours (Fujita et al, 1992) and also in patients with the polycystic ovarian 
syndrome (Zimmermann et al, 1992): this latter group of patients have profound 
insulin resistance with proportionate increases in insulin and proinsulin levels 
(Conway et al, 1993). A number of plausible biological explanations have been 
proposed by which insulin might produce a rise in blood pressure.
(i) Insulin induced antinatriuresis.
An increase in plasma insulin, within, or slightly above the physiological range 
markedly reduces fractional sodium excretion (DeFronzo 1981; Baum 1987), and 
during euglycaemic hyperinsulinaemia urinary sodium excretion may fall by as much 
as 50% (DeFronzo et al, 1975). The exact mechanisms for this antinatriuresis are 
unknown, but they appear to be related in part to a direct effect on renal tubular 
reabsorption (Gupta et al, 1992). In theory, if hyperinsulinaemia causes a sustained 
antinatriuretic effect, chronic hypertension could result from an expansion of the
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extracellular fluid volume. Preliminary evidence suggests however that insulin’s direct 
antinatriuretic actions are insufficient alone to elevate blood pressure (Hall et al, 
1990). Brands has studied the effects of chronic hyperinsulinaemia on conscious dogs 
using a glucose clamp technique. He reported an antinatriuretic effect most 
pronounced in the acute stage which was due to increased renal tubular sodium 
reabsorption. Despite this transient sodium retention, mean arterial pressure actually 
decreased during the 7 days of insulin infusion (Brands et al, 1991). Furthermore, 
young patients with essential hypertension do not demonstrate an increase in body 
sodium content, nor do they show a reduction in plasma renin concentration which 
m ight be anticipated if there was expansion of ex tracellu lar fluid volume 
(Beretta-Piccoli et al, 1982).
(ii) Activation of the sympathetic nervous system.
The second mechanism by which hyperinsulinaemia may elevate blood 
pressure is via activation of the sympathetic nervous system. Acute insulin infusion 
elevates plasma noradrenaline levels (Rowe et al, 1981), but the interpretation of these 
studies is difficult because pharmacological doses of insulin have been used. Anderson 
recently used physiological insulin concentrations in normal volunteers and reported 
increased sympathetic activity with decreased forearm vascular resistance but no 
increase in blood pressure (Anderson et al, 1991). Furthermore, in normal subjects 
insulin infusion into the forearm opposes the vasoconstriction caused by sympathetic 
activation (Sakai et al, 1993).
(iii) Altered vascular smooth muscle structure and function.
Insulin can be shown in vitro to increase vascular smooth muscle cell growth, 
acting via IGF-1 receptors (Banskota et al, 1989). If this occurs in vivo, long term
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hyperinsulinaemia might promote vascular hypertrophy, which will act as an 
amplification mechanism for the maintenance and development of high blood 
pressure. However, the concentrations of insulin which are required to show this effect 
on vascular cells in vitro are much higher than those found under physiological or 
pathophysiological conditions.
The relationship between insulin action and intracellular cation concentrations 
is also complex. Insulin causes relaxation of pre-constricted cultured vascular smooth 
muscle cells, and this appears to relate to an enhancement of vascular cell recovery 
from intracellular calcium loads (Zemel et al, 1992). However, Resnick has proposed 
that insulin resistance is a primary consequence of altered intracellular calcium/plasma 
membrane calcium handling (Resnick, 1993), and a recent study by Ohno showed that 
in vivo insulin sensitivity was negatively associated with intracellular platelet calcium 
concentrations in subjects with essential hypertension (Ohno et al, 1993).
The vasodilator action of insulin has been discussed above [section 1.1.4], and 
may relate to the effects of insulin on intracellular calcium handling. Limitation of this 
action of insulin (i.e. to reduce intracellular calcium concentrations) in subjects with 
hyperinsulinaemia or insulin resistance, might account for the reported loss of 
insulin-related vasodilatation in this circumstance, and provide an explanation for the 
apparently contradictory finding of Ohno of increased levels of intracellular calcium in 
patients with hyperinsulinaemia.
(iv) Interactions with endothelial dependent relaxation and contraction.
The effects of insulin and proinsulin on endothelial function remain unclear. 
There is evidence that subjects with essential hypertension have reduced vascular 
endothelial dependent relaxation (Panza et al, 1990). While there are reports of 
impaired endothelial function in insulin resistant states including NIDDM (McVeigh 
et al, 1992) and hypercholesterolaemia (Creager et al, 1990), no direct relationship
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with either insulin levels or insulin sensitivity has been shown. Indeed, insulin has 
vasodilator properties in some vascular beds [section 1.1.4] and there is evidence from 
the San Antonio cohort that individuals who went on to become diabetic (and hence 
insulin resistant) had a hyperdynamic circulation (Stern et al, 1992). In patients with 
insulin dependent diabetes mellitus (IDDM) who are without vascular complications, 
endothelial dependent vasorelaxation appears normal (Calver et al, 1992). However, in 
patients with microalbuminuria a defect in endothelial dependent relaxing factor 
(EDRF) activity, which would be consistent with abnormal generation of nitric oxide, 
is reported (Elliott et al, 1993). As other studies show that microalbuminuria is closely 
associated with insulin resistance (Yip et al, 1993), the role of hyperinsulinaemia and 
insulin resistance in this abnormality merit further study.
Insulin is also reported to increase the expression of receptors for endothelin in 
vitro (Oliver et al, 1991), and levels of this vasoconstrictor peptide rise during acute 
hyperinsulinaemia in man (Wolpert et al, 1993). Again, there are no data on the effects 
of hyperinsulinaemia on endothelin-mediated vasoconstriction in human vascular 
tissue.
In summary, there are several p lausible m echanism s by which 
hyperinsulinaemia and insulin resistance may influence blood pressure control; 
however, much of the evidence is circumstantial and direct studies in patients with 
essential hypertension are required.
1.1.6. LONG TERM CONSEQUENCES OF INSULIN RESISTANCE AND
HYPERINSULINAEMIA
The chronic vascular complications of hypertension result from a complex 
interaction among the haemodynamic changes of high blood pressure with a variety of 
other metabolic abnormalities. It has been proposed that hyperinsulinaemia is one of
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the factors associated with hypertension which promotes developm ent of 
atherosclerosis; there are both experimental and clinical data that support the notion 
that insulin  per se is atherogenic, independent o f glucose 
(Stout 1989).
(i) Experimental studies.
The atherosclerotic plaque is characterised by excessive amounts of lipid, 
collagen, foam cell macrophages and proliferated smooth muscle cells. The effects of 
insulin on the constituents and formation of the atheromatous plaque has been 
examined in cell and tissue culture and in animal studies. For example, long term 
treatment with insulin produces lipid-containing lesions and thickening of the arterial 
wall in experimental animals (Stout 1970); insulin inhibits the regression of 
diet-induced experimental atherosclerosis (Marquie 1978); insulin in physiological 
concentrations stimulates proliferation and migration of cultured arterial smooth 
muscle cells (Stout et al, 1975) and also stimulates cholesterol synthesis and LDL 
binding in both arterial smooth muscle cells and monocyte macrophages (Krone et al, 
1988). Thus, under experimental conditions, insulin has been reported to have a 
number of effects on the constituents of atherosclerotic plaques that are consistent with 
our understanding of the progression of atherosclerosis.
(ii) Clinical studies.
As the formal techniques for measuring insulin sensitivity such as the 
euglycaemic hyperinsulinaemic clamp and insulin suppression test are labour intensive 
[section 1.2.1], simple tests, such as fasting serum insulin  and C-peptide 
concentrations or measurements after an oral glucose tolerance test, have been used in 
epidemiological studies to indirectly infer the presence of insulin resistance.
Two large cross-sectional studies have examined the relationships between
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insulin concentrations and cardiovascular disease. Lichtenstein and colleagues (1987) 
in a study of 2512 men aged 45-59 years from Caerphilly reported an association 
between fasting insulin and the prevalence of coronary artery disease independent of 
age, body mass index, blood pressure and serum triglyceride levels. Similarly, in a 
Finnish population, Ronnemaa and colleagues (1991) in a study of 1373 non-diabetic 
men aged 45-64 years reported increased fasting insulin concentrations in those 
subjects with clinical manifestations of coronary artery disease, but this association 
was lost when corrected for body mass index, blood pressure, triglyceride levels and 
HDL cholesterol levels.
There are three large and two small prospective studies which have examined 
the relationship between plasma insulin levels and subsequent coronary artery disease. 
In the Helsinki Policeman study, 982 men aged between 35 and 64 years and free of 
coronary artery disease at baseline received an oral glucose load and were followed up 
for ten years. Both fatal and non-fatal myocardial infarctions were more common in 
those with the highest quintile of fasting, 1 hour, 2 hour and total (AUC) insulin 
responses to glucose. On multivariate analysis this association was independent of 
blood glucose, plasma lipids and body mass index (Pyolara 1979). Similarly, the Paris 
Prospective study of 7038 male civil servants aged 43-54 years examined the 
incidence of fatal and non-fatal myocardial infarctions and has reported at 5 years 
(Ducimetiere et al, 1980), 10 years (Eschwege et al, 1985), and 15 years (Fontbonne et 
al, 1991). At baseline, plasma insulin and glucose concentrations were measured 
fasting and 2 hours after an oral glucose tolerance test. At 5,10 and 15 years there was 
no relationship between the plasma glucose concentrations and incidence of coronary 
artery disease, but the fasting and 2 hour insulin levels were related to the incidence 
of coronary artery disease independent of glucose tolerance and blood pressure, and 
were greater in obese compared with than non-obese subjects. In the Busselton study 
blood samples were collected for insulin levels 60 minutes after a 50 gramme oral 
glucose tolerance test in 3390 Australian male and female adults aged 21 to 70 years.
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The individuals were not instructed to fast. In a univariate analysis, insulin was 
shown to be associated with the 6 year incidence and the 12 year mortality rate from 
coronary vascular disease in men aged 60 to 69 years, but not in women of any age; 
using multiple linear regression analysis, 13 year all-cause mortality rate (but not 
coronary vascular mortality) was significantly and positively related to insulin 
concentrations in those men aged 40 to 70 years at entry (Cullen et al, 1983). In a 
smaller study of 895 Swedish men born in 1913, Welin and colleagues (1992) 
performed oral glucose tolerance tests and collected samples for insulin at baseline, 1 
hour and 2 hours. They demonstrated that the incidence of coronary artery disease was 
related to triglyceride, cholesterol and fasting, 60 and 120 minute plasma glucose 
concentrations, but that the fasting serum insulin concentration was of borderline 
significance: in fact when known diabetic patients were excluded from the study only 
serum cholesterol and triglyceride levels emerged as statistically significant risk 
factors. Lastly, the Edinburgh study of 107 men aged 40 years at baseline examined 
the 12 year incidence of coronary artery disease. In those who developed coronary 
heart disease, the fasting insulin concentration was higher but not significantly so. 
Body mass index and abdominal skin folds were stronger indicators of subsequent 
disease. This is the only large study where HDL cholesterol was measured at baseline: 
regression analysis demonstrated a significant inverse relationship with subsequent 
coronary artery disease (Hargreaves et al, 1992).
These studies have correlated absolute insulin levels to the incidence of 
atherosclerotic complications; there are no data available on the relationship of insulin 
resistance per se, using more direct measures of insulin sensitivity. All of these studies 
(with one exception) only included white middle aged males and the effects of all but 
the highest concentrations of insulin on cardiovascular events were relatively minor. It 
must be borne in mind that hyperinsulinaemia and insulin resistance are associated 
with other potential metabolic risk factors for coronary artery disease including 
fibrinogen, lipoprotein (a) and plasminogen activator inhibitor levels. Many of these
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variables were not measured in the above major epidemiological studies and it is 
possible that insulin is acting as a surrogate marker for other, more potent coronary 
risk factors.
1.2. CLINICAL ASSESSMENTS OF INSULIN SENSITIVITY.
There are various reasons for measuring insulin sensitivity in vivo. Firstly we 
may wish to define the importance of diminished insulin sensitivity as opposed to 
other associated factors such as exhausted beta-cell reserve. Secondly, the 
demonstration of impaired insulin sensitivity in vivo allows the identification of 
conditions in which a specific defect in insulin action should be sought. Lastly, the 
ability to measure insulin sensitivity accurately and reproducibly facilitates the 
evaluation of the efficacy of therapeutic regimens, for example, either drug treatments 
or a change in lifestyle.
The expression of insulin action in any isolated tissue is measured by 
establishing a dose response relationship between the concentration of insulin and 
some index of insulin action. Such data may then be amenable to standard analysis 
such as the application of Michaelis-Mentin kinetics to express insulin action in terms 
of Vmax or Km. Thus the satisfaction of these needs ideally requires a stable, 
quantitative relationship between plasma insulin concentration and some measurable 
insulin-dependent metabolic response. Three techniques, each with a different set of 
limitations, fulfil this requirement, and have found widespread use in clinical research: 
the euglycaemic hyperinsulinaemic clamp, the insulin suppression test, and the 
frequently sampled intravenous glucose tolerance test with model analysis. 
Unfortunately, each of these techniques is relatively labour intensive and not suitable 
for large scale measurement of insulin resistance in epidemiological studies. Thus, 
simple tests such as the measurement of serum insulin or C-peptide levels in the
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fasting state or after an oral glucose load have been used to infer indirectly the 
presence of insulin resistance.
1.2.1. ORAL GLUCOSE TOLERANCE TEST
In the 1930’s, Himsworth introduced the first standard approach to measuring 
insulin sensitivity in vivo (Himsworth, 1936 & 1939). Two oral glucose tolerance tests 
(OGTT) were performed on individual subjects: one with and one without an 
intravenous insulin injection. Insulin sensitivity was expressed as the ratio of the areas 
under the respective glucose tolerance curves, but without direct measurements of 
plasma insulin concentrations Himsworth could only infer differences in tissue insulin 
sensitivity, e.g. between type I (insulin dependent) and type II (non-insulin dependent) 
diabetic patients. Thus, he was unable to exclude differential effects of exogeneous 
insulin on glucose absorption and suppression of endogenous insulin release, or 
differences due to variation in insulin clearance.
Since its initial use by Himsworth, the OGTT has been used by many 
investigators to examine metabolic responses in a variety of disorders. It can provide a 
simple, albeit indirect, estimation of whole-body insulin sensitivity. Inappropriately 
elevated plasma insulin concentrations, e.g. 2 hours after an oral or intravenous 
glucose load, in the face of normal or above-normal plasma glucose concentrations, is 
generally accepted as evidence for decreased overall tissue sensitivity to insulin. 
However, the heterogeneity of OGTT profiles in both normal and diabetic subjects has 
been widely emphasised (Reaven & Miller, 1968), and it is essentially impossible to 
draw conclusions about insulin sensitivity when an intervention (e.g. drug) or disease 
(e.g. NIDDM) under investigation is potentially associated with changes in insulin 
secretion as well as insulin action. For example, changes in peripheral insulin 
sensitivity affect plasma glucose concentrations, which in turn affect glucose-induced 
insulin release, making it impossible to differentiate between pancreatic and
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extra-pancreatic effects. Thus, an OGTT characterises the net effect of several 
glucoregulatory mechanisms but provides only limited information about individual 
pathways and insulin sensitivity; it is nevertheless useful for larger studies, when 
absolute measurements of insulin-mediated glucose uptake are not required, and when 
the study design uses individuals as self-controls.
1.2.2. INTRAVENOUS GLUCOSE TOLERANCE TEST.
A conventional intravenous glucose tolerance test (IVGTT) characterises the 
early and late phases of insulin secretion following bolus injection of a glucose load. 
The net fractional glucose disappearance rate (K value) is easily calculated from the 
profile of plasma glucose concentrations, but differences in K cannot distinguish 
between effects on insulin secretion and insulin action.
Bergman and colleagues have described a modification of the IVGTT - the 
so-called "minimal model" or frequently sampled IVGTT - that provides a quantitative 
index of insulin sensitivity (Yang et al, 1987). An intravenous bolus of glucose is 
followed 20 minutes later by an injection of insulin or tolbutamide 500mg; some 30 
blood samples are then collected over 180 minutes for glucose and insulin 
measurements which are analysed using computer-based model predictions of 
insulin’s effect on glucose kinetics. The crucial piece of software, marketed and 
apparently understood only by the authors, calculates an index of insulin sensitivity 
with few details of how the measurement was derived. Despite the complexity of this 
method, parameters derived from the minimal model correlate well with other 
techniques (Bergman et al, 1987).
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1.2.3. EUGLYCAEMIC HYPERINSULINAEMIC CLAMP AND 
HYPERGLYCAEMIC CLAMP TECHNIQUES.
Andres (1966) was the first to propose that a dose-response measure of insulin 
action in the whole body could be derived by maintaining a stable plasma insulin 
concentration, thus disrupting the glucose-insulin feedback mechanism which 
regulates insulin action and secretion.
Thus, the widely popular, though labour intensive, euglycaem ic 
hyperinsulinaemic clamp was initially described by Andres and he evaluated it further 
in collaboration with DeFronzo (DeFronzo et al, 1979). The technique uses a 
constant intravenous infusion of soluble insulin (e.g. 1.5 mU/kg/min) to increase 
circulating insulin concentrations by about lOOuU/ml. Many rates of insulin infusion 
have been used, and the resultant hyperinsulinaemia also depends on the metabolic 
clearance rate of insulin itself. However, as insulin clearance is rapid, "steady state" 
insulin concentrations are usually attained within 30 minutes in healthy subjects.
Normally the glucose level would decline under these conditions, reflecting the 
action of insulin to increase glucose utilisation by some tissues and to reduce hepatic 
glucose output. However, a substantial decline is prevented by making rapid and 
frequent measurements of the plasma glucose during the procedure and by the 
administration of a variable-rate infusion of 20% glucose to maintain plasma glucose 
at a target value, usually 5-6 mmol/L. Although the increase in plasma insulin 
concentration is within 30 minutes, there is a time lag of 1-2 hours before the maximal 
hypoglycaemic stimulus is observed. Thus, during a typical clamp, the glucose 
infusion rate is increased progressively until a steady state equilibrium is achieved, 
usually at around 120 minutes [figure 1.4]. Calculations of insulin sensitivity are based 
on a 30-40 minute period of steady state infusion when the rate of glucose input 
approxim ates to whole body insulin  sensitivity (M value expressed in mg 
glucose/kg/min). Thus it is necessary to maintain the infusions for at least 3 hours.
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Figure 1.4.: Representative euglycaemic hyperinsulinaemic clamp in a healthy 
volunteer. The exogenous insulin infusion (1.5 mU/kg/min) produces a "steady-state" 
serum insulin concentration approx. lOOuU/ml above the basal fasting value (top panel). 
A dose dependent fall in serum potassium is observed (middle panel). Whole body 
glucose disposal, M, in mg glucose/kg min is calculated during "steady state" at the end 
of the 3 hour clamp. ▼ = plasma glucose concentration (lower panel).
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The glucose infusion rate can be adjusted manually in response to rapid 
measurements of plasma glucose at the bedside, or automatically with a computerised 
glucose-controlled infusion system derived from mathematical formulae [Biostar] 
(Ponchner et al, 1984). Manual corrections are perfectly adequate, but as they can be 
influenced by subjective bias, estimated to be up to 15% (Greenfield et al, 1981), in 
clinical pharmacological studies it is still important that the investigator remains blind 
to drug administration. Rebound hypoglycaemia is a potential complication if glucose 
and insulin infusions are stopped simultaneously. This is easily avoided by continuing 
intravenous glucose for an extra 20 minutes and promptly feeding the subject at the 
end of the infusions. In vivo insulin infusion with maintenance of euglycaemia causes 
a dose-dependent fall in plasma potassium concentrations by promoting potassium 
uptake into the liver and peripheral tissues. However, below a threshold potassium 
level the splanchnic potassium exchange switches from a net uptake to a net release, 
so preventing further hypokalaemia (DeFronzo et al, 1980). Thus, potassium 
replacement in the infusate is usually unnecessary.
The clamp provides an overall measurement of whole-body insulin sensitivity, 
which represents the net balance of peripheral glucose utilisation and endogenous 
hepatic glucose production, but there has to be some concern that measurements 
derived under such artificial conditions might not be a true reflection of physiological 
responses to insulin. In insulin resistant states, especially NIDDM, it is unlikely that 
the insulin stimulus will completely suppress glucose secretion from the liver. 
However, by combining the clamp with a constant infusion of radiolabelled tracer 
([3H] - or [2H] - glucose), it is possible to quantify rates of glucose appearance (Ra) 
and disappearance (Rd) which correspond to hepatic glucose production and peripheral 
glucose utilisation respectively (Finegood et al, 1987). These methods depend upon 
steady-state conditions at the time of blood sampling but some investigators doubt 
whether a true equilibrium is achieved after 3 hours, raising questions about the 
accuracy and reproducibility of these measurements.
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The glucose taken-up by skeletal muscle is processed through oxidative (i.e. 
glycolytic) or non-oxidative (e.g. glycogen synthetic) pathways of metabolism, and by 
combining the euglycaemic clamp with a [3H]-glucose infusion and indirect 
calorimetry (Ferrannini et al, 1989), it is possible to quantify peripheral glucose 
utilisation in terms of oxidative and non-oxidative rates of disposal.
The glucose clamp technique is a measure of insulin sensitivity but provides no 
information on insulin secretion. The hyperglycaemic clamp is a method based on the 
same principle but devised to quantify beta-cell sensitivity; the plasma glucose 
concentration is acutely raised to a plateau (e.g. 14 mmol/L) by a priming infusion of 
glucose, and the resultant biphasic insulin response measured (DeFronzo et al, 1979).
The euglycaemic hyperinsulinaemic clamp is discussed in more detail in 
chapter 2.3 and chapter 3.
1.2.4. INSULIN SUPPRESSION TEST.
The principle of the insulin (or pancreatic) suppression test involves 
pharm acological inhibition of endogenous insulin  secretion, and other 
counter-regulatory hormones (e.g. glucagon and growth hormone), during constant 
infusions of glucose and insulin. Endocrine suppression was originally achieved using 
intravenous infusions of epinephrine and propranolol (Porte, 1967), but lately this has 
been replaced by somatostatin (Harano et al, 1987), or the somatostatin-analogue 
octreotide, which is more widely available and appears to be better tolerated. As with 
the clamp, plasma glucose and insulin concentrations gradually reach a plateau [figure 
1.5]; the steady state plasma glucose concentration (SSPG) is a reflection of whole 
body insulin sensitivity.
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Figure 1.5.: Representative insulin suppression test in a healthy volunteer. After around 
120 minutes infusion of insulin, glucose and somatostatin the steady state plasma 
insulin SSPI, and steady state plasma glucose SSPG are calculated, o = plasma glucose 
(mmol/L), A = serum insulin (uU/ml).
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1.2.5. MODEL DERIVED PARAMETERS OF INSULIN SENSITIVITY
Mathematical models have been derived to describe the complex kinetics of 
glucose and insulin under physiological conditions, to derive parameters for peripheral 
insulin sensitivity and to evaluate 6-cell dysfunction. The technique of HOMA 
(homeostatic model assessment), for example, uses measurements of fasting plasma 
glucose and insulin to derive an index of insulin sensitivity (S) which shows good 
correlation with parameters derived from infusion techniques (Turner et al, 1979; 
Matthews et al, 1985). Since basal (fasting) insulin concentrations are particularly 
subject to assay variability, Hosker and colleagues (1985) attempted to improve on the 
assessment of insulin sensitivity from HOMA by stimulating endogenous insulin 
secretion by a constant infusion of glucose. Thus, CIGMA (continuous infusion of 
glucose with model assessment) defines insulin sensitivity from the steady state levels 
of glucose and (endogenous) insulin after 2 hours. These "structural" model 
predictions have many advantages - not least that measurements reflect physiological 
responses to endogenous insulin, rather than "pharmacological" infusions - but as with 
all models there are some inherent assumptions that may be over simplistic; for 
example, that various tissues in different subjects behave similarly with respect to 
glucose metabolism, and many of the variables used to calculate insulin sensitivity are 
not individualised for each subject.
1.2.6. ARTERIALISED BLOOD SAMPLING.
For both of the principal infusion techniques for assessing insulin sensitivity, 
the euglycaemic hyperinsulinaemic clamp and minimal model, it has been emphasised 
that blood used to measure plasma glucose concentrations should preferably be 
sampled from the arterial side of the circulation. Thus, during hyperinsulinaemic 
stimulation glucose extraction across the capillary bed is high, resulting in a
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significant arterio-venous difference in glucose concentration. As arterial cannulation 
is associated with increased morbidity, cannulation of a dorsal hand vein surrounded 
by a heated box is often preferred. The hand is warmed either by hot air (McGuire et 
al, 1976) or a heated pad (Forster et al, 1972). The theory of this manoeuvre is that the 
hand has relatively little muscle bulk and the local application of heat will create a 
physiological arteriovenous shunt (Roddie et al, 1956), thus minimising glucose 
extraction.
The methods for arterialisation of venous blood are discussed in more detail in 
chapter 2 [section 2.3] and chapter 3.
1.2,7. GLUCOSE CLAMP VERSUS IVGTT VERSUS MINIMAL MODEL:
WHICH IS BETTER?
None of the three methods for evaluating insulin sensitivity can categorically 
be said to be "better" as they were developed for different purposes. The clamp is 
frequently the method of choice when resources are available which allow a controlled 
laboratory environment The procedure is compromised however by being relatively 
time-consuming and labour intensive and therefore studies using the clamp are usually 
restricted to a relatively small number of subjects. Nevertheless, the performance of a 
series of clamp experiments within an individual gives an excellent index of insulin 
sensitivity and allows accurate assessment of both peripheral glucose utilisation and 
hepatic glucose output. The inventors of the minimal model claim it has attributes not 
possessed by the clamp. It allows simultaneous assessment of B-cell secretory function 
and requires less blood sampling and less intervention than the clamp. It therefore 
would be the method of choice in studies requiring assessment of insulin sensitivity in 
a large number of subjects. L ikew ise, the insulin  suppression test is less 
time-consuming than the clamp technique and may be preferable in larger scale 
studies.
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1.3 EFFECTS OF PHARMACOLOGICAL AND NON
PHARMACOLOGICAL INTERVENTIONS ON INSULIN 
SENSITIVITY,
The notion that an im provem ent in insulin  sensitiv ity  may reduce 
cardiovascular risk and perhaps lower blood pressure has focussed attention on the 
effects of both pharmacological and non-pharmacological interventions on insulin 
resistance.
1.3.1. NON-PHARMACOLOGICAL METHODS OF MODIFYING INSULIN
SENSITIVITY
(i) Physical exercise.
It is well established that physical exercise can improve glucose tolerance in 
obese individuals, patients with diabetes and in normal subjects. A relationship 
between physical fitness and insulin-stimulated glucose disposal has been established 
in both cross-sectional and exercise training studies (Rosenthal et al, 1983; Rodnick et 
al, 1987); regular aerobic exercise is antihypertensive and is associated with an 
improvement of insulin sensitivity and progressive lowering of plasma insulin 
responses to a glucose challenge (Bogardus et al, 1984; DeFronzo et al, 1987). The 
relationship of physical training to enhanced insulin sensitivity is independent of 
obesity, as brief training bouts can improve insulin sensitivity in the absence of any 
changes in body weight in patients with NIDDM (Rogers et al, 1988) and essential 
hypertension (Saito et al, 1992). The improvement in insulin sensitivity observed 
appears to be shortlived; for example, trained atheletes who do not exercise for several 
days show a deterioration in insulin sensitivity in the absence of changes in body 
weight (Heath et al, 1983).
Thus, there is ample evidence that regular exercise can improve insulin
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sensitivity in humans. The associated benefits of regular exercise of reduction in blood 
pressure and plasm a trig lyceride  concentrations make it an im portant 
non-pharmacological measure in the reduction of cardiovascular risk.
(ii) Obesity and weight loss.
There is much evidence suggesting a relationship between insulin resistance 
and obesity (Despr6s et al, 1990; Cambien et al, 1987). Several studies in obese 
patients both with and without diabetes have shown that weight reduction, whether 
induced by low-calorie diets (Olefsy et al, 1974; Calle Pascual et al, 1991; Fukagawa 
et al, 1990) or gastric bypass surgery (Hughes et al, 1984; Hale et al, 1988) results in 
improvement in glycaemic control and insulin sensitivity. The mechanisms underlying 
these changes remain poorly defined. What is evident is that the improvement in 
insulin sensitivity observed with weight loss is unrelated to the baseline body weight 
or to the absolute or relative weight loss achieved. For example, Olefsky and 
colleagues (1974) demonstrated that a weight loss of 10kg in moderately obese 
individuals resulted in approximately a 37% increase in insulin sensitivity whether the 
subjects weight decreased from 108kg to 97kg or 86kg to 75kg.
A recent randomised study in 64 obese hypertensive men which compared the 
effects of dietary weight reduction versus antihypertensive drug therapy upon insulin, 
glucose, lipid metabolism and blood pressure reported that dietary therapy was inferior 
in controlling hypertension but superior in lowering plasma insulin concentration and 
improving the serum lipid profile (Faberberg et al, 1992).
Much recent work has focussed on the relationships between regional fat 
distribution, most commonly waist-hip ratio, and insulin resistance. It has been shown 
that a subjects with upper body fat distribution are more insulin resistant than subjects 
with the same body mass index, but with lower body fat distribution (Evans et al, 
1984; Peiris et al, 1988).
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(iii) SmQ^ag.
Cigarette smoking is associated with the lipid abnormalities of increased 
plasma triglyceride concentrations and decreased HDL cholesterol concentrations. A 
recent cross-sectional study which evaluated the insulin sensitivity  of 20 
normotensive, glucose tolerant male smokers as compared to 20 age and weight 
m atched non-sm oking controls suggested that the smokers were both 
hyperinsulinaemic and insulin resistant (Facchini et al, 1992). Further studies are 
required to define the relationship between both acute and chronic effects of cigarette 
smoking on in vivo insulin action
1.3.2 PHARMACOLOGICAL METHODS OF MODIFYING INSULIN
SENSITIVITY
Numerous drugs affect glucose tolerance (Pandit et al, 1993), usually via 
changes in insulin secretion, while some exert peripheral effects on insulin target 
tissues. In general, the nature and magnitude of drug effects on insulin-dependent 
metabolic pathways have been poorly characterised and sometimes misrepresented. 
Non-pharmacological measures that improve insulin sensitivity, e.g. weight loss and 
physical exercise [chapter 1.3.1] are effective in lowering glucose and triglyceride 
levels but few drugs, other than the biguanides, enhance insulin signalling. Much 
recent research has focussed on the metabolic effects of drugs used to treat 
hypertension. This section will review the studies evaluating the effects of 
antihypertensive drugs on glycaemic control. The effects of the currently available oral 
hypoglycaemic agents and novel insulin sensitising drugs which are undergoing 
clinical development will also be discussed.
The notion that insulin resistance and hyperinsulinaemia might increase the 
risk of atherosclerosis has focussed attention on the differential effects that
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antihypertensive drugs may exert on glucose homeostasis and insulin resistance.
These studies have largely been prompted by the hypothesis that the use of the 
more traditional antihypertensive agents may explain the "paradox" that treatment of 
mild hypertension fails to reverse the excess risk of coronary heart disease (Pollare et 
al, 1989b; Poulter et al, 1990). For example, a recent meta-analysis suggests that the 
mean reduction in diastolic blood pressure of 5-6mm Hg in the large hypertension 
trials results in virtually all the epidemiologically predicted stroke reduction (42%), 
but that coronary heart disease was reduced by only half (14%) of that expected 
(Collins et al, 1990). Data from these trials, however, suggest that clinically important 
glucose intolerance occurred in only 2.5% of patients taking thiazides and 1% of those 
taking propranolol or placebo over the 5 year period (MRC Trial, 1985). Other 
authors have therefore seriously questioned the clinical importance of "iatrogenic" 
worsening of insulin resistance (Yudkin 1991).
Many of the studies in the literature are unfortunately compromised by poor 
trial design, lack of full placebo data, various indirect measurements of insulin 
sensitivity and heterogeneous patient groups in whom the biochemical mechanisms of 
insulin resistance may not be the same.
(i) Thiazide diuretics.
Diuretic therapy is of proven efficacy in the control of hypertension and has 
been part of the therapeutic regimen used in most of the major blood pressure 
intervention trials. It has long been recognised that diuretic therapy for the treatment of 
hypertension may be associated with impaired glucose tolerance. This complication 
was highlighted in a study published in 1982 which performed serial oral glucose 
tolerance tests over a 14 year period in diuretic treated hypertensive patients (Murphy 
et al, 1982). They demonstrated substantial deterioration in glucose tolerance but the 
results are difficult to interpret in the absence of a control group. Diuretic therapy has 
recently undergone considerable scrutiny and data from numerous controlled trials are
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now available which have established a relationship between diuretic treatment and 
impaired glucose tolerance. For example, in the single blind MRC trial in mild 
hypertension (1985), bendrofluazide (lOmg daily) was compared with placebo and 
oral glucose tolerance tests were performed if the random plasma glucose was greater 
than 8.3 mmol/L or the fasting value was greater than 6.0 mmol/L. Over the 3 years, 
the incidence of impaired glucose tolerance (per 1000 treated patient years) was 9.4 
for bendrofluazide vs. 2.5 for placebo in men, and 6.0 vs. 0.8 in women. Similar 
results have been reported in large scale double blind studies. For example, in the 
Systolic Hypertension in the Elderly Programme (SHEP) trial (1988) blood sugar was 
significantly higher after 12 months of treatment with chlorthalidone. In the European 
Working Party on High Blood Pressure in the Elderly (EWPHE) trial (Amery et al, 
1989), fasting blood sugar was increased by diuretic therapy after 12 months and 
remained significantly elevated (by approximately 6%) after 3 years. Therefore, there 
is good evidence that long term diuretic treatment is associated with increased 
incidence of impaired glucose tolerance in hypertensive patients.
Peripheral insulin resistance has been implicated as one possible mechanism of 
thiazide induced glucose intolerance but in contrast to the wealth of evidence that 
impaired glucose tolerance occurs with diuretic treatment, there is a surprising lack of 
clinical trials examining the effects of thiazides on insulin sensitivity. In Pollare’s 
study comparing captopril to hydrochlorthiazide at an average dose of 40mg/day for 
14 weeks, it was reported that the diuretic significantly impaired insulin sensitivity, 
but this study was not placebo-controlled (Pollare et al, 1989a). Swislocki also 
reported impaired peripheral insulin sensitivity with thiazides in an uncontrolled study 
(Swislocki et al, 1989). However, a recent crossover study using the euglycaemic 
hyperinsulinaemic clamp showed no effect of bendrofluazide 1.25mg or 5mg on 
insulin sensitivity after 12 weeks (Harper et al, 1993).
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(ii) Angiotensin converting enzvme inhibitors.
Incidental observations appeared in the m id -^ S O ’s suggesting an 
improvement in glucose tolerance after treatment with an ACE inhibitor. Anecdotal 
reports from diabetic clinics also described a reduction in insulin requirements or 
discontinuation of oral hypoglycaemic therapy after the introduction of either captopril 
or enalapril (Ferriere et al, 1985; McMurray & Fraser, 1986); even hypoglycaemic 
episodes were attributed to ACE inhibition (Rett et al, 1988). When given acutely to 
hypertensive patients with NIDDM (Torlone et al, 1991), or normotensive individuals 
(Jauch et al, 1987), captopril has been reported to increase insulin-mediated glucose 
disposal. Jauch proposed that the increase in insulin sensitivity is secondary to 
increased glucose uptake into skeletal muscle; the amount of glucose taken up 30 
minutes after a single oral dose of captopril was 2.22uM/100g/min compared with 
0.83 uM/lOOg/min after placebo. In a similar study but in patients with insulin 
dependent diabetes mellitus, Helve and colleagues (1993) reported no acute effect of 
captopril on insulin sensitivity using the euglycaemic hyperinsulinaemic clamp.
The most widely quoted study of ACE inhibitors and insulin sensitivity is by 
Pollare and colleagues (Pollare et al, 1989a). This study was performed in 50 
non-diabetic hypertensive subjects to compare captopril and hydrochlorothiazide, each 
administered for 16 weeks, in a randomised, cross-over design. Despite a 4-week 
washout phase, carry-over effects hampered the intended analysis, so results were 
presented for two parallel groups during the first treatment phase only. There was no 
difference in fasting plasma glucose and insulin levels, or glycosylated haemoglobin, 
but insulin stimulated glucose disposal increased marginally from 5.7 to 6.3 mg 
glucose kg/min after captopril, compared with a change from 6.4 to 5.7 mg 
glucose/kg/min with the diuretic. In a similar study with enalapril (Prince et al, 1988), 
haemoglobin Alc decreased after 4 weeks of the ACE inhibitor but there was no 
change in the glucose disposal rate. Likewise, a placebo-controlled open trial which
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evaluated the effects of 3 months therapy of the ACE inhibitor cilazapril on glucose 
tolerance and insulin sensitivity in 20 patients with essential hypertension reported no 
effect of chronic ACE inhibition on insulin sensitivity, substrate oxidation or 
thermogenesis (Santoro et al, 1992).
Thus, there are conflicting data which demonstrate striking inconsistencies 
concerning the effects of ACE inhibitors on insulin sensitivity. For example, of 34 
studies in which some parameter of glycaemic control was assessed in patients with 
NIDDM and hypertension receiving an ACE inhibitor, improvements were noted in 
only 13: 3 out of 9 studies with enalapril and 8 out of 24 with captopril (Stein & 
Black, 1991). However, few, if any, studies of the metabolic effects of ACE 
inhibitors have been properly controlled, and there are no direct comparisons with 
placebo.
(iii) Calcium channel blockers
Many investigators have reported the effects of calcium antagonists on 
glucose homeostasis, but often these studies are not comparable because of different 
design and heterogeneous patient groups. Furthermore, the calcium antagonists are a 
heterogeneous group of compounds (i.e. dihydropyridines, benzothiazepines, 
phenylalkalamines) which may exert differential effects on the peripheral vasculature 
and cardiac conduction system. Acute treatment may influence glucoregulatory control 
d ifferently  from chronic treatm ent; this is especially  im portant for the 
dihydropyridines which are characterised by sympathetic augmentation on acute 
dosing.
In two placebo-controlled acute experiments, neither single therapeutic doses 
of oral nifedipine (Joffe et al, 1983) nor a bolus of intravenous verapamil (Rodjmark et 
al, 1980) affected the fasting glucose concentrations or plasma insulin levels in healthy 
normotensive subjects. These findings have been confirmed in other studies. In 
contrast, several studies examining the "short-term" effects of different calcium
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antagonists on glucose tolerance, as assessed by either an oral or intravenous glucose 
challenge, have yielded conflicting results. For example, a detrimental effect of 
verapamil was reported in a small placebo-controlled study of 7 healthy subjects when 
5g of intravenous glucose was administered with an infusion of verapamil [9.6mg/hr] 
(Giugliano et al, 1981). The disappearance rate of glucose and the insulin output were 
both diminished. However, when 20g of glucose was administered under similar 
experimental conditions by the same group, glucose and insulin levels remained 
unchanged. Likewise, the areas under the curve of glucose and insulin were similar 
after a lOOg OGTT with or without concomitant infusion of verapamil [5mg/hr over 2 
hours] (Andersson & Rodjmark, 1981). In contrast, an almost identical protocol led to 
a significant increase in blood glucose and a decrease in plasma insulin between 30 
and 120 minutes after the verapamil infusion was started (De Marinis & Barbarino, 
1980).
Such conflicting results are not unique to verapam il; studies with 
dihydropyridines have caused similar confusion. Two placebo-controlled studies 
reported no change in the profiles of blood glucose and insulin profiles when lOmg 
(Donnelly & Harrower, 1980), and 20mg (Pasanisi et al, 1986) of nifedipine were 
given after a 50g OGTT and IVGTT in healthy volunteers and patients with essential 
hypertension, respectively. However, in another study, when repeated doses of 
nifedipine were given after a lOOg OGTT (20mg of nifedipine in total) the AUC 
glucose profile was significantly increased but the AUC insulin profile remained 
unchanged (Ferlito et al, 1980).
Several studies have examined the effects of long term administration of 
calcium antagonists on glucose homeostasis. Patients with angina pectoris or essential 
hypertension undergoing long term treatment with calcium antagonists (6 weeks to 62 
weeks) have been studied. Trials of 5 different calcium antagonists, nifedipine 
(Landmark, 1985), verapamil (Lang et al, 1981), diltiazem (Pool et al, 1985) and 
nitrendipine (Ferrara et al, 1985) have concluded that there is no adverse effect on
blood glucose, plasma insulin and C-peptide concentrations. Again, there are 
conflicting data; Oehman and colleagues (1985) studied 25 hypertensive patients in a 
placebo-controlled crossover study of nifedipine over a 6 week period. They 
concluded that blood glucose and insulin levels were both significantly elevated, but 
conversely, the glycosylated haemoglobin concentration was significantly lower after 
6 weeks of treatment. Another study with diltiazem and metoprolol in 52 non-diabetic 
hypertensive patients (Hedner et al, 1990), concluded that diltiazem had a significant 
detrimental effect, but the endpoint was fasting blood sugar concentration and the 
resultant values were still within the normal range.
Few studies of calcium antagonists have used direct measurements of insulin 
sensitivity. In two studies using the euglycaemic hyperinsulinaemic clamp, neither 
diltiazem (Pollare et al, 1989b) nor verapamil (Berne et al, 1991) had any effect on 
insulin sensitivity.
In single dose or short term experiments of patients with NIDDM, conflicting 
results have also been reported. Most studies, with or without a glucose challenge, 
report a neutral effect; for example, when lOmg of nifedipine was administered to 8 
elderly diabetics, no effect on fasting blood sugar and plasma insulin levels was found 
(Donnelly & Harrower, 1980). A similar neutral effect has been reported by other 
groups for nifedipine (Collins et al, 1986), verapamil (Ferlito et al, 1982) and 
diltiazem (Wada et al, 1982). In contrast, a beneficial effect of an intravenous infusion 
of verapamil on the AUC of glucose following an OGTT has been reported in two 
placebo-controlled studies (Andersson & Rodjmark, 1981; Rodjmark et al, 1981). The 
plasma insulin concentrations remained unchanged however. Other studies have 
reported significantly increased blood glucose concentrations and reduced plasma 
insulin concentrations for nifedipine, (Deedwania et al, 1984; Sando et al, 1983), but 
the doses studied were high. A poorly controlled single blind study of felodipine 
(Kjellstrom et al, 1991) reported a significant increase in the glucose AUC following 
an OGTT.
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Long term studies have generally only studied small numbers of patients. 
Despite anecdotal reports that a deterioration in glucose tolerance may occur in 
individual cases when a calcium antagonist is prescribed (Bhatnagar et al, 1984; 
Iversen et al, 1990), the majority of controlled studies, for example, with nifedipine 
(Winocour et al, 1986), verapamil (Whitcroft et al, 1986) and nitrendipine (Trost et al, 
1987) have detected no deterioration in fasting blood sugar levels, fasting insulin 
levels or glycosylated haemoglobin concentration. Similar results have been reported 
following an oral glucose challenge with diltiazem (Wada et al, 1982) and nitrendipine 
(Odigwe et al, 1986). A recent double-blind placebo-controlled crossover study, using 
the euglycaemic clamp, evaluating the effects of long term isradipine administration 
on peripheral insulin sensitivity also reported a neutral effect (Klauser et al, 1991).
In summary, currently available data suggest that calcium antagonists do not 
alter glucose homeostasis when given acutely in therapeutic doses, although some 
short term studies in non-diabetic hypertensive patients have reported increased fasting 
blood sugar levels and reduced insulin sensitivity with the dihydropyridines. 
Interpretation of many of these studies is difficult because of uncontrolled study 
designs.
(iv) Beta-adrenoceptor blockers.
The suggestion that B-adrenergic blocking agents may increase the risk of 
developing diabetes mellitus in patients with essential hypertension first emerged from 
longitudinal studies which compared treated hypertensive patients with a healthy 
normotensive control group and attributed the higher incidence of diabetes in the 
hypertensive patients to their therapy (Bengston et al, 1984; Skarfors et al, 1989). 
Such longitudinal, poorly controlled reports should be viewed with caution; for 
example, in a large cross-sectional study Halkin and colleagues (1989) reported no
71
difference in the prevalence of glucose tolerance and diabetes mellitus between an 
untreated hypertensive group and patients treated with B-adrenergic blocking agents.
Nevertheless, B-adrenergic blocking agents have been shown in smaller studies 
to increase fasting blood sugar and to decrease glucose tolerance in diabetic and non 
diabetic hypertensive subjects (Helgeland et al, 1984; Struthers et al, 1985). The 
release of insulin from the pancreas is modulated by B-adrenergic receptors and 
B-adrenergic blocking agents are reported to inhibit insulin secretion by as much as 
50% (Kendall et al, 1988).
Whether B-adrenergic blocking agents influence insulin sensitivity remains 
uncertain. In a study using the euglycaemic hyperinsulinaemic clamp, Pollare and 
colleagues (1989c) reported a deterioration in insulin sensitivity in hypertensive 
patients after treatment with the B 1-adrenergic blocking agents metoprolol and 
atenolol, but the results may have been confounded by weight gain in the B-blocker 
treated group. In contrast, in subjects with impaired glucose tolerance, metoprolol and 
atenolol have been reported to improve insulin sensitivity as compared with placebo 
(Faberberg et al, 1990).
(v) Alpha receptor blockers
Alphaj -adrenergic receptor antagonists such as prazosin, terazosin and 
doxazosin effectively reduce blood pressure without affecting lipid or glucose control. 
A study evaluating the metabolic effects of prazosin reported an improvement in 
insulin sensitivity but this was not placebo controlled (Pollare et al, 1988).
In summary, a disappointing feature of many of the published trials which have 
evaluated the effects of antihypertensive therapy on glucoregulatory control 
mechanisms is that many are uncontrolled or have used "indirect" endpoints such as 
fasting glucose and insulin concentrations to infer information about changes in
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insulin resistance. There are few, if any, well controlled studies using direct, 
reproducible measurements of insulin sensitivity.
1.3.3. ORAL HYPOGLYCAEMIC AGENTS.
(i) Metformin.
Metformin is widely used in the treatment of NIDDM, both as monotherapy 
and in combination with sulphonylureas. The glucose-lowering effect occurs without 
stimulation of insulin secretion and several mechanisms have been suggested, 
including delayed gastrointestinal absorption of glucose (Czyzyk et al, 1968), 
enhanced insulin sensitivity (Gin et al, 1983) and suppression of hepatic glucose 
production through inhibition of gluconeogenesis (Wollen & Bailey, 1988). Although 
the principal underlying mechanism remains unclear, several studies have shown 
increases in insulin-stimulated glucose uptake and oxidative metabolism in muscle 
(Fantus & Bousseau, 1986; De Fronzo et al, 1991; Widen et al, 1992). However, this 
is not a universal finding (Jackson et al, 1987), and many believe that the 
hypoglycaemic effect is largely due to a reduction in hepatic glucose output (Wollen 
& Bailey, 1988). Consistent with its putative insulin-mimetic actions, metformin has 
other beneficial effects on lowering triglyceride levels, body weight and even blood 
pressure.
(ii) Sulphonvlureas.
These drugs form the mainstay of oral therapy for NIDDM but there is still 
some debate about whether sulphonylureas lower glucose levels by mechanisms in 
addition to stimulation of insulin secretion (Feldman & Lebovitz, 1969). Part of the 
controversy about extrapancreatic effects stems from studies evaluating insulin 
responses during chronic therapy; hypoglycaemic effects were observed with little or 
no change in plasma insulin concentrations (Barnes et al, 1974). In addition, several
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studies have demonstrated improved insulin sensitivity (Kolterman et al, 1984; 
Simonson et al, 1984) and increased receptor binding (Beck-Nielsen et al, 1979). 
However, at present, the balance of evidence is probably against significant 
extrapancreatic effects; for example, sulphonylureas do not lower plasma glucose 
levels in patients with IDDM or patients with NIDDM rendered insulinopaenic with 
somatostatin (Widen et al, 1991), and it is quite possible that the apparent increase in 
insulin sensitivity is a non-specific response secondary to improved glycaemic control, 
rather than any direct peripheral effect of the drug itself.
1.3.4. NEW PHARMACOLOGICAL APPROACHES TO NON-INSULIN
DEPENDENT DIABETES MELLITUS.
NIDDM is characterised by a triad of metabolic abnormalities: peripheral and 
hepatic insulin resistance, im paired insulin  secretion and hepatic glucose 
overproduction. There is some debate about which disorder arises first but insulin 
resistance, affecting multiple pathways of glucose and lipid metabolism, is generally 
regarded as the principal defect (DeFronzo et al, 1992). It therefore seems somewhat 
anomalous that sulphonylurea drugs, which are primarily insulin secretagogues, 
should form the mainstay of oral therapy; the ideal treatment should logically focus on 
reversing the peripheral defects in glucose and lipid oxidation. This is supported by 
the relatively high rates of secondary failure of sulphonylurea therapy (Groop & 
Pelkonen, 1984), which presumably reflect islet cell exhaustion in the face of sustained 
tissue insulin resistance. The last decade has seen enormous progress in defining the 
biochemistry of NIDDM, and has led to a variety of new pharmacological innovations, 
some of which are now entering early clinical development.
The thiazolidinedione derivatives represent a new structural class of 
antidiabetic compounds. Included in this group are ciglitazone, pioglitazone, 
englitazone and troglitazone. At least three are at present undergoing phase I and II
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studies, and a recent report demonstrated hypoglycaemic efficacy in patients with 
NIDDM (Suter et al, 1992; Iwamoto et al, 1991; Kuzuya et al, 1991). Analogues of 
this class lower plasma glucose, insulin and triglyceride levels in a variety of rodent 
models in which insulin resistance is a conspicuous feature, and biochemical studies 
have shown insulin-mimetic effects in each of the key target tissues (Hofmann & 
Colca, 1992). Thus, thiazolidinediones increase glucose oxidation in adipose tissue 
and muscle, increase glycogen and lipid synthesis from glucose and decrease 
glycogenolysis (Steiner & Lien, 1987; Colca & Morton, 1990). In vitro studies have 
shown that this group of drugs act as insulin -sensitisers; for exam ple, 
insulin-stimulated uptake of deoxyglucose in isolated adipocytes from KKAy mice 
was markedly more sensitive to insulin after pretreatment of these insulin sensitive 
animals with pioglitazone (Hofmann & Colca, 1992), and thiazolidinedione effects 
(like those of metformin) are dependent upon the presence of insulin (Hofmann et al, 
1991). In addition to their hypoglycaemic effects, these drugs have other properties 
that may be particularly useful in patients with NIDDM, including effects on 
HDL-cholesterol and possibly blood pressure (Yoshioka et al, 1993).
D ichloroacetate (DCA) represents a potentially  novel class of oral 
hypoglycaemic agents. DCA has no effect on insulin secretion but reduces plasma 
glucose levels via inhibition of hepatic glucose production and stimulation of 
peripheral utilisation (Stacpoole & Greene, 1992). The peripheral effect is due mainly 
to the stimulation of pyruvate dehydrogenase, which is the rate-limiting enzyme of 
glucose oxidation. In patients with NIDDM, short-term treatment with DCA was 
associated with a significant fall in triglycerides (Stacpoole et al, 1978). Clinical trials 
with DCA were discontinued due to one case of reversible neuropathy, but new DCA 
derivatives are now available (Stacpoole et al, 1987).
Elevation of free fatty acid levels is a well recognised feature of NIDDM, and 
there is evidence that this may be causally related to hyperglycaemia. Fatty acid 
release from adipocytes is dependent on the net balance between lipolysis and
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re-esterification. In NIDDM there is resistance to insulin-mediated suppression of 
lipolysis, which is the rate limiting step in free fatty acid re-esterification. The 
principal mechanism by which free fatty acids may be causal in hyperglycaemia is in 
stimulating gluconeogenesis in the liver. In addition, Randle and colleagues (1963) 
showed that free fatty acids exacerbate insulin resistance in skeletal muscle.
Insulin therapy and other inhibitors of lipolysis, e.g. nicotinic acid and its 
analogue acipimox, reduce levels of free fatty acids and glucose (Dulbecco et al, 
1989). Clinical trials with acipimox have shown useful effects on triglyceride levels 
and glycaemia (Fuccella et al, 1980), but rebound effects with these anti-lipolytic 
agents has focussed attention on different approaches to lowering elevated free fatty 
acid levels. One approach is with novel adenosine A-l receptor antagonists, for 
example, GR79236 (Strong et al, 1993), which inhibit catecholamine induced 
lipolysis. In addition, a series of inhibitors of free fatty acid oxidation are presently in 
various stages of development. In particular, a group of drugs that irreversibly inhibit a 
key mitochondrial enzyme involved in long-chain fatty acid oxidation, carnitine 
palmitoyltransferase-1 (CPT 1) have entered clinical development (Foley 1992). For 
example, preliminary studies with etomoxir in patients with NIDDM using the 
euglycaemic hyperinsulinaemic clamp showed a 33% increase in insulin-stimulated 
glucose disposal (Ratheiser et al, 1991).
1.4 SCOPE OF THE THESIS*
In recent years it has become recognised that clustering of metabolic 
abnormalities is an inherent feature of the hypertensive individual; patients with 
untreated essential hypertension have higher than norm al plasm a insulin  
concentrations, are resistant to insulin-stimulated glucose uptake, and often have 
accompanying lipid abnormalities. The extent to which insulin resistance is involved 
in the initiation and maintenance of high blood pressure remains unknown, but these
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observations have potentially important implications for long term hypertensive 
complications, as insulin has mitogenic properties and can potentiate vascular smooth 
muscle growth thus promoting structural changes and atherosclerosis.
Much recent interest has focussed on the potential confounding or beneficial 
effects of drugs on metabolic function. Antihypertensive and oral hypoglycaemic 
agents may have differential effects on carbohydrate metabolism and insulin resistance 
but their effects have often been poorly characterised because of concerns about the 
methodology used to assess insulin sensitivity and limitations of study design.
This thesis incorporates a series of studies of insulin sensitivity using the 
euglycaemic hyperinsulinaemic clamp in healthy male volunteers, patients with 
essential hypertension and patients with NIDDM.
The studies consist of 211 individual clamp procedures performed in 75 
individuals. Chapter 3 is a series of 3 experiments performed in 24 healthy male 
volunteers and 6 patients with essential hypertension designed to evaluate critically the 
euglycaemic hyperinsulinaemic clamp technique. This research technique has been 
used for over 20 years for the in vivo determination of insulin mediated metabolic 
responses. Despite its widespread use, several aspects of the method have been poorly 
documented. This chapter firstly describes the validation of the technique in my hands, 
secondly evaluates the use of a heated hand box to achieve "arterialisation" of 
venous blood, and lastly analyses the metabolic and haemodynamic effects associated 
with euglycaemic hyperinsulinaemia and arterialisation of venous blood with a heated 
hand box.
Few studies in the literatu re  which have evaluated the effects of 
antihypertensive drugs on insulin sensitivity have used a placebo-controlled, crossover 
study design. Chapters 4 and 5 evaluate the effects of two new antihypertensive agents 
on insulin induced metabolic responses. Chapter 4 evaluates the effects of the new 
dihydropyridine calcium antagonist, lacidipine, on whole body insulin sensitivity in 12 
healthy volunteers and 6 patients with essential hypertension. As the dihydropyridine
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calcium antagonists are associated with reflex sympathetic augmentation on acute 
dosing, both the acute and chronic effects of drug administration on insulin sensitivity 
are evaluated. Chapter 5 evaluates the effects of the ACE inhibitor trandolapril on 
whole body insulin sensitivity and metabolic parameters in 12 patients with both 
essential hypertension and impaired glucose intolerance or NIDDM.
At both in vitro and in vivo levels, numerous studies have suggested important 
pathophysiological links between glucose and insulin metabolism and the 
neuroendocrine systems involved in cardiovascular regulation, particularly the renin 
angiotensin system and the sympathetic nervous system; for example, the insulin 
antagonist effects of the catecholamines are well established. Insulin augments the 
aldosterone response to angiotensin II, there is in vitro evidence that angiotensin II 
may possess some glycogenolytic and gluconeogenic properties, and there are limited 
data that suggest that ACE inhibitor drugs may enhance insulin sensitivity, but the in 
vivo effects of angiotensin II on insulin mediated metabolic responses have not been 
previously reported. Chapter 6 examines the effects of angiotensin II on insulin 
stimulated metabolic responses using the euglycaemic clamp technique in 12 healthy 
male volunteers and 11 patients with NIDDM.
It is well recognised that even within a group of age matched healthy 
volunteers, insulin sensitivity may vary by more than threefold. Using data collected 
from all 75 subjects in whom insulin sensitivity was determined by the euglycaemic 
clamp technique, chapter 7 uses a multiple linear regression analysis to investigate the 
inter subject variability in insulin sensitivity and identifies factors which may be of 
clinical importance in predicting the insulin sensitivity of an individual.
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CHAPTER 2 
GENERAL METHODS
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2.1. GENERAL CLINICAL PROTOCOL
Healthy male volunteers were recruited by advertising. Patients with essential 
hypertension were recruited from the cardiovascular risk factor clinic at the Western 
Infirmary and patients with non-insulin dependent diabetes mellitus (NIDDM) were 
recruited from Dr. M. Small’s diabetic clinic at Gartnavel General Hospital or from 
the joint dietetic/medical obesity clinic at the Western Infirmary. In total, seventy-five 
subjects gave informed consent to participate in the projects, all of which were 
individually approved by the Research and Ethical Committee of Greater Glasgow 
Health Board (Western District).
Hypertensive patients were either newly diagnosed and previously untreated, 
or patients in whom current antihypertensive therapy was ineffective or poorly 
tolerated. Each patient discontinued any previous m edication and, after a 
treatment-free period of at least 4 weeks, was entered into a study if blood pressure on 
three consecutive occasions was within the range 160/90 to 210/115 mmHg. Patients 
with secondary forms of hypertension, co-existent disease requiring regular 
prescription medication, or with a history of myocardial infarction in the preceding 12 
months were excluded from participation.
All patients with NIDDM were diagnosed either by a documented random 
blood sugar of greater than 14 mmol/L, or by a 75 gram oral glucose tolerance test 
(OGTT) (WHO Study Group, 1987) [section 2.1.4], No patients were receiving any 
oral hypoglycaemic agent or insulin therapy.
Before entering a study, all patients and volunteers underwent full clinical 
screening, performed by myself, including physical examination, routine biochemistry, 
haematology, urinalysis and an electrocardiogram to exclude other significant 
cardiovascular disease, or significant end-organ damage. All subjects had a 75 gram 
OGTT at screening.
After informed consent was obtained, each individual was asked to refrain 
from any strenuous exercise for the duration of the study and asked to maintain his or
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her usual diet. The diabetic patients were advised to adhere to an isocaloric diabetic 
diet throughout the study consisting of approximately 55% carbohydrate, 25% fat and 
20% protein.
The general clinical protocol for each study was similar. On each study day, 
following an overnight fast, each subject attended the CIRU at 8 a.m. After 20 
minutes supine rest, baseline blood pressure and heart rate were recorded before the 
insertion of indwelling cannulae into a left antecubital vein and a right dorsal hand 
vein. The 3 hour euglycaemic hyperinsulinaemic clamp was than commenced, during 
which blood pressure and heart rate were measured at regular intervals. A standard 
light lunch was provided at the end of the procedure.
2.2. CLINICAL AND MORPHOMETRIC MEASUREMENTS.
2.2.1. Body mass index.
Body weight and height were measured with subjects in undershorts and 
without shoes to the nearest 0.5kg of weight and to the nearest 0.5cm of height. Body 
mass index (BMI) was calculated as:
Body weight (kg)
Body height (m)2
2.2.2. Waist hip ratio.
Hip circumference, at the greater trochanter, and waist circumference, at the 
umbilicus, were measured to the nearest 0.5cm while the subject was standing.
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2.2.3. Blood pressure and heart rate.
During all the clinical studies the technique of blood pressure and heart rate 
measurement was uniform. Systolic and diastolic blood pressure and heart rate were 
measured using a previously validated (Johnson & Kerr, 1985) Datascope Accutorr 
Semiautomatic Sphygmomanometer, maintained and calibrated at regular intervals by 
the Clinical Physics Department at the Western Infirmary. This machine uses an 
oscillometric technique for indirect blood pressure and direct heart rate measurement. 
All subjects had supine and erect measurements taken at screening. On each study day, 
duplicate recordings were made 30 minutes before and at 15 minute intervals during 
the euglycaemic hyperinsulinaemic clamp.
2.2.4. Oral glucose tolerance test.
An OGTT was performed in all subjects in the morning after ten hours of 
overnight fasting. The subjects were resting in the semi-recumbent position and took 
75 grams of glucose orally with 100 mis of water after 20 minutes of rest. Blood was 
withdrawn from a peripheral venous cannula at time zero and at 30 minute intervals 
throughout the test for 2 hours for measurement of plasma glucose and serum insulin 
concentrations. The diagnosis of diabetes was made if the fasting plasma glucose was 
greater or equal to 7.8 mmol/L and/or the 2-hour post-load plasma glucose was greater 
or equal to 11.1 mmol/1. The diagnosis of impaired glucose tolerance was made if the 
fasting plasma glucose was less than 7.8 mmol/L and the 2-hour post load plasma 
glucose was between 7.8 and 11.1 mmol/L (WHO Study Group, 1987).
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2.3. THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP.
In each individual study, the whole-body insulin sensitivity was assessed 
using a modification of the euglycaemic hyperinsulinaemic clamp described by 
DeFronzo et al (1979).
2.3.1. Infusions of insulin and glucose.
Two 18 gauge intravenous cannulae {Venflon, Helsinborg, Sweden) were 
inserted: the first retrogradely into a dorsal hand vein for blood sampling and the 
second antegradely into the contralateral antecubital fossa for administration of insulin 
and 20% Dextrose.
The infusion of soluble insulin (Actrapid, Novo Nordisc, Denmark) was 
prepared in 45 mis of 0.9% NaCl plus 5 mis of the patients’ own blood to prevent 
adsorption of insulin to plastic surfaces, and was administered using a Braun Perfusor 
pump.
The insulin was administered as a primed, constant rate infusion at a rate of 
1.5 mU/kg/min for 180 minutes, with the aim of achieving a steady state serum insulin 
concentration approximately 100 uU/ml above the basal fasting level. The primed 
infusion regimen used was as follows:
A variable rate infusion of 20% dextrose was administered to maintain 
euglycaemia (5.2 mmol/1). The 20% dextrose was infused from 4-180 minutes using 
an IMEDIV infusion system (IMED, Abingdon, UK). The infusion rate was adjusted 
for body weight for each individual and expressed as mg glucose/kg/min. For
0-4 minutes
4-7 minutes
7-180 minutes
4.5 mU/kg/min 
3.0 mU/kg/min
1.5 mU/kg/min
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example, the infusion rate of 20% Dextrose equal to lmg glucose per kilogramme per 
minute for a 70kg individual would be calculated as:
60 mins + 200g glucose x 70 kg = 21 mis 20% Dextrose/hour.
A 3 way tap enabled simultaneous infusion of the insulin and 20% Dextrose 
solutions.
At 5 minute intervals, 2 ml blood samples were collected from the cannulated 
dorsal hand vein surrounded by a heated box (55°C) with the aim of arterialisation of 
venous blood for plasma glucose measurements [section 2.3.3].
2.3.2. Calculation of whole body insulin sensitivity from the euglycaemic 
hyperinsulinaemic clamp.
Under steady state plasma glucose conditions, usually the last 40-60 mins of 
the clamp, the glucose infused must equal the glucose being removed out of the 
glucose space (i.e. glucose metabolised, M) provided that endogenous glucose 
production is completely suppressed. If hepatic glucose synthesis was quantified using 
labelled glucose, it would be possible to calculate peripheral glucose disposal; as this 
was not done, the measurements equate with whole body glucose disposal.
In practice, the glucose infusion (I) must be modified by two factors before it 
can be equated with M:
M = I - U C - SC
where I is the glucose infusion rate, UC is the correction for urinary glucose loss (only 
relevant in a hyperglycaemic clamp), SC is the space correction for inevitable 
variations from absolute euglycaemia, and all values are calculated in units of mg 
glucose/kg/min. This "space correction" (in mg glucose/kg/min) is calculated as
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follows (De Fronzo et al, 1979):
SPACE CORRECTION = (52 - G) x 17.86 x 0.095
G = Ambient glucose concentration over last 40 
minutes of the clamp in mmol/L.
17.86 = Conversion factor to mg/dl.
0.095 = Space correction.
Obviously if SC is negative (i.e. the glucose level has fallen), the correction is 
added to I and M is greater than I. If too much glucose has been infused, SC is 
subtracted from I. In clamps of good quality the SC is usually small; approximately 
0.1 mg/kg/min. To calculate I  the infusion rate over the last 40 minutes of the clamp is 
averaged. For example, if I was calculated between 120-140 minutes:
Clamp Time 
118mins
Infusion Rate 
5.0
131 5.5 11x5 =55
136 5.5 5x5.5 =27.5
139 6.0 3x5 = 15
1x6 = 6
140------------------------------------------------------
Total 103.5
I = 103.5 = 5.17 mg/kg/min
20 mins
2.3.3. Arterialisation of venous blood
A dorsal hand vein was cannulated in a retrograde fashion to enable 
placement of the hand into a cylindrical heated box (Department of Physiology,
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Nottingham University, UK) which under thermostatic control maintains the ambient 
temperature at 55#c. The patency of the cannula was maintained with an infusion of 
0.9% NaCl which was attached to a 3 way tap to facilitate venous sampling. During 
the euglycaemic hyperinsulinaemic clamp, approximately lOOmls of 0.9% NaCl was 
administered via the dorsal hand vein cannula. The rationale behind the use of the 
heated hand box is discussed in chapter 1.3.3. The metabolic and haemodynamic 
effects of the heated hand box are discussed in chapter 3.
2.4. LABORATORY METHODS.
Venous blood samples for laboratory assay were withdrawn from the 
indwelling right dorsal hand cannula and collected into normal clotted, and chilled 
lithium heparin and EDTA tubes. Plasma was separated by centrifugation at 4°C for 
15 minutes at 3000 rpm and stored at -70#C until assay. Whenever possible, within 
each study, the samples for each individual were performed in batches.
2.4.1. Serum insulin and C-peptide concentrations.
Human insulin and proinsulin originate as a single polypeptide chain known as 
proinsulin, which is formed on the surface of the rough endoplasmic reticulum in the 
beta cells of the islet of Langerhans. Proinsulin is then transported to the Golgi 
apparatus where it is packed into granules. It is in these granules that proinsulin is 
cleaved proteolytically into insulin and C-peptide. Insulin and C-peptide are stored in 
these beta granules until their secretion is stimulated, at which time approximately 
equimolar amounts of each are released into the portal vein. While insulin has a 
pervasive influence on the body, affecting virtually every organ and biochemical 
component, C-peptide has no known physiological function.
Serum insulin  and C-peptide concentrations were m easured using 
radioimmunoassay (INCSTAR) kits. To perform these equilibrium assays, samples are
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combined with an antibody and a tracer and incubated for 16 hours at 5°C. A 
pre-precipitated second antibody complex is then added as a single reagent. The assay 
is then centrifuged and decanted after 20 minutes incubation at 20°C.
The normal range for fasting serum C-peptide in our laboratory is 0.5-3.0 
ng/ml. The normal range for fasting serum insulin in our laboratory is less than 25 
uU/ml. The within-assay and between-assay coefficients of variation for C-peptide are 
6.7% and 14.3% respectively. The within-assay and between-assay coefficients of 
variation for serum insulin are 6.4% and 8.5% respectively. For each study, all 
samples for each individual were performed in batch analysis.
2.4.2. Plasma glucose concentrations.
At baseline and at 30 minute intervals during the OGTT, and at 5 minute 
intervals throughout the euglycaemic hyperinsulinaemic clamp, blood samples were 
collected for plasma glucose measurements. Samples were collected into 1.5ml tubes 
and loaded into a Beckman microfuge (Beckman Instruments, Fullarton, California, 
USA) situated at the bedside. Samples were spun for 60 seconds. An Accustroke Pipet 
was than used to aspirate 10 microlitres of plasma. The pipetting technique included a 
post aspiration rinse of the disposable pipet in sterile water to avoid carryover effects 
from material retained on the outside of the tip. Samples were analysed using a 
Beckman Glucose Analyser II (Beckman Instruments, Fullarton, California, USA) 
which measures the rate of change in oxygen consumption when a sample is injected 
into an enzyme reagent sample.
When a sample is injected into the enzyme reagent solution, B-D-glucose from 
the sample combines with dissolved oxygen from the solution according to the 
reaction:
B-D-Glucose + 0 2--------> Gluconic acid +
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In the reaction, oxygen is consumed at the same rate as glucose reacts to form 
gluconic acid. At all times during the reaction, the rate of oxygen consumption is 
directly proportional to the concentration of glucose present in the reaction cup. The 
maximum observed rate has been shown to be a direct measure of the concentration of 
glucose originally in the sample at the time of injection (Kadish et al, 1968). The 
analyser measures and holds this maximum rate and permits the digital readout to be 
scaled, providing a number corresponding to glucose concentration in mmol/L.
On each study day, the Beckman glucose analyser was calibrated to 8.3mmol/L 
with an aqueous standard, and typically, checked once every ten samples during the 
euglycaemic hyperinsulinaemic clamp. The intra-assay coefficient of variation in 
plasma glucose concentrations was 3.6%.
2.4.3. Serum aldosterone concentrations.
Serum aldosterone concentration was measured by radioimmunoassay 
(Biodata, Milan) according to the technique described by MacKenzie and Clements 
(1974). Samples were incubated for 3 hours at 20°C with a tracer (125I - Aldosterone); 
these two compete for binding sites on the antibody. After incubation the amount of 
tracer bound to the antibody is inversely proportional to the amount of aldosterone 
present in the plasma sample. Separation of the bound fraction is performed by 
addition of a second antibody coupled to magnetic particles and the immunocomplex 
is collected by the application of a magnetic field: the quantity of antibody-ligand 
complex is measured by radioactive counting using a gamma camera.
The normal range for serum aldosterone in the supine position in our 
laboratory is 12-150 pg/ml. The within-assay and between-assay coefficients of 
variation are 5.0% and 5.4% respectively.
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2.4.4. Plasma renin activity.
Plasma renin activity was determined by radioimmunoassay of angiotensin I 
(Biodata, Milan). Before radioimmunoassay, plasma was incubated so that renin 
generated angiotensin I under standardised conditions. This then competes with a 
radioactive tracer (125I - Angiotensin) for the binding sites of the antibody. After 
incubation the amount of tracer bound to the antibody is inversely proportional to the 
amount of renin present in the plasma sample. The separation of the bound from the 
free fraction is performed by addition of a double antibody coupled to magnetic 
particles. The application of a magnetic field allows the sedim entation of 
immunocomplexes, avoiding the centrifugation step. The normal range for plasma 
renin activity in the supine position in our laboratory is 0.12 -1.59 ng/ml/AI/hour. The 
within-assay and between-assay coefficients of variation are 4.9% and 7.8% 
respectively.
2.4.5. Plasma catecholamine concentrations.
Plasm a noradrenaline was assayed by high perform ance liquid 
chromatography with electrochemical detection (HPLC-ED) as previously described 
by Howes et al (1985). Catecholamines were extracted from plasma by acid-washed 
alumina (50mg) and were then eluted by vigorously mixing the alumina with 250ul of 
0.2 M perchloric acid. A 200 ul aliquot of the eluate was injected into the liquid 
chromatograph onto a home packed 5 micron spherisorb octadecylsilane (ODS) 
reversed phase column. The normal range for resting supine plasma noradrenaline and 
plasma adrenaline is 0.3 - 7.5 nmol/1 and 0 -1 .0  respectively. The within-assay and 
between-assay coefficients of variation are 15% and 13% respectively.
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2.4.6. Plasma angiotensin II concentrations.
Plasma angiotensin II concentration was determined by radioimmunoassay 
according to the technique as described by Dusterdieck and McElwee (1971). Venous 
blood was collected into EDTA/phenanthroline to inhibit converting enzyme and 
angiotensinase enzymes. Angiotensin II was extracted from plasma using cartridges 
containing a reverse phase non-polar medium. The cartridges were pretreated with 
methanol and then water. Angiotensin II was eluted from the column with aqueous 
20% methanol. The extracts were dried and redissolved in Tris buffer for assay. The 
normal range for plasma angiotensin n  in the supine position in our laboratory is 3.0 -
12.0 pg/ml. The within-assay and between-assay coefficients of variation are 6.4% and 
8.8% respectively (Morton and Webb, 1984).
2.4.7. Serum potassium concentrations.
Serum potassium ion activity was measured by a direct ion selective electrode 
on a Coming Model Na/K analyser (Ciba Coming Diagnostics, Halstead, Essex, UK).
2.4.8. Blood gas analysis.
Samples for blood gas analysis were collected into heparinised syringes and 
immediately placed on ice. Oxygen saturation and oxygen concentration were 
measured on a Coming 288 analyser (Ciba Coming Diagnostics, Halsted, U.K.).
2.4.9. Glycosylated haemoglobin concentrations.
Glycosylated haemoglobin (HbAj) was determined by electroendosmosis using 
a Coming Glytrac Haemoglobin Set (Coming 470064, U.S.A.). The reference range of 
the Biochemistry Laboratory at Gartnavel General Hospital Glasgow, derived from the 
endogenous population, is 4.8% to 7.8%.
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2.4.10. Plasma angiotensin converting enzvme activity.
Angiotensin converting enzyme (ACE) converts the decapeptide angiotensin I 
to the octapeptide angiotensin II through cleavage of the carboxy-terminal dipeptide 
histidyl-L-leucine. The assay that was used to determine plasma ACE activity is based 
on an HPLC technique for measuring the rate of release of hippuric acid from an 
artificial substrate of angiotensin I (Chiknas,1979). One unit of enzyme generates one 
nanomole of hippuric acid per minute and the normal range in our laboratory for 
plasma ACE activity is 5-32 EU/ml. The inter- and intra-assay coefficients of variation 
are 6% and 2% respectively, with a limit of detection of 0.1 EU/ml.
2.4.11. Plasma lipid and lipoprotein concentrations
Plasma and lipoprotein cholesterol concentrations were measured using a 
CHOD-PAP kinetic method (Boehringer Mannheim, East Sussex, U.K.), standardised 
with primary cholesterol standards (Reference Laboratory for Cholesterol Assays, 
Bilthoven, the Netherlands). Triglycerides were measured using an enzymatic method 
(Merck Diagnostics, Darmstadt, Germany). Measurements were performed using a 
Cobas Bio Analyser (Roche Diagnostics, Welwyn Garden City, U.K.).
2.5. STATISTICAL ANALYSIS.
All data were formally checked to ensure a Gaussian distribution by plotting 
normal plots using the statistical package Minitab. Coefficients of variation (c.v.) were 
calculated according to the method of Bland (1987).
Whole-body insulin sensitivity in mg/kg/min was calculated under steady
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state conditions during the last 40 minutes of each ‘clamp* (DeFronzo et al, 1979). 
Insulin sensitivity values for individual subjects on each study morning were 
compared between treatments by analysis of variance (ANOVA) using the statistics 
package, Rummage, and the Bonferroni method for calculating 95% confidence 
intervals. To ensure that the euglycaemic clamps were of good quality, the c.v. of 
glucose measurements from time 0-180 minutes of all the clamps, and the mean 
plasma glucose levels over the last 40 minutes of the clamps for each treatment period 
were calculated.
Measurements of serum insulin, C-peptide, triglyceride, potassium, plasma 
renin activity, plasma aldosterone and plasma noradrenaline at individual time points 
were compared between study mornings by repeated measures ANOVA.
Blood pressure and heart rate measurements were evaluated by repeated 
measures ANOVA.
Linear regression analysis was used to investigate the relationship between the 
derived value for insulin sensitivity, and factors such as patients age, body mass index, 
fasting serum insulin concentration and baseline blood pressure [see chapter 7.2].
Results throughout are expressed as mean + standard deviation.
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CHAPTER 3
THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP:
AN EVALUATION OF THE METHODOLOGY INCLUDING THE 
ARTERIALISATION OF VENOUS BLOOD
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3.1. INTRODUCTION:
The euglycaemic clamp [chapter 1.2.3] has been used extensively over the last 
15 years to quantify in vivo insulin sensitivity. Despite some recognised limitations of 
this technique (Bergman et al, 1989), the clamp has found widespread application in 
both cardiovascular and endocrine research but a number of important technical 
aspects of the method have not been clearly documented. For example:
(1) since the original report by DeFronzo and colleagues (1979), in which 
reproducibility was assessed in only 4 volunteers, few investigators have evaluated 
the intra-subject variation in metabolic responses across a range of glucose disposal 
rates (and without the confounding influence of dietary or drug interventions).
(2) whether insulin sensitivity should be expressed in terms of glucose uptake (M) 
or the insulin sensitivity index (SJp) is controversial, and the merits of these two 
parameters have not been directly compared in the same individuals.
(3) the optimal duration of the clamp is unclear: although glucose requirements 
may increase steadily for up to 5 hours (Dobeme et al, 1981), infusions are usually 
m aintained for either 2 or 3 hours, but differences in insulin sensitivity  
measurements from 120 versus 180 minute clamps have not been clearly evaluated.
(4) the importance of sampling "arterialised" blood from a heated dorsal hand 
vein - a cumbersome and sometimes painful procedure - is disputed (Andrews et 
al, 1984), and few studies have assessed the overall impact of hand-warming on 
both the haemodynamic and metabolic response to a euglycaemic clamp.
Before embarking on the main series of studies that comprise this thesis, the 
aim of this study was to address some of these methodological issues pertinent to the
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euglycaemic hyperinsulinaemic clamp itself. In particular, (1) to evaluate the 
reproducibility of insulin sensitivity (expressed as M and S;p) in subjects with a range 
of glucose disposal rates - i.e. both insulin sensitive and insulin resistant; (2) to 
compare the quality of information obtained from clamps of 120 and 180 minutes 
duration; and (3) to assess the haemodynamic and metabolic effects of hand-warming 
using a purpose-built warm air device (manufactured commercially by the Department 
of Physiology and Pharmacology, University of Nottingham). •
3.2. SUBJECTS AND METHODS.
3.2.1. General methods.
A total of twenty-four healthy male volunteers (age range 20-34 years, BMI
22.1 + 2.2 kg/m2), and six patients (4M, 2F), with mild to moderate essential 
hypertension (age range 49-59 years, BMI 26.2 + 4.6 kg/m2), gave written consent to 
participate in these studies. The 6 patients and 12 volunteers in chapter 4 [table 4.1] 
who underwent two euglycaemic hyperinsulinaemic clamps while taking placebo 
therapy are included in the reproducibility analysis (protocol A).
In each study, the general clinical protocol was similar. All subjects attended 
the Clinical Research and Investigation Unit (CIRU) at 8 am following an overnight 
fast. In each study, whole-body insulin sensitivity was assessed with the euglycaemic 
hyperinsulinaemic clamp as described in chapter 2.3. At baseline, and at 60-minute 
intervals during the 3-hour clamp, blood samples were collected for measurements of 
serum insulin, C-peptide and potassium concentrations. In addition, in 4 healthy 
subjects, insulin concentrations were measured at 5 minute intervals for the first 60 
minutes of the clamp to evaluate the serum insulin profile induced by the priming 
phase of the insulin infusion (chapter 2.3). Measurements of supine blood pressure and 
heart rate were recorded at 15 minute intervals during the clamp.
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3.2.2. Study designs
Three separate studies were performed:
Protocol A: Specific aim: to evaluate the reproducibility of M values and Sip values
derived from the euglycaemic clamp.
Eighteen healthy volunteers and six patients with essential hypertension 
attended for 2 study mornings at least 1 week apart. On each occasion, a 3 hour clamp 
was performed with blood sampled from a heated dorsal hand vein for the 
determination of insulin sensitivity. In both the volunteer group and the patient group, 
the inter-subject and intra-subject variability of whole body insulin sensitivity was 
assessed by calculating the coefficient of variation (c.v.) [chapter 2.5]. In addition, 
insulin sensitivity was calculated using data from two time periods of the 3 hour 
clamp; 80 to 120 minutes, and 140 to 180 minutes. The reproducibility of SJp and the 
insulin stimulus were also calculated for the same time periods.
Protocol B: Specific aim: to evaluate the effects of hand warming on plasma
glucose concentrations and oxygen saturation of venous blood.
Six healthy volunteers attended for 2 study mornings at least 1 week apart. On 
each occasion, a 3 hour clamp was performed with the following modifications: (1) a 
cannula was inserted into the antecubital fossa of both arms for infusions of glucose 
and insulin [right arm], and for sampling of mixed venous blood [left arm]. In 
addition, a cannula was inserted into a dorsal hand vein of the right arm which was 
heated with the warm air box (55°); and (2) at 10 minute intervals antecubital and 
"arterialised" blood samples were collected simultaneously for analyses of plasma 
glucose and (every 60 minutes) oxygen saturation. The glucose infusion rate was 
adjusted according to the arterialised plasma glucose concentrations.
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Protocol C: Specific aim: to evaluate the effects of hand warming on
haemodynamic and metabolic responses.
Six healthy volunteers attended for 2 study mornings 1 week apart. On each 
occasion, a 3 hour clamp was performed. On the first study day arterialised blood (i.e. 
with the warm air box) from a heated dorsal hand vein was used to adjust the glucose 
infusion rate required to maintain euglycaemia. On the second study day, mixed 
venous blood (i.e. without the warm air box) from the antecubital fossa was used to 
guide the glucose infusion and calculate insulin sensitivity. The order of the 2 study 
days was randomised.
For each study, whole-body insulin sensitivity (M) in mg glucose/kg/min was 
calculated under steady state conditions during the last 40 minutes of each clamp, as 
described in chapter 2.3. The S/p was calculated as the steady state ratio of the 
increment in glucose uptake (A/?,) to the increment in plasma insulin concentration 
(A/), normalised to the ambient plasma glucose concentration (G) at which the clamp 
was performed (Bergman et al, 1989): S/p= 100 x  ARd / (Al x  G). Values for M and 
SJp for individual subjects on each study morning were compared between treatments 
by analysis of variance [chapter 2.5].
3.3. RESULTS.
3.3.1. Evaluation of priming phase of the insulin infusion.
Individual profiles of serum insulin in 4 healthy subjects during the first 60 
minutes of the clamp are shown in figure 3.1. The priming protocol tended to cause an 
"overshoot" in serum insulin concentration within the first 10 minutes, but a 
steady-state p lateau was achieved thereafter, with insulin  concentrations 
approximately 80uU/ml above baseline (fasting) levels (figure 3.1).
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3.3.2. Protocol A: Evaluation of the reproducibility of the technique.
There was no significant difference between the steady state plasma glucose 
concentration at 80-120 minutes compared with 140-180 minutes; mean values were 
5.1±0.2 and 5.2+0.4 mmol/L, respectively, for the healthy volunteers and 
correspondingly 5.3±0.4 and 5.2+0.2 mmol/L for the hypertensive patients. 
Satisfactory euglycaemia was maintained throughout the clamps as reflected by the 
mean c.v. of plasma glucose concentrations of 7% for healthy subjects and 8% for 
hypertensive patients. In both healthy male volunteers and patients with essential 
hypertension mean values for M and S[p calculated for the period of 140-180 minutes 
were significantly higher than values obtained at 80-120 minutes; for example, in 
healthy volunteers M was 9.8+2.0 mg/kg/min at 180 minutes compared with 9.0+1.9 
mg/kg/min at 120 mins (p<0.001). S[p values for the corresponding time points were
8.1 ± 2.6 and 8.8 ± 2.7 mg/kg/min per uU/ml (x 100) respectively (p<0.001) (table
3.1). Intra-subject reproducibility was the best for M values derived from clamps of 
180 minutes duration; for example, the c.v. was 6% in the healthy subjects and 5% in 
patients with essential hypertension. SJp values, however, demonstrated greater 
variability; the corresponding c.v.’s for SJp values at 180 minutes were 21% and 13% 
respectively (table 3.1).
There was wide inter-subject variability in insulin sensitivity in both groups of 
subjects. In healthy subjects and essential hypertensives the inter-subject c.v. in M at 
180 minutes was 30% and 47% respectively. The corresponding c.v for the 
inter-subject variability in the insulin stimulus was 20% and 36% respectively (table
3.1). There were no significant changes in blood pressure or heart rate during the 
hyperinsulinaemic stimulus in the normotensive or hypertensive subjects.
3.3.3. Protocol B: Evaluation of arterialisation of venous blood.
"Arterialised" samples had higher and less variable oxygen saturations than
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HEALTHY SUBJECTS
MEAN RANGE INTERSUBJECT INTRASUBJECT
C.V. (%) C V . (%)
M VALUES 120 mint 9 .0 + /-1 .9 5.3 -13 .0 22 8
mg kg/min 180m ins 9 .8 + /-2 .0 5.6 -13.8 21 6
INSULIN 120m ins 8.1 +/- 2.6 3.0 -16.3 32 21
SENSITIVITY 180m ins 8 .8 + /-  2.7 3 .7 -18 .1 30 21
INDEX
INSULIN 120 mint 1 1 8 + /-2 6 9 3 -2 2 0 22 12
STIMULUS 180 mint 1 1 7 + /-2 4 8 8 -2 0 8 20 10
uU/ml
HYPERTENSIVE PATIENTS
MEAN RANGE INTERSUBJECT INTRASUBJECT
C V . (%) C V . (%)
M VALUES 120m ins 5 .9 + /-2 .5 1.5 -10 .0 43 14
mg kg/min 180 mint 6 .6 + /-1 5 1 0  -10.3 38 5
INSULIN 120 mint 5 .4 + /-  2.6 0.7 - 8.7 48 17
SENSITIVITY 180 mint 6 .4 + /-3 .0 1 .0 -9 .9 47 13
INDEX
INSULIN 120 mint 1 2 1 + /-4 0 90 - 221 33 15
STIMULUS 180 mint 115+ /-41 8 2 -1 9 7 36 10
uU/ml
Table 3.1: Table summarising the reproducibility of M values and insulin sensitivity 
index values derived from time periods 80-120 minutes and 140-180 minutes during 
the euglycaemic hyperinsulinaemic clamp in 18 healthy subjects and 6 patients with 
essential hypertension.
Insulin sensitivity index is expressed as the increase in glucose uptake divided by the 
increment in plasma insulin concentration (mg/glucose/kg/min per uU insulin x 100).
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mixed venous blood withdrawn simultaneously (figure 3.2). For example, at 180 
minutes 0 2 saturation was 95±2% in arterialised venous blood compared with 
79±18% in mixed venous blood. In keeping with this, there was a difference between 
arterialised and mixed venous plasma glucose concentrations; 5.2+0.2 vs. 4.5±0.4 
mmol/L at 150 minutes (figure 3.3). This difference in plasma glucose was smallest at 
the beginning of the procedure and increased progressively until 60 minutes. The 
difference between arterialised and mixed venous blood glucose concentrations 
correlated significantly with the difference in arterialised and mixed venous oxygen 
saturations (r=0.609, p<0.01).
3.3.4. Protocol C: Evaluation of metabolic and haemodvnamic effects of hand 
y fl-ming.
Mean steady state plasma glucose concentrations during the two clamps were 
5.2+0.4 and 5.1+0.4 mmol/L for the arterialised and non-arterialised day respectively. 
Mean steady state increments in serum insulin concentration were similar in both 
studies; the mean c.v. of the insulin stimulus was 1% and 8% for the arterialised and 
non-arterialised days respectively. Individual values obtained for M during the clamp 
studies are seen in table 3.2. It is apparent that individual values for M were quite 
comparable, but there was a small but significant trend for the derived measurement of 
insulin sensitivity to be higher using arterialised as compared with mixed venous 
blood; 11.7±3.2 mg/kg/min compared with 10.5±3.0 mg/kg/min {p<0.05). 
Confidence intervals for this observation were 0.4,1.9. Blood pressure profiles of the 
two days are shown in figure 3.4. There was a significant reduction in blood pressure 
on the days when arterialised venous blood was used; e.g. 6 mmHg reduction in 
diastolic blood pressure at 120 minutes (p<0.05), and a corresponding increase in 
heart rate (figure 3.4).
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Subject
No.
M value
Arterialised
Blood
M value
Mixed venous 
Blood
Difference
1 11.6 11.4 0.2
2 12.8 11.5 1.3
3 13.1 11.4 1.7
4 10.0 9.6 0.4
5 6.6 5.2 1.4
6 16.2 14.1 2.2
Mean 11.7 10.5 1.2
S.D 32 3.0 0.7
Table 3.2: Individual M values (mg glucose/kg/min) of 6 healthy subjects who 
underwent 2 euglycaemic hyperinsulinaemic clamps one week apart. Insulin 
sensitivity values derived from the clamp were significandy greater on the day when 
arterialised blood was used to adjust the glucose infusion rate.
(p<0.05) 95% confidence intervals; 0.4,1.9.
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3.4. DISCUSSION.
Although the euglycaemic hyperinsulinaemic clamp has been widely practised 
for over 15 years, important aspects of the methodology have been poorly validated. 
With more widespread application of the technique it is important that the 
methodology is subjected to critical evaluation. To the best of my knowledge, this is 
the largest study to report the intra-subject reproducibility of M and Sfp values derived 
from the clamp. The only available data comes from DeFronzo’s original description 
of the technique. He studied 4 healthy subjects, 3 to 4 weeks apart, and reported mean 
M values of 8.5 ±  0.8 mg/kg/min on the first study day, compared with 8.4 ± 0.8 
mg/kg/min on the second day. My studies have therefore demonstrated good 
reproducibility of M values derived from the clamp in both healthy subjects and 
hypertensive patients, but have confirmed large inter-individual variations; insulin 
mediated glucose disposal varied almost threefold in healthy subjects and more than 
fivefold in patients with hypertension. This variation in insulin sensitivity in healthy 
subjects is consistent with that reported by others (Reaven, 1988a) and cannot entirely 
be explained by differences in BMI or age. These results serve to highlight the 
importance, whenever possible, of using a crossover rather than parallel group design 
when evaluating insulin mediated metabolic responses with the clamp. This large 
variation in glucose disposal rates may in part be related to the variation in the insulin 
stimulus observed; even in this group of apparently homogeneous male subjects, the 
weight adjusted insulin infusion produced steady-state insulin concentrations which 
varied almost threefold [table 3.1]. Insulin clearance rates are known to vary with 
obesity (Meistas et al, 1983) and age (Minaker et al, 1982) and these variables may 
account for the differences observed in the hypertensive patients but not in the group 
of healthy subjects.
A notable feature of this study is the poor reproducibility of SJp values despite 
the clamps achieving stable euglycaemia and glucose disposal rates as demonstrated 
by the acceptable coefficients of variation of the glucose measurements from 0-180
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minutes. Bergman (1989) advocates the use of SJp when reporting values of insulin 
sensitivity derived from clamp experiments. He argues that a number of difficulties are 
associated with the use of M values derived from clamp experiments as the value of M 
obtained is highly dependent on the ambient glucose and insulin concentrations 
obtained which are difficult to match among groups. Bergman warrants that the SJp is 
not confounded by non-insulin mediated glucose uptake and does not change over the 
physiological range of insulin or glucose (Bergman et al, 1989). Thus, the S/p is 
widely used but there are no published data on its reproducibility. My results 
demonstrate marked variability in the Sfp within an individual from day to day. My 
data therefore suggest that despite the theoretical advantages of using S/p values from 
clamp experiments, M values are less variable and are probably a better index for 
comparison of possible changes in insulin sensitivity derived from clamp experiments.
The utility of the euglycaemic hyperinsulinaemic clamp technique is limited by 
its labour intensiveness; furthermore, it is time consuming for patients and volunteers. 
Many investigators have attempted to minimise discomfort to subjects by performing 
2 hour clamps. My data suggest that 2 hour clamps have acceptable reproducibility but 
may underestimate insulin sensitivity by up to 10% when compared with the 3 hour 
clamp. In contrast, Reaven’s group reported an underestimation of up to 20% in obese 
subjects and patients with NIDDM (Dobeme et al, 1981). It is notable however that 
the reproducibility of the 2 hour clamp in the hypertensive subjects was the poorest at 
14% - this may reflect a longer time to reach steady state in these insulin resistant 
subjects; a phenomenon observed in insulin resistant obese individuals (Reaven et al, 
1988b). Therefore, a three hour clamp is optimal when evaluating insulin sensitivity, 
especially in groups of patients with insulin resistance.
In analysing whole body glucose metabolism, measurement of arterial rather 
than venous glucose concentrations has been preferred because arterial kinetic data 
represent an average of the processes occurring in the tissues comprising the total 
body, whereas venous data, although more easily obtainable in man, will be affected 
by the particular tissue which is being drained. During the hyperinsulinaemic stimulus
107
of the clamp, there is increased extraction of glucose into skeletal muscle, which gives 
rise to a large and variable arterio-venous difference in plasma glucose concentration. 
Arterial cannulation would therefore be desirable during the clamp but tends to be 
avoided in clinical research protocols because of increased risks compared with 
venous cannulation. Investigators have compromised by sampling from a heated hand 
vein (McGuire et al, 1976). As the hand has relatively little skeletal muscle bulk, 
heating effectively shunts blood from the arterial to the venous side of the circulation. 
The extent to which this is effective, or necessary is controversial; additionally, it 
remains unknown whether this local application of heat may have systemic effects on 
cardiovascular or metabolic variables. For example, Liu and colleagues (1992) 
evaluated the effects of the warm air box in 6 healthy subjects during 
hyperinsulinaemic euglycaemia and hypoglycaemia. They concluded that the heated 
hand technique sufficiently arterialises venous blood so that the glucose measurement 
in the arterialised blood gives a reasonable estimate of the true arterial value. They 
noted however that venous blood from the opposite forearm was also markedly 
arterialised, probably reflecting a generalised vasodilator effect of heating. There were 
no haemodynamic measurements in this study. Gallen and Macdonald (1990) 
evaluated the effects of two methods of hand heating for 60 minutes on body 
tem perature, forearm  blood flow and oxygen saturation. Again, adequate 
arterialisation was achieved by the use of the warm air box, but a consistent 
(non-significant) increase in forearm blood flow was recorded above baseline values.
My study demonstrates that the arterialisation technique used can sufficiently 
arterialise venous blood and achieve a blood oxygen saturation close to the true 
arterial value as reported by others (Liu et al, 1992). The variability in saturation in the 
non-arterialised blood was much higher when compared with arterialised blood; 
54%-97% and 91%-97% respectively. The high non-arterialised blood oxygen 
saturation in our study is likely to be, in some individuals at least, a result of heating 
the contralateral hand for 180 minutes resulting causing a vasodilating effect on the 
forearm superficial vasculature with increased cutaneous blood flow (Gallen &
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MacDonald, 1990).
As the heated hand box possibly exerts a confounding influence on the results 
derived from euglycaemic hyperinsulinaemic clamps, my last study addressed; (1) 
whether results obtained from the use of mixed venous blood in clamp studies differ 
from results using arterialised venous blood; and, (2) the overall impact of hand 
warming on haemodynamic variables. Previous studies have reported that results are 
not appreciably diminished if mixed venous blood is substituted for arterialised blood 
(Andrews et al, 1984; Wahab et al, 1993). However, in the study reported by Wahab 
and colleagues (1993), "mixed venous" blood was sampled in the antecubital fossa of 
the arm ipsilateral to the heated hand; therefore it may have been partially arterialised, 
obscuring any possible difference. My results suggest, however, that in healthy 
subjects, values of insulin sensitivity derived from mixed venous blood are 
significantly lower than clamps using arterialised blood. This is somewhat surprising 
in view of the results of my second study which demonstrate effective arterialisation 
of venous blood by heating the dorsal hand vein: in this study the plasma glucose 
concentration of the mixed venous blood was consistently lower than that of 
arterialised blood. It would therefore be expected that if mixed venous blood glucose 
concentrations are used to alter the glucose infusion rate, the calculated value for 
insulin sensitivity would be consistently higher than the value derived from 
arterialised blood samples. The haemodynamic data (i.e. an increase in heart rate and 
decrease in blood pressure) may provide an explanation for this apparent paradox: 
there is evidence that skeletal blood flow is an important determinant of glucose 
disposal in man (Julius et al, 1991) [chapter 1.1.4]. It is possible that the heating of 
the hand for 3 hours may cause a significant increase in perfusion of skeletal muscle 
blood flow by reducing systemic blood pressure via sympathetic deactivation. There 
are reports of increased forearm blood flow when the contralateral hand is heated with 
a hot blanket (Abramson et al, 1965) and in the study of Gallen and MacDonald 
(1990). Interestingly, there is evidence that lower body negative pressure may induce 
acute insulin resistance in the human forearm by a decrease in blood flow and reflex
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sympathetic activation (Jamerson et al, 1993). Without direct measures of forearm 
blood flow or sympathetic tone it is impossible to assess however whether dorsal hand 
heating affects insulin sensitivity by altering muscle perfusion.
In summary, this study has evaluated the methodology of the euglycaemic 
clamp technique. In particular:
(1) My studies have confirmed the reproducibility of the clamp in a group of 
subjects with a range of glucose disposal rates but have questioned the value of the 
S[p as a measure of insulin sensitivity derived from the clamp. The use of a 2 hour 
clamp is reproducible but underestimates insulin sensitivity by 10%. It is important 
that study designs take account of the large inter-individual variations in insulin 
sensitivity and steady-state insulin concentrations observed even in a group of 
homogeneous healthy male subjects. Whenever possible, a crossover study design 
should be employed and the investigator should remain blind to the treatment under 
investigation.
(2) The heated hand box effectively provides arterialised blood samples with 
oxygen saturations similar to those of arterial blood. My data suggest, however, that 
the heated hand box may exert independent confounding effects on whole body insulin 
sensitivity via vasodilatory and haemodynamic actions. Further studies incorporating 
measurements of skeletal muscle blood flow will be required to evaluate the systemic 
vasodilator effects of the heated hand box.
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CHAPTER 4
THE EFFECTS OF THE DIHYDROPYRIDINE CALCIUM ANTAGONIST 
LACIDIPINE ON INSULIN SENSITIVITY 
IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS
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4.1. GENERAL INTRODUCTION
Although the metabolic effects of antihypertensive drugs have been widely 
reported, few, if any, previous studies with calcium antagonists have used a 
placebo-controlled, cross-over design and many have obtained only indirect 
measurements of insulin sensitivity from oral glucose tolerance tests [chapter 1.3.2]. 
Thus, inadequate study designs may partly explain why there are so many conflicting 
reports about the effects of dihydropyridine calcium antagonists on insulin sensitivity 
and glycaemic control; for example, nifedipine has been shown to impair glucose 
tolerance in both diabetic (Bhathagar et al, 1984) and non-diabetic subjects (Oehman 
et al, 1985), whereas others have reported neutral metabolic effects with nifedipine 
(Landmark 1985), nisoldipine (Odigwe et al, 1986) and amlodipine (Ferrari et al, 
1991b). There is also evidence that dihydropyridines may enhance insulin sensitivity 
following a glucose load (Beer et al, 1993; Giugliano et al, 1980).
This placebo-controlled, crossover study evaluates the effects of a new 
long-acting dihydropyridine, lacidipine, on insulin sensitivity in normotensive and 
hypertensive subjects.
4.1.1. Clinical pharmacology of lacidipine.
Lacidipine (Glaxo, Italy) is a new calcium antagonist which has been granted a 
licence in the United Kingdom as once daily therapy for the treatment of hypertension. 
It has a pharmacological profile typical of the dihydropyridine group of agents; 
vascular selectivity and extensive first pass metabolism. It causes a dose-related fall in 
vascular resistance accompanied by reflex tachycardia at single doses of 3-5mg in 
normal subjects (Hall et al, 1991). Lacidipine does not affect sino-atrial or 
atrioventricular dysfunction in healthy subjects or patients with atrial fibrillation 
(Frank et al, 1990). Lacidipine is rapidly absorbed and undergoes extensive first pass
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metabolism to inactive metabolites. Absolute bioavailability is 2-9% and reported 
half-life 1-3 hours; protein binding is greater than 90% (Hall et al, 1991). In acute dose 
studies of lacidipine in essential hypertension, single doses of 4-6 mg were required to 
produce a definite pharmacodynamic effect (Perelman 1991). Despite its remarkably 
short half-life there are data suggesting lacidipine has a sustained duration of action 
with 24 hour blood pressure control following single daily dosing (Lyons et al, 1994; 
Heber et al, 1990). For example, after one weeks treatment, lacidipine 4-6 mg resulted 
in a significant reduction in blood pressure 24 hours after the last dose when compared 
to placebo. After single doses, lacidipine 4 mg has similar efficacy to that of nifedipine 
10 mg but a longer duration of action (Perelman 1991). In chronic therapy, lacidipine 
4-6 mg has been compared with hydrochlorothiazide (Chiariello, 1991; Leonetti et al, 
1991a), atenolol (United Kingdom Lacidipine Study Group, 1991) and nifedipine 
(Leonetti et al, 1991b) in a series of double-blind, parallel group dose titration studies. 
Efficacy at the end of the dosing interval was similar to that of hydrochlorothiazide 25 
- 50 mg daily, atenolol 50 - 100 mg daily or slow release nifedipine 20 - 40 mg daily. 
However, in the comparator groups, response rate was generally higher and fewer 
patients required dose titration.
Thus, the available data suggest that lacidipine may have comparable 
antihypertensive efficacy to a range of conventional alternative agents. Despite its 
short half-life there are data suggesting that a sustained antihypertensive response may 
be achieved across 24 hours following once-daily dosing. This long duration of action 
has been attributed to accumulation in a cellular lipid compartment, allowing 
continuous release into the binding site of the calcium channel (Herbette et al, 1993).
There are no studies evaluating the effects of lacidipine on glucoregulatory 
mechanisms. This placebo-controlled study evaluates the effects of single and multiple 
doses of lacidipine on whole-body insulin sensitivity in healthy male subjects and in 
patients with essential hypertension using the euglycaemic hyperinsulinaemic 
clamp.
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4.2. SUBJECTS AND METHODS.
Twelve healthy male volunteers and six patients with a diagnosis of essential 
hypertension gave written informed consent to participate in the study (table 4.1.).
Following routine screening as outlined in chapter 2.1.1, each subject received 
lacidipine 4 mg once daily (Glaxo, Italy) and matching placebo, each for 2 weeks, in a 
randomised, double-blind crossover design with a 2-week washout period between 
each treatment phase (figure 4.1).
Clam p Clam p C lam p ClampI I 1 I
LacidipineLacidipine
P laceb oP laceb o
W eek 0  2 4  6
Figure 4.1: Schematic of study design.
Each subject attended four 5-hour study mornings to evaluate the metabolic 
effects of acute and chronic lacidipine and the corresponding placebo administrations. 
On each occasion, following an overnight fast, subjects attended the CIRU atX)745 
am. A fter 20 m inutes supine rest, baseline blood pressure and heart rate 
measurements were recorded (i.e. 24 hours after the last dose). Venous cannulae were 
inserted and subsequently lacidipine or placebo was administered orally with 100 mis 
water.
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On each study day, whole-body insulin sensitivity was calculated using the 
euglycaemic hyperinsulinaemic clamp as described in chapter 2.3. The clamp was 
commenced 60 minutes after drug administration. Systolic and diastolic blood 
pressure and heart rate (HR) were recorded in duplicate 60 minutes before and at 15 
minute intervals during the clamp. At baseline, and at 60-minute intervals during the 
3-hour clamp, additional blood samples were collected for measurements of serum 
insulin, C-peptide, serum potassium, triglyceride, plasma noradrenaline, plasma renin 
activity and serum aldosterone concentrations.
It was calculated from data in chapter 3 that the volunteer arm of this study 
would have greater than 80% power to detect a 15% change in insulin sensitivity.
4.3. RESULTS: (V) NORMAL VOLUNTEERS.
4.3.1. Tolerance
Lacidipine was generally well tolerated; apart from transient headache in one 
subject, no adverse events were reported, there were no significant adverse 
biochemical events, e.g. hypoglycaemia or hypokalaemia, and there were no 
withdrawals from the study. One subject had an episode of micturition syncope at time 
138 minutes following acute lacidipine administration. The plasma glucose at the time 
of symptoms was 5.1 mmol/L; his supine blood pressure was 74/50, pulse rate 47 
bpm. The subject made a prompt recovery.
4.3.2. Blood pressure and heart rate.
There were no statistically significant differences in supine blood pressure 
between the 4 study days in this group of normotensive volunteers. For example, 
average blood pressure between 0-180 mins was 124/63 mmHg after the first dose of
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lacidipine compared with 125/62 mmHg following placebo (figure 4.2). There was a 
trend towards higher heart rates following active treatment: on average (0-180 mins) 
68 and 69 bpm after the first dose and two weeks of lacidipine compared with 62 and 
61 bpm following placebo (figure 4.3). The increase in heart rate was maximal and 
significantly greater than the corresponding placebo 30 - 75 minutes after the start of 
the clamp, i.e. 90- 135 minutes after drug administration, and was observed following 
acute dosing and after 2 weeks of drug administration.
4.3.3. Serum insulin and C-peptide concentrations.
Serum insulin levels increased to a plateau within the first 60 minutes of the 
infusion and there were no significant differences in insulin concentration between the 
4 study days (figure 4.4); for example, at 120 minutes, serum insulin concentrations 
were 125.3 ± 55.4 and 116.9 ±  37.2 uU/ml for acute and chronic lacidipine 
respectively, compared with 122.6 ±  35.7 and 116.3 ± 29.8 uU/ml on the 
corresponding placebo study days. The acute rise in serum insulin concentration was 
associated with a significant decrease in endogenous insulin release. C-peptide 
concentrations at 120 -180 minutes were 25-30% lower than baseline fasting levels 
(figure 4.4.) (p<0.001).
4.3.4. Plasma glucose and whole-bodv insulin sensitivity.
Lacidipine had no significant effect on insulin-stimulated glucose uptake. 
Mean values for insulin sensitivity were 8.9 and 9.6 mg/kg/min after first dose and 2 
weeks lacidipine respectively, compared with 9.1 and 9.7 mg/kg/min following 
placebo. Confidence intervals for this observation were -0.9,1.3 for 2 weeks placebo 
versus 2 weeks lacidipine. Individual values for whole body insulin sensitivity on the 
four study days are shown in table 4.2.
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Figure 4.4: Mean profiles of insulin and C -Pep tide  of 
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SUBJECT FIRST DOSE 
PLACEBO
2 WEEKS 
PLACEBO
FIRST DOSE 
LACIDIPINE
2 WEEKS 
LACIDIPINE
1 5.6 6.8 6.3 7.0
2 8.7 7.4 9.4 8.3
3 9.6 10.0 10.0 12.0
4 11.0 11.7 11.4 12.0
5 8.8 8.9 9.4 8.5
6 8.5 10.2 5.9 7.1
7 10.6 10.4 9.0 11.0
8 7.5 9.8 8.4 6.7
9 9.9 10.4 9.2 8.5
10 11.7 11.8 13.0 11.8
11 7.9 10.3 6.5 10.5
12 9.6 9.2 8.9 11.5
MEAN 9.1 +/- 2.0 9.7 +/-1.5 8.9 +/-1.6 9.6+/-2.1
Table 4.2: Individual values for whole body insulin sensitivity 
of healthy subjects in lacidipine study.
Values expressed as mg glucose/kg/min.
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4.3.5. Serum triglyceride concentrations.
After 2 weeks treatment with lacidipine there was a significant reduction in 
fasting serum triglyceride concentrations at baseline: 0.7 ± 0.3 mmol/1 vs 0.9 + 0.6 
(p< 0.01). In addition, there were significant reductions in serum triglyceride 
concentrations during each clamp; for example, after 2 weeks of lacidipine, 
triglyceride levels fell from 0.7 ±  0.3 to 0.5 ± 0.3 mmol/1 at 180 mins, compared with 
a corresponding change of 0.9 ± 0.6 to 0.7 ±  0.5 mmol/1 after placebo. There was no 
significant effect of lacidipine on insulin-stimulated reductions in triglyceride 
concentration during the clamp (figure 4.5).
4.3.6. Serum potassium concentrations.
There was a significant reduction in serum potassium concentration at the end 
of each clamp: on average 0.5mmol/l (figure 4.5). However, the insulin-stimulated 
reductions in serum potassium concentration were not significantly different between 
the four study days. The reduction in serum potassium was maximal within 60 minutes 
of commencing the infusion; there were no further significant reductions thereafter.
4.3.7. Plasma noradrenaline, plasma renin activity and serum aldosterone.
Baseline plasma renin activity was significantly higher after 2 weeks 
lacidipine compared with placebo; for example, 3.25 ± 0.60 ng Al/ml/hr after 2 weeks 
of lacidipine compared with 1.82 ± 0.79 ng Al/ml/hr following 2 weeks placebo 
(figure 4.6). There were no significant differences in plasma renin activity, serum 
aldosterone or catecholamines during the clamp (figure 4.7).
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4.4. RESULTS OP: HYPERTENSIVE PATIENTS.
4.4.1. Tolerance.
Lacidipine was generally well tolerated and there were no withdrawals from 
the study. In one patient (patient 2, study day 2) the euglycaemic hyperinsulinaemic 
clamp was discontinued after 120 minutes for safety reasons because of failure of the 
Beckman glucose analyser. The plasma glucose at the time was 5.8 mmol/1. The 
hormonal data from all four study days are included for this patient but no value for 
whole body glucose disposal was obtained. Two patients complained of headache on 
acute dosing with lacidipine, but these symptoms had resolved after 2 weeks.
4.4.2. Blood pressure and heart rate.
After 2 weeks treatment with lacidipine there was a significant reduction in 
baseline systolic blood pressure, i.e. 24 hours after the last dose, compared with 
screening values (p<0.05) but no significant difference compared with placebo. After
2 weeks lacidipine, supine values were 136/79 ± 16/12 following lacidipine compared 
with 143/78 ± 22/12 following 2 weeks placebo. Profiles of blood pressure during the
3 hour period of intervention and hyperinsulinaemia were not significantly different 
between study days (figure 4.8). Reflex tachycardia was observed after both first dose 
and after 2 weeks of lacidipine treatment; this increase in heart rate was maximal 60 
minutes after drug administration (figure 4.9).
4.4.3. Serum insulin and C-peptide.
Lacidipine had no significant effect on fasting serum insulin concentrations; 
for example, 10.3±6.6 uU/ml after 2 weeks lacidipine, compared with 6.5±3.0 uU/ml
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after 2 weeks placebo. Serum insulin levels increased to a plateau within the first 60 
minutes of the insulin infusion and there were no significant differences in insulin 
concentration between the 4 study days (figure 4.10); for example, at 120 minutes, 
serum insulin concentrations were 106.8 ± 31.4 and 98.7 ± 29.8 uU/ml for first dose 
and 2 weeks lacidipine respectively, compared with 119.9 ± 28.2 and 100.2 ± 21.4 
uU/ml on the corresponding placebo study days. As with the volunteers, the acute rise 
in serum insulin concentration was associated with a significant decrease in C-peptide 
concentrations; for example at 180 minutes C-peptide levels were about 15% lower 
than baseline fasting levels (figure 4.10) (p<0.05).
4.4.4. Plasma glucose and whole body insulin sensitivity.
Lacidipine had no significant effect on fasting plasma glucose concentrations; 
for example, 5.6±0.9 mmol/L after 2 weeks lacidipine, compared with 5.2+0.4 
mmol/L after 2 weeks placebo. The individual values of whole body insulin 
sensitivity on the four study days are shown in table 4.3. Lacidipine had no significant 
effect on insulin-stimulated glucose uptake. Mean values for insulin sensitivity were 
6.6+3.0 and 5.7±2.2 mg/kg/min after first dose and 2 weeks respectively, compared 
with 6.6±2.4 and 6.5±2.0 mg/kg/min following placebo. Confidence intervals for this 
observation were (-2.0,3.0) for 2 weeks lacidipine versus 2 weeks placebo.
4.4.5. Serum triglyceride and potassium concentrations.
Lacidipine had no effect on fasting serum triglyceride concentrations at 
baseline. There were, however, significant reductions in both triglyceride and 
potassium concentrations during each clamp; for example, after 2 weeks of lacidipine, 
triglyceride levels fell from 2.3 ± 2.0 at baseline to 1.6 ± 2.0 mmol/1 at 180 mins, 
compared with a corresponding change of 2.2 + 1.9 to 1.9 ± 1.6 mmol/1 after placebo
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Figure 4.10: Mean profiles of serum insulin, C-peptide and potassium 
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PATIENT FIRST DOSE 
PLACEBO
2 WEEKS 
PLACEBO
FIRST DOSE 
LACIDIPINE
2 WEEKS 
LACIDIPINE
1 5.5 6.4 5.5 6.0
2 11.0 9.0 9.9 NR
3 2.1 3.0 3.3 2.3
4 8.3 8.0 7.1 8.0
5 6.9 6.6 7.1 7.0
6 6.0 6.0 6.6 5.3
MEAN 6.6+/-2.4 6.5 +/- 2.0 6.6 +/- 3.0 5.7 +/- 2.2
Table 4.3: Individual values for whole body insulin sensitivity 
of hypertensive patients in lacidipine study.
Values expressed as mg glucose/kg/min.
131
(figure 4.11.). Correspondingly, potassium levels fell from 4.0 ± 0.3 to 3.5 ±0.1, and 
from 4.4 + 0.3 to 3.4 ± 0 .1  mmol/L, during the same study days (figure 4.10.). 
Lacidipine had no significant effect on these insulin-stimulated reductions in 
triglyceride and potassium concentrations.
4.4.6. Plasma noradrenaline, plasma renin activity and serum 
aldosterone.
There were no significant differences in plasma catecholamine concentrations 
(figure 4.12), plasma renin activity and serum aldosterone concentrations (figure 4.13) 
following 2 weeks treatment with lacidipine.
4.5. DISCUSSION.
Lacidipine had no effect on whole body insulin-stimulated glucose uptake in 
this group of insulin sensitive healthy male volunteers or in patients with essential 
hypertension. The confidence intervals for the effect of chronic lacidipine on insulin 
sensitivity in the healthy volunteers excludes a 10% decrease and a 15% increase in 
insulin-sensitive glucose transport, i.e. effects similar to those reported with 
hydrochlorothiazide and captopril respectively in patients with essential hypertension 
(Klauser et al, 1991; Pollare et al, 1989b). In the patient group, there was a tendency 
for whole body insulin sensitivity to decrease after 2 weeks lacidipine (5.7 vs 6.6 
mg/kg/min) but the confidence intervals were relatively wide and a type II statistical 
error cannot be excluded. An additional finding in the healthy volunteer group was 
that, after chronic dosing, there was a significant reduction in fasting serum 
triglyceride concentrations.
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It should be borne in mind, however, that the results of this 2 week 
"short-term" study may not necessarily reflect the metabolic effects of long term 
treatment with lacidipine in hypertensive patients.
The role of calcium in glucose-induced insulin release is well established but 
the significance of this intracellular cation in regulation of insulin mediated responses 
remains to be clearly defined (Levy et al, 1989). There are some data, however, that 
suggest that the intracellular calcium concentration correlates with in vivo insulin 
sensitivity (Resnick et al, 1993).
Calcium antagonists may affect glucose and insulin metabolism via a number 
of different mechanisms, e.g. decreased insulin secretion, enhanced release of 
glucagon and altered hepatic glucose output (Giugliano et al, 1980; Charles et al, 
1981). In addition, since blood flow is an important determinant of glucose uptake 
into skeletal muscle (Baron et al, 1991b; Julius et al, 1991), vasodilatation per se may 
increase peripheral glucose utilisation. With dihydropyridines, however, the 
vasodilator response observed after acute dosing is often associated with reflex 
increases in plasma renin activity and catecholamines which might attenuate 
insulin-dependent glucose transport during short-term  administration. This 
sympathetic activation often subsides during chronic treatment when baroreflex 
mechanisms reset. An interesting feature of this study in both the healthy subjects and 
patients with essential hypertension was that increases in plasma noradrenaline and 
significant increases in supine heart rate were observed following the first dose of 
lacidipine and also after 2 weeks of drug administration. This reflex tachycardia 
observed after 2 weeks would be entirely consistent with the once-daily administration 
of a dihydropyridine with a short half life, and in keeping with the observed plasma 
half-life of lacidipine of 1 - 3 hours (Hall et al, 1991). In addition, the lack of a 
significant reduction in supine blood pressure in the patient group 24 hours after the 
last dose compared with placebo does not suggest a sustained 24 hour duration of 
action of lacidipine, although the number of patients studied was small. Despite this
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evidence of sympathetic activation after single dosing and after two weeks there was 
no change in insulin sensitivity compared with placebo administration.
Calcium antagonists have generally been reported to have neutral effects on 
glucose tolerance [chapter 1.3.2.] but there have been conflicting reports about the 
specific effect of dihydropyridines on insulin-stimulated glucose uptake by peripheral 
tissues. Diabetogenic effects of nifedipine (Bhatager et al, 1984) and enhanced insulin 
sensitivity with nitrendipine (Beer et al, 1993) are frequently cited, though 
uncontrolled studies. Many other investigators have reported contrasting effects of 
dihydropyridines on glucoregulatory control (Trost et al, 1984; Gill et al, 1987; 
Chellingsworth et al, 1989; Klauser et al, 1991; Oehman et al, 1985). The 
conflicting results may be due, in part, to limitations of study design (often a lack of 
placebo data), differences in methodology for assessing insulin sensitivity, and 
heterogeneous patient groups in whom the biochemical mechanisms of insulin 
resistance, and drug effects, may not be the same, e.g. in diabetic patients compared 
with hypertensive patients. Many of these uncontrolled studies have used oral glucose 
tolerance tests as an indirect measure of peripheral insulin sensitivity. The difficulty 
with this method is that while profiles of glucose and insulin concentration for groups 
of subjects are usually quite smooth, curves for individuals are often erratic and the 
interpretation is hampered because both dependent variables, glucose and insulin, are 
changing simultaneously [chapter 1.2.1]. To the best of my knowledge, the present 
study is the one of the first double-blind, placebo-controlled, crossover studies to 
evaluate both the acute and short-term metabolic effects of a calcium antagonist in 
healthy subjects and patients with uncomplicated essential hypertension.
In the healthy volunteer group, steady state treatment with lacidipine resulted 
in a significant reduction in fasting serum triglyceride concentrations at baseline, but 
this effect was not observed in the patients with essential hypertension, although the 
number of patients studied was small limiting the power of the study. Increased 
triglyceride tolerance has been reported previously with dihydropyridines (Marrotta et
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al, 1989; Trost & Weidmann, 1987) but the mechanism of this action remains unclear. 
There is limited evidence that calcium antagonists may enhance secretion of 
lipoprotein lipase which is the principal enzyme involved in triglyceride removal 
(Pasanisi et al, 1988). In both groups, lacidipine had no effect on insulin-stimulated 
triglyceride uptake during the 180 minute clamp. Thus, there was no evidence from 
this study that lacidipine exerted an additive or synergistic effect on the effect of 
insulin on triglyceride disposal which is also mediated via lipoprotein lipase.
In summary, this placebo-controlled study has shown a reduction in fasting 
triglyceride levels with lacidipine in the healthy volunteer group and no adverse 
effects on insulin-stimulated uptake of glucose, potassium and triglyceride in both the 
patients with essential hypertension and the healthy volunteers. These data are relevant 
to the debate of the inter-relationship between insulin resistance, non-insulin 
dependent diabetes and essential hypertension. Thus, it is well established that 
lacidipine lowers blood pressure by vasodilatation of resistance arterioles, many of 
which perfuse skeletal muscle, yet in this study, despite significant cardiovascular 
effects (and presumably a modest increase in peripheral blood flow), there was no 
change in whole body insulin sensitivity. In order to draw any firm conclusions 
regarding regional tissue perfusion, however, it would clearly be necessary to repeat a 
similar study with direct measurements of skeletal muscle blood flow.
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CHAPTER 5
THE EFFECTS OF THE ACE INHIBITOR TRANDQLAPRIL 
ON INSULIN SENSITIVITY IN PATIENTS WITH ESSENTIAL 
HYPERTENSION AND IMPAIRED GLUCOSE TOLERANCE OR NIDDM
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5.1. GENERAL INTRODUCTION
Angiotensin converting enzyme (ACE), also known as kininase II, is 
responsible for the enzymatic conversion of angiotensin I to the potent vasoconstrictor 
peptide angiotensin n. The ACE inhibitor drugs, of which captopril and enalapril were 
the first to be licensed for clinical use, have become established in the treatment of 
hypertension (Brunner et al, 1981) and cardiac failure (CONSENSUS, 1987).
There is some debate about the metabolic effects of ACE inhibitors [chapter 
1.3.2]. Anecdotal reports and small clinical studies have suggested increased insulin 
sensitivity following ACE inhibition, but few, if any, of these reports are based upon a 
placebo-controlled, cross-over design. Furthermore, most of the available evidence is 
based on indirect measurements of insulin sensitivity derived from oral or intravenous 
glucose tolerance tests. Thus, deficiencies in study design may be partly responsible 
for conflicting results about the effects of ACE inhibitors on insulin action and 
glycaemic control. For example, it has been shown that single doses of captopril 
increase insulin sensitivity in hypertensive diabetics (Torlone et al, 1991; Uehara et al, 
1994; Rett et al, 1988), whereas others have found no effect (Helve et al, 1993). 
Likewise, there are confusing reports regarding metabolic changes after long-term 
administration of ACE inhibitors; while the studies of Pollare et al (1989a), Paolisso 
et al (1992) and Torlone et al (1993) report an increase in insulin sensitivity with 
captopril, other investigators have reported neutral effects of various ACE inhibitor 
drugs, including captopril (Seefeldt et al, 1990), perindopril (Bak et al,1992), enalapril 
(Moore et al, 1988) and cilazapril (Santoro et al, 1992). However, none of these 
uncontrolled studies is entirely satisfactory. The present study, therefore evaluates the 
effects of a new ACE inhibitor, trandolapril, on whole body insulin sensitivity in 
patients with at least two cardiovascular risk factors, namely glucose intolerance or 
NIDDM, and essential hypertension, using a double-blind, placebo-controlled study 
design with the euglycaemic hyperinsulinaemic clamp.
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5.1.1. Clinical pharmacology of trandolapril
Trandolapril is a potent non-sulphydryl ACE inhibitor which, following oral 
administration is hydrolysed to the active diacid metabolite, trandolaprilat, which 
inhibits both serum and tissue ACE (figure 5.1). Since trandolapril is a pro-drug, it is 
subject to extensive first-pass metabolism and its absolute bioavailability is about 
7.5% (De Ponti et al, 1991). The absolute bioavailability of trandolaprilat administered 
as trandolapril is 40-60%. The pharmacokinetics of trandolapril are linear whereas 
those of trandolaprilat are non linear; this may be explained by the saturation of 
binding to angiotensin converting enzyme (Bree et al, 1992). The effective half-life of 
trandolapril at steady state is between 16 and 24 hours, thus allowing once daily 
dosing. In terms of efficacy, results of double blind placebo-controlled comparative 
studies have shown that trandolapril administered at a single daily dose of 2 to 4mg is 
effective in lowering blood pressure for up to 24 hours in patients with mild to 
moderate hypertension (Mancia et al, 1992). Trandolapril is fully licensed in the U.K. 
(Knoll Pharmaceuticals).
COOH
CH R :' C2H5: Trandolapril 
0  3 - H: Trandolaprilat (diacid)
I
,c
NH
^ C H — -C H 2 ------CH2
COO-R
Figure 5.1: Chemical structure of trandolapril.
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5.2. PATIENTS AND METHODS
The study group consisted of 12 male patients with untreated essential 
hypertension and either impaired glucose tolerance (IGT) or (diet-controlled) NIDDM. 
A further 10 patients were screened and randomised, but were excluded from the study 
after visit 2  because they failed to meet blood pressure or glucose tolerance entry 
criteria. On entry into the study, the median age was 54 years, mean BMI 31.7 ±5.2 
kg/m2 and mean blood pressure 164/95 ± 19/8 mmHg. Four patients were smokers, 
with a mean consumption of 15 cigarettes daily. On the basis of the screening OGTT, 
6  of the patients were diagnosed as having IGT and six had NIDDM according to 
standard WHO criteria [chapter 2.1.2]. All patients were asked to adhere to an 
isocaloric diabetic diet throughout the study consisting of approximately 55% 
carbohydrate, 25% fat and 20% protein [chapter 2.1.4]. They were asked to refrain 
from strenuous exercise and none of the subjects was receiving any proprietary or 
prescription medication. The clinical details of the patients are shown in table 5.1.
Following routine screening [chapter 2.1.1], the study consisted of a single 
blind placebo run-in period for 2 weeks followed by 2  double-blind crossover periods, 
each of 4 weeks, when patients were randomised to receive trandolapril 2mg once 
daily or matching placebo. A 2 week washout period was included between the 
crossover phases [figure 5.2].
Visit I Visit 2
OGTT Clamp
Visit 3 Visit 4 
Clamp Washovt
Visit 5 
Clamp
Trandolapril Placabo
Sing/a
blind
placabo Placabo Trandolapril
WEEKS 0 2 6 8 12
Figure 5.2: Schematic of study design.
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Each subject attended three 5-hour study mornings (once after the single blind 
run in phase, and after each crossover period) to evaluate the metabolic effects of 
trandolapril and the corresponding placebo administrations. On each occasion, 
following an overnight fast, subjects attended the CIRU at 0745 am. After 20 minutes 
supine rest, baseline blood pressure and heart rate measurements were recorded (i.e. 
24 hours after the last dose of trandolapril or placebo). Baseline blood samples were 
collected and trandolapril or placebo was administered orally with 100 mis water.
On each study day, whole-body insulin sensitivity was calculated using the 
euglycaemic hyperinsulinaemic clamp as described in chapter 2.3. The clamp was 
commenced 60 minutes after drug administration. Systolic and diastolic blood 
pressure and heart rate (HR) were recorded in duplicate 60 minutes before and at 15 
minute intervals during the clamp. At baseline, and at 60-minute intervals during the 
3-hour clamp, additional blood samples were collected for measurements of serum 
insulin, C-peptide, serum potassium, triglyceride, plasma noradrenaline, plasma renin 
activity, serum aldosterone concentrations and serum ACE activity.
It was calculated from previous data that this study would have greater than 
80% power to detect a 15% change in insulin sensitivity.
5.3. RESULTS
5.3.1. Tolerance
The euglycaemic clamp was generally well tolerated and there were no adverse 
biochemical events. One patient (no. 11) experienced an episode of micturition 
syncope on his final study day and the procedure was abandoned after 12 0  minutes. 
The plasma glucose concentration at the time was 5.5 mmol/L. As steady-state had not 
been reached, the biochemical data are included in the analyses but the insulin 
sensitivity data from visit 5 have been omitted.
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5.3.2. Blood pressure and heart rate
Chronic treatment with trandolapril was associated with a significant decrease 
in baseline blood pressure (i.e. 24 hours after the last dose) compared with placebo. 
Mean supine values were 167/97 ±  10/7 mmHg after the placebo run-in phase and 
160/93 ± 17/9 and 152/88 ± 13/7 mmHg after 4 weeks of placebo and trandolapril 
respectively (p<0.05 ANOVA). At subsequent time points during the clamp, 
trandolapril was associated with significant decreases in supine blood pressure from 
30 to 180 mins; for example, after 4 weeks treatment, supine blood pressure at 180 
minutes was 138/72 ± 12/7 mm Hg compared with 153/82 ± 13/12 mm Hg after 
placebo (figure 5.3). There were no statistically significant differences in heart rate 
between the 3 study days (figure 5.4).
5.3.4. Serum insulin and C-peptide concentrations
Serum insulin levels increased to a plateau within the first 60 minutes of the 
infusion and there were no significant differences in insulin concentrations between 
the 3 study days (figure 5.5); for exam ple, at 120 m inutes, serum insulin  
concentrations were 143 ± 35,141 ± 47 and 151 ± 30 uU/ml after the placebo run-in, 
and after 4 weeks placebo and trandolapril respectively. The acute rise in serum 
insulin concentration was associated with a significant decrease in endogenous insulin 
release. C-peptide concentrations at 180 minutes were 30-40% lower than baseline 
fasting levels; for example, baseline values were 2.3 ±1.1  ng/ml after 4 weeks 
placebo and 2.3 ±1.1 ng/ml after 4 weeks trandolapril. The corresponding values at 
180 minutes were 1.2 ± 0.1 ng/ml and 1.7 ±  1.3 ng/ml respectively (figure 5.5) 
(p<0.001). Thus, trandolapril appeared to have no effect on insulin clearance.
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5.3.5. Plasma glucose and whole body insulin sensitivity
There was no significant difference in plasma glucose concentrations during 
the 3 clamps; mean fasting plasma glucose concentrations were 6.6  +1.2 mmol/L, 6.8  
±1.4  and 6.8  ±1.2  for the run-in, placebo and trandolapril study days respectively. 
The corresponding mean plasma glucose concentrations for the last 40 minutes of each 
clamp were 5.2 ± 0.3,5.3 ± 0.3 and 5.2 ± 0.3 mmol/L.
There was no significant difference in insulin-stimulated glucose uptake 
between the 3 study days; mean values for whole body insulin sensitivity were 4.6 ± 
1.7,4.7 ±1.9 and 4.7 ± 1.3 mg glucose/kg/min on the run-in, placebo and trandolapril 
study days respectively (p=0.75). Confidence intervals for this observation were 
(-0.6,1.1) for 4 weeks placebo versus 4 weeks trandolapril (table 5.2).
5.3.6 Plasma ACE activity
Trandolapril was associated with a significant decrease in baseline ACE 
activity (i.e. 24 hours after the last dose); mean values were 16.9 ± 6.3 EU/L and 23.4 
± 5.4 EU/L after 4 weeks trandolapril and 4 weeks placebo respectively (p<0.01) 
(figure 5.6). Following drug administration on the active study day, trandolapril was 
associated with a prompt decrease in plasma ACE activity. The mean percentage ACE 
inhibition at 120-180 minutes was 70 ±  15% (figure 5.6).
5.3.7. Serum potassium concentrations
The time course of changes in serum potassium concentrations during the 
clamp are depicted in figure 5.5. There was a significant reduction in serum potassium 
concentration during each clamp; the reduction was maximal within 60 minutes and
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SUBJECT RUN IN 
PLACEBO
4 WEEKS 
PLACEBO
4 WEEKS 
TRANDOLAPRIL
1 4.3 5.0 4.5
2 4.9 3.5 4.3
3 6.5 8.3 5.4
4 3.6 2.2 2.7
5 5.6 6.4 6.4
6 4.1 5.6 4.8
7 6.0 4.9 6.3
8 3.9 4.4 4.5
9 1.4 2.2 2.2
10 5.0 4.8 6.3
11
2.8 2.3 NR
12 7.5 5.2 5.2
MEAN 4.6 +/-1.7 4.7 +/-1.9 4.7 +/- 1.3
Table 5.2: Individual values of whole body insulin 
sensitivity of patients in trandolapril study.
Values expressed as mg glucose/kg/min.
There was no significant effect of trandolapril on insulin sensitivity 
p = 0.75 4 weeks placebo vs. 4 weeks trandolapril (ANOVA).
95% confidence intervals -0.6,1.1.
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there were no further significant reductions thereafter. Treatment with trandolapril had 
no significant effect on insulin-stim ulated reductions in serum potassium  
concentration during the clamp.
5.3.8. Serum aldosterone, plasma renin activity and plasma noradrenaline
The time course of changes in serum aldosterone concentrations during the 
clamp are shown in figure 5.7. Both trandolapril and placebo clamps were associated 
with a significant (P<0.004) decline in plasma aldosterone, and chronic ACE 
inhibition had a further independent (2 0 %) effect of lowering plasma aldosterone 
concentrations; for example, at 120 minutes aldosterone levels were 67 ± 30 pg/ml 
and 100 ± 64 pg/ml after 4 weeks trandolapril and placebo respectively.
There was a significant increase in plasma renin activity after trandolapril 
administration; for example, at 180 minutes plasma renin activity was 4.6 ± 3.7 ng 
Al/min after trandolapril compared with 1.6 ± 0.2 and 1.9 + 1.5 ng Al/min after the 
run-in and placebo phases respectively (p<0.001) (figure 5.7).
The acute rise in serum insulin was not associated with any significant change 
in plasma noradrenaline concentrations during any of the three study days (figure 5.8).
5.3.9. Serum triglyceride concentrations
Treatment with trandolapril was associated with a significant reduction in 
fasting triglyceride concentrations. Thus, baseline values were 2.1 + 0.9 mmol/1 and
2.0 ± 1 .2  following placebo run-in and 4 weeks placebo, compared with 1.4 + 0.6 
mmol/1 after 4 weeks trandolapril treatment (p<0.01). Both the trandolapril and 
placebo clamps were associated with a significant (P<0.05) decline in serum 
triglyceride concentrations during the procedure, but chronic ACE inhibition had no 
further independent effects on lowering plasma triglycerides during the clamp (figure 
5.8).
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5.4. DISCUSSION
This study has shown that in patients with essential hypertension and glucose 
tolerance ACE inhibition with trandolapril reduced blood pressure but had no effect on 
whole body insulin-stimulated glucose uptake. The confidence intervals for the effect 
of trandolapril (after 4 weeks) excludes a 12% increase or a 23% decrease in insulin 
sensitivity. The patients in this study were moderately hypertensive, obese (10 of the 
12 patients had a BMI greater than 27) and glucose intolerant. These three factors are 
all recognised to have additive detrimental effects on insulin sensitivity; accordingly 
the group as a whole were markedly insulin resistant with a mean baseline insulin 
sensitivity of only 4.6 ± 1.3 mg glucose/min, although limited evidence suggests that 
hypertension does not add significantly to the magnitude of the insulin resistance that 
is already present in obesity and NIDDM (Bonora et al, 1993).
The primary aim of this study was to evaluate the effects of chronic ACE 
inhibition on insulin-stimulated glucose uptake. Much recent research has focused on 
mechanisms whereby ACE inhibition might contribute to enhanced glucose uptake by 
skeletal muscle. It has been suggested, for example, that microcirculatory changes in 
muscle, secondary to vascular hypertrophy and rarefaction, might contribute to insulin 
resistance, especially in essential hypertension (Julius et al, 1991) [chapter 1.2.1]. It is 
therefore reasonable to propose that any drug with vasodilatory actions may increase 
insulin sensitivity by virtue of improved regional perfusion. There are uncontrolled 
data suggesting that augmented forearm glucose uptake in diabetics receiving captopril 
is due to a modest increase in limb blood flow (Rett et al, 1986; Jauch et al, 1987; 
Kodama et al, 1990), although another possible mechanism is blockade of the RAS. 
ACE inhibitors reduce angiotensin n  formation and there are in vitro data that suggest 
angiotensin n  has some gluconeogenic and glycogenolytic actions (Kaley et al, 1967; 
Kneer & Lardy, 1983). Thus, activation of the RAS might be expected to have a 
deleterious effect on insulin sensitivity and conversely, ACE inhibition might have an 
opposite effect. This issue is addressed in chapter 6 . The last possible mechanism
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relates to elevation in systemic kinin levels associated with ACE inhibition. Jauch and 
colleagues (1988) reported that during a euglycaemic hyperinsulinaemic clamp, the 
administration of bradykinin was associated with a marked increase in forearm 
glucose uptake and a reduction in hepatic glucose output in post-surgical patients.
Despite various theoretical mechanisms whereby ACE inhibition might 
increase insulin-mediated glucose uptake, the principal finding of this study was that 
ACE inhibition failed to change whole body insulin sensitivity. This result is in 
agreement with previous studies examining the long term effects of ACE inhibition on 
whole body insulin sensitivity with cilazapril (Santoro et al, 1992), and captopril 
(Seghieri et al, 1992), but stands in contrast to well publicised reports that whole body 
insulin sensitivity is increased after chronic ACE inhibition with captopril (Pollare et 
al, 1989a; Torlone et al, 1993; Paolisso et al, 1992). Several explanations may account 
for the disparity in these observations. Firstly, the study of heterogeneous patient 
groups in whom the defect in insulin sensitivity may not be the same is a possible 
explanation. This appears unlikely as an improvement in insulin sensitivity has been 
reported in both glucose tolerant hypertensive patients (Pollare et al, 1989a) and 
diabetic hypertensive patients (Torlone et al, 1993; Paolisso et al, 1992). Secondly, 
differences in experimental design may be responsible. For example, in Pollare*s 
study, a small but significant decrease in insulin sensitivity was observed when 3 
months treatment with captopril was compared with 3 months of treatment with 
hydrochlorothiazide. There was no direct comparison with placebo and the study was 
analysed as parallel groups although it had been designed as a placebo-controlled 
crossover study. Torlone*s study did utilise a placebo-controlled crossover design in 
2 0  diabetic hypertensive patients, but the study was open, used an incremental 
infusion regimen of insulin to evaluate insulin sensitivity during a euglycaemic 
hyperinsulinaemic clamp, and patients were allowed to continue oral hypoglycaemic 
therapy (sulphonylureas and biguanides) throughout the study. And thirdly, it is 
possible that the effect reported is drug-specific, rather than class-specific. 
Uncontrolled studies have suggested that the acute improvement in insulin sensitivity
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observed with captopril therapy is because it contains a sulphydryl group (Jauch et al 
1987; Uehara et al, 1994). Finally, a potentially important feature of the study design 
is whether the ACE inhibitor is administered on the morning of the euglycaemic 
hyperinsulinaemic clamp. As discussed above, it is well established that ACE inhibitor 
drugs acutely vasodilate forearm blood vessels. Such a mechanism of increasing 
insulin sensitivity would be common to any vasodilator and not specific to 
manipulation of the renin-angiotensin system. It is of interest that in the studies of 
Santoro and Seghieri, drug administration was omitted on each study day, whereas in 
the studies demonstrating a beneficial effect of captopril, drug treatment was 
administered immediately prior to the measurement of insulin sensitivity. Lastly, a 
possible explanation is that some studies have had inadequate power to detect a 
change in insulin sensitivity. With reference to my study, this appears unlikely, as the 
95% confidence intervals exclude a 12% increase in insulin sensitivity with 
trandolapril treatment.
These results also clarify the response of the RAS to insulin administration in 
hypertensive diabetic patients. Trovatti and colleagues (1989) reported that during a
1.0 nmol/1 euglycaemic hyperinsulinaemic clamp in healthy subjects, plasma renin 
activity and angiotensin II levels increased while reducing serum aldosterone 
concentrations. The activity of serum ACE was not affected. These hormonal changes 
were abolished by potassium supplementation. My results have confirmed adequate 
inhibition of plasma ACE in this group of hypertensive diabetic patients after once 
daily dosing of trandolapril; 4 weeks therapy was associated with a 30% reduction in 
serum ACE activity compared with placebo at baseline (i.e. 24 hours after the last 
dose) and maximal enzyme inhibition (65-70%) was achieved within 2-4 hours during 
the clamp. ACE activity was unaffected by the insulin stimulus alone. In this group of 
patients, trandolapril treatment was associated with a non significant increase in 
plasma renin activity at baseline and a further significant increase during the clamp. 
The insulin stimulus alone had no effect on plasma renin activity. The rise in plasma 
insulin concentrations induced by intravenous insulin caused marked hypokalaemia
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with mean serum potassium decrements of 0.44 + 0.05 and 0.33 + 0.05 following 4 
weeks placebo and 4 weeks trandolapril respectively; the corresponding decrements in 
serum aldosterone concentrations from baseline were 37% and 52% respectively.
In summary, this is one of the first double-blind, placebo-controlled crossover 
study to evaluate the effects of ACE inhibitor therapy on insulin dependent metabolic 
responses in hypertensive patients with impaired glucose tolerance or NIDDM. 
Despite conflicting evidence from previous uncontrolled studies, there was no 
evidence that sustained ACE inhibition affected whole body insulin sensitivity after 4 
weeks. There has been much speculation as to potential mechanisms whereby ACE 
inhibitors may improve insulin action in both short-term and long- term studies, 
including increased bradykinin concentrations (Dietze 1982), increased blood flow to 
’’insulin sensitive" tissues (Junichi et al, 1991), via an angiotensin n  sparing effect [see 
chapter 6], or even a direct metabolic effect of the ACE inhibitor itself. The present 
data suggest no such beneficial effect with a non-sulphydryl group ACE inhibitor. The 
interpretation of results of studies of insulin sensitivity following treatment with ACE 
inhibitors are highly dependent upon the type of protocol used.
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CHAPTER 6
EFFECTS OF SUB-PRESSOR AND PRESSOR DOSES OF 
ANGIOTENSIN II ON INSULIN SENSITIVITY IN HEALTHY SUBJECTS
AND PATIENTS WITH NIDDM
159
6.1. GENERAL INTRODUCTION.
Peripheral and hepatic insulin resistance, affecting multiple pathways of 
glucose and lipid metabolism, plays a major role in the development of NIDDM 
(DeFronzo et al, 1992) [chapter 1.1.1]. In addition, resistance to insulin-mediated 
glucose transport and hyperinsulinaemia (short of overt diabetes) have been implicated 
as both slow-pressor and atherogenic mechanisms that might contribute to increased 
blood pressure and the long term development of hypertensive vascular complications 
(Reaven, 1988; Ferannini et al, 1987; Stout, 1989). Thus, the significance of common 
associations among metabolic and haemodynamic abnormalities, not only in patients 
with diabetes but also in non-diabetic subjects, has attracted widespread interest 
[chapter 1.1.4]. Since hypertension is at least twice as common in patients with 
NIDDM (independent of body weight and renal dysfunction) and the combination of 
diabetes and hypertension exerts a greater-than-additive effect on coronary heart 
disease risk (Hypertension in Diabetes Study Group 1993), there are important reasons 
for pursuing the nature of this association and for identifying possible sites of 
interaction between mechanisms of blood pressure and endocrine regulation. Thus, at 
both in vitro and in vivo levels, numerous studies have suggested important 
pathophysiological links between glucose and insulin m etabolism  and the 
neuroendocrine systems involved in cardiovascular regulation, particularly the 
renin-angiotensin-aldosterone system (RAS) and the sympathetic nervous system 
(Trovatti et al, 1989; Ferrannini et al, 1992; Rowe et al, 1981). In particular, it has 
been proposed that changes in glucose and insulin metabolism might be secondary to 
hypertensive microvascular complications (Baron et al, 1993), and much discussion 
has focussed on the importance of skeletal muscle blood flow as a determinant of 
glucose disposal rate and the potential insulin-antagonist effects of neuroendocrine 
mechanisms involved in cardiovascular regulation (Baron et al, 1991a; Julius et al, 
1991). Thus, the insulin antagonist effects of catecholamines are well established
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(Deibert & DeFronzo, 1980), and insulin augments vascular reactiv ity  to 
noradrenaline (Gans et al, 1991a).
More recently, attention has focussed on the role of the RAS in insulin 
resistant states. There is evidence that the circulating and tissue-based RAS may be 
implicated in the pathogenesis of common diabetic complications including 
hypertension, microalbuminuria, renal dysfunction and both micro- and macrovascular 
disease. Local generation of angiotensin peptides occurs in the microvascular network 
of skeletal muscle (Vicaut & Hou, 1993), and might potentially regulate blood flow 
distribution to muscle fibres of varying insulin sensitivity. In addition, there is limited 
evidence that components of the RAS directly affect metabolic control; in vitro 
studies have shown hyperglycaemic effects of angiotensin II on the liver, via increased 
glycogenolysis and decreased gluconeogenesis (Kaley et al, 1967). 
Hyperinsulinaemia enhances the aldosterone response to angiotensin II with no effect 
on the vasoconstrictor response (Gans et al, 1991a; Vierhapper et al, 1983). However, 
there are no in vivo data examining the direct metabolic effects of angiotensin n. The 
only evidence comes indirectly from the metabolic effects of renin-angiotensin system 
blockade with angiotensin converting enzyme inhibitor drugs (chapters 1.3.2. and 5.1.) 
and from studies evaluating insulin sensitivity after dietary salt modification; thus, 
there is evidence that angiotensin converting enzyme inhibitors may enhance insulin 
sensitivity in both diabetic and non-diabetic subjects (Pollare et al, 1989a; Prince et al, 
1988; Gans et al, 1991b), even after single-dose administration (Jauch et al, 1987), and 
that dietary salt restriction in "salt-sensitive" normotensive volunteers may increase 
insulin sensitivity (Sharma et al, 1991; Donovan et al, 1993).
Therefore, there is evidence suggesting involvement of the RAS in some of the 
metabolic as well as the haemodynamic features of diabetes. Since the metabolic 
derangements associated with diabetes produce structural as well as functional 
changes in arteries and resistance arterioles, and since haemodynamic responses to 
angiotensin II (as well as other vasoconstrictor peptides) are reported to differ
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significantly in diabetic compared with non-diabetic subjects (Tuck et al, 1980; 
Chrisdieb, 1976), the present study was designed to evaluate the effects of two doses 
of angiotensin II on blood pressure and insulin sensitivity in both healthy subjects and 
in patients with NIDDM.
6.2. SUBJECTS AND METHODS.
Twelve healthy normal volunteers, median age 25 years with mean BMI 24.0 ±
2.0, and eleven diet-controlled patients with NIDDM, median age 56 years, BMI 27.5 
+ 2.0, with mean duration of diabetes of 4 years, gave written informed consent to 
participate in this study. Clinical details of the individual subjects are shown in table
6.1.
Each subject attended three 5-hour study mornings, one week apart, in the 
CIRU to evaluate the effects of placebo, subpressor (1 ng/kg/min) and pressor (5 
ng/kg/min) doses of angiotensin II on insulin stimulated metabolic responses in a 
randomised, double blind, crossover design. On each occasion, following an overnight 
fast, subjects attended the CIRU at 0745 hours. After 20 minutes supine rest, baseline 
blood pressure and heart rate measurements were recorded. On each study day, whole 
body insulin sensitivity was assessed using the euglycaemic hyperinsulinaemic clamp 
[chapter 2.3]. In addition to the infusions of insulin and 20% dextrose, a third constant 
rate infusion of either saline, low (1 ng/kg/min), or high (5 ng/kg/min) dose 
angiotensin II was administered for 180 minutes. The angiotensin II or placebo 
infusion was prepared in 50 mis of saline by an independent investigator in the 
Pharmacy Department at the Western Infirmary, Glasgow and administered 
intravenously into the left antecubital fossa using a Braun perfusor pump.
Systolic and diastolic blood pressure and heart rate were recorded at 15 minute 
intervals during the euglycaemic clamp. At baseline, and at 60 minute intervals
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additional blood samples were collected for measurements of serum insulin, 
C-peptide, plasma renin activity, serum aldosterone and plasma catecholamine 
concentrations. A single 10ml blood sample for the measurement of plasma 
angiotensin II concentration was collected at 120 minutes.
It was calculated from previous work that these studies would have greater 
than 80% power to detect a 15% change in insulin sensitivity in both the healthy 
volunteers and patients with NIDDM.
6.3. RESULTS (I) - HEALTHY VOLUNTEERS.
6.3.1. Tolerance.
The euglycaemic clamp was well tolerated; there were no adverse biochemical 
events and there were no withdrawals from the study.
6.3.2. Blood pressure.
The high dose infusion of angiotensin II was associated with a significant 
increase in supine systolic and diastolic blood pressure from 15 to 180 mins; for 
example, at 150 minutes, supine blood pressure was 131/65 ± 13/11 mmHg compared 
with 118/57 ± 14/10 for the corresponding placebo infusion. The subpressor infusion 
of ANGII was not associated with any significant change in blood pressure (figure 
6.1).
6.3.3. Heart rate.
There were no statistically significant differences in heart rate between the 3 
study days (figure 6 .2 ).
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6.3.4. Serum insulin and C-peptide concentrations.
There were no significant differences in insulin concentrations during the 
clamp on the 3 study days; a "steady-state" insulin concentration was achieved within 
the first 60 minutes of the clamp (figure 6.3). For example, at 120 minutes, serum 
insulin concentrations were 122 ± 22, 129 ± 43 and 126 ± 38 uU/ml after placebo, 
subpressor angiotensin II and pressor ANG II respectively. The acute rise in serum 
insulin was associated with a significant decrease in C-peptide concentrations; for 
example, at 180 minutes values were 20-25% lower than baseline fasting levels (figure 
6.3) (p<0.01).
6.3.5. Plasma glucose and whole body insulin sensitivity.
Angiotensin II had no significant effect on insulin-stimulated glucose uptake. 
Mean values for whole body insulin sensitivity were 10.5 ± 2.0,10.5 ± 2.2 and 10.9 ± 
3.4 mg glucose/kg/min on the placebo, sub-pressor angiotensin II and pressor 
angiotensin II study days respectively (table 6.2). Confidence intervals for this 
observation were (-1.9,1.1) for placebo versus high dose angiotensin n. There was no 
significant difference in plasma glucose concentrations between the clamps on the 3 
study days; mean plasma glucose concentration for the last 40 minutes of the clamp 
were 5.2 ± 0.4, 5.1 ± 0.3 and 5.2 ± 0.3 mmol/1 for placebo, low and high dose 
angiotensin n  respectively. The mean c.v. of plasma glucose concentrations during all 
the clamps was 8%.
6.3.6. Plasma angiotensin II concentrations.
Plasma angiotensin II levels at 120 minutes were 11 ± 5,27 ± 9 and 125 ± 28 
pg/ml after placebo, low dose and high dose infusions of angiotensin II respectively. 
Individual values of plasma angiotensin II concentrations are shown in table 6.3.
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Figure 6.3: Mean profiles of serum insulin, C-peptide and serum potassium 
of healthy subjects during euglycaemic clamp in angiotensin II 
infusion study
■ -  placebo, □ ■ sub-pressor ANQ II, A -  pressor ANG II 
* -  p<0.01 from baseline fasting values
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SUBJECT PLACEBO LOW DOSE 
ANGH
HIGH DOSE 
ANGH
I 10.2 10.0 10.5
2 8.8 5.0 5.0
3 9.3 10.0 10.7
4 12.0 12.0 12.2
5 12.5 11.8 13.5
6 9.5 11.5 10.0
7 9.0 11.0 9.0
8 7.5 9.3 6.5
9 8.8 11.9 9.0
10 13.0 13.1 12.8
11 11.3 9.5 12.0
12 14.0 13.0 18.2
MEAN 10.5 ± 2.0 10.7 + 2.2 10.9 + 3.4
Table 6.2: Individual values of whole body insulin 
sensitivity of healthy subjects in angiotensin II study.
Low dose ANG II = 1 ng/kg/min. High dose ANG II = 5 ng/kg/min. 
Values expressed as mg glucose/kg/min.
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SUBJECT PLACEBO LOW DOSE 
ANGH
HIGH DOSE 
ANGH
1 NR 35.0 20.0
2 9.8 NR 106.4
3 14.4 24.6 140.8
4 8.8 26.7 150.0
5 4.6 20.8 131.5
6 6.8 11.2 159.6
7 4.6 23.6 91.0
8 10.9 24.0 148.2
9 13.2 27.8 139.2
10 17.6 27.0 135.7
11 10.3 46.4 83.2
12 10.7 31.8 85.0
MEAN 11+5 27+9 125 + 28
Table 6.3: Individual values of plasma angiotensin II 
concentrations in healthy subjects at 120 minutes 
in angiotensin II infusion study. NR = not recorded.
Low dose ANG II = 1 ng/kg/min. High dose ANG II = 5 ng/kg/min 
Values expressed as pg/ml.
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6.3.7. Serum potassium concentrations.
There was a significant reduction in serum potassium concentration during 
each clamp; the reduction was maximal within 60 minutes and there were no further 
significant reductions thereafter (figure 6.3). Angiotensin II had no significant effect 
on insulin stimulated reductions in serum potassium concentration during the clamp.
6.3.8. Plasma noradrenaline, plasma renin activity and serum aldosterone.
The high dose of angiotensin II was associated with a significant increase in 
plasma aldosterone concentration at all time points after starting the infusion; for 
example, at 120 minutes, 314 ± 161 pg/ml compared with 62 ± 19 pg/ml during the 
placebo infusion (p<0.001) (figure 6.4). There was no significant change in plasma 
renin activity after angiotensin II administration; for example, after the high dose 
angiotensin II infusion; at 180 minutes the plasma renin activity was 1.62 ± 0.97 ng 
Al/min compared with 1.65 ± 0.63 ng Al/min after the placebo infusion. The mean 
profiles of plasma catecholamines are shown in figure 6.5. There was no significant 
change in the concentrations of plasma noradrenaline or adrenaline during the 
euglycaemic hyperinsulinaemic clamp.
6.4. RESULTS (II) - PATIENTS WITH NIDDM.
6.4.1. Tolerance.
In the patients with NIDDM, the clamp was well tolerated and there were 
neither any adverse biochemical events nor any withdrawals from the study.
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6.4.2. Blood pressure
The high dose infusion of angiotensin II was associated with a significant 
increase in supine systolic and diastolic blood pressure from 15 to 180 mins; for 
example, at 180 minutes, supine blood pressure was 138/81 ± 23/13 mmHg compared 
with 122/68 ± 16/12 for the corresponding placebo infusion. The subpressor infusion 
of angiotensin II had no significant effect on blood pressure (figure 6.6).
6.4.3. Heart rate.
There were no differences in heart rate between the 3 study days (figure 6.7).
6.4.4. Serum insulin and C-peptide concentrations.
The profiles of serum insulin and C-peptide concentrations on the 3 study days 
are depicted in figure 6.8. Serum insulin levels increased to a plateau within the first 
60 minutes of the infusion and there were no significant differences between the 
placebo and angiotensin II study days. The hyperinsulinaemic stimulus was associated 
with a decrease in C-peptide concentrations; at 180 minutes values were 30-40% 
lower than baseline fasting levels (figure 6.8.) (p<0.001).
6.4.5. Plasma glucose and whole body insulin sensitivity.
There was no significant difference in fasting plasma glucose concentrations or 
the glucose concentration during the clamps; mean fasting plasma glucose values on 
the three study days were 8.8 + 3.2 mmol/L, 9.0 + 3.6 mmol/L and 8.8 ± 3.2 mmol/L 
for placebo, sub-pressor angiotensin II and pressor angiotensin II respectively. The 
corresponding mean plasma glucose concentrations for the last 40 minutes of the 
clamp were 5.3 ± 0.3,5.2 ± 0.3 and 5.3 ± 0.3 mmol/L.
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Figure 6.8: Mean profiles of serum insulin, C-peptide and serum potassium 
concentrations of diabetic patients during euglycaemic clamp in 
angiotensin II infusion study
■ * placebo, □ -  sub-pressor ANG II, A -  pressor ANG II.
* -  p<0.001 from corresponding baseline value.
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Angiotensin II increased insulin-stimulated glucose uptake; mean values for 
whole body insulin sensitivity  were 4.3 ± 2.3, 5.5 ± 2.3 and 4.9 ± 2.4 mg 
glucose/kg/min on the corresponding study days (p<0.05). Confidence intervals for 
this observation were (-0.1, -1.7) for placebo versus angiotensin II (table 6.3).
6.4.6 Plasma angiotensin II concentrations.
Plasma angiotensin II levels at 120 minutes were 8 ± 4, 28 ± 9 and 162 ± 45 
pg/ml after placebo, low dose and high dose infusions of angiotensin n  respectively. 
The individual values of plasma angiotensin n  concentrations are shown in table 6.4.
6.4.7. Serum potassium concentrations.
There was a significant reduction in serum potassium concentration on each 
study day which was maximal within 60 minutes after starting the clamp. There were 
no further significant reductions thereafter (figure 6.8). Angiotensin II had no 
significant effect on insulin stimulated reductions in serum potassium during the 
clamp.
6.4.8. Plasma noradrenaline, plasma renin activity and serum aldosterone
concentrations.
The high dose of angiotensin II was associated with a significant increase in 
plasma aldosterone concentration at all time points after starting the infusion; for 
example, at 120 minutes, 325 ± 128 pg/ml compared with 79 ± 25 pg/ml during the 
placebo infusion (p<0.01) (figure 6.9.). There was no significant change in plasma 
renin activity after angiotensin II administration; for example, after the high dose 
angiotensin II infusion; at 180 minutes the plasma renin activity was 1.53 ± 1.58
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PATIENT PLACEBO LOW DOSE 
ANGH
HIGH DOSE 
ANGH
1 4.7 6.6 6.2
2 2.6 4.1 2.8
3 5.2 6.6 4.9
4 8.9 9.5 8.1
5 1.5 2.1 0.6
6 2.8 3.5 5.2
7 5.2 5.5 7.0
8 3.4 3.5 3.3
9 4.1 5.5 5.7
10 7.4 8.2 8.0
11 1.1 5.1 2.1
MEAN 4.3+ 2.3 5.5+ 2.3 4.9+ 2.4
Table 6.4: Individual values of whole body insulin 
sensitivity of patients with diabetes in angiotensin II study.
Low dose ANG II = lng/kg/min. High dose ANG II = 5 ng/kg/min 
Values expressed as mg glucose/kg/min.
Angiotensin II significantly increased insulin sensitivity 
p<0.05; 95% confidence intervals -0.1,-1.7
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PATIENT PLACEBO LOW DOSE 
ANG n
HIGH DOSE 
ANGH
1 NR NR NR
2 9.3 23.0 203.0
3 6.7 18.3 235.0
4 6.0 27.5 164.0
5 9.3 46.0 198.8
6 3.0 24.5 105.6
7 15.2 42.3 NR
8 10.8 30.0 161.3
9 9.1 23.8 168.8
10 3.5 16.0 111.8
11 11.8 29.7 112.8
MEAN 8.5+4.0 28.0 + 9.0 162.1 +45.6
Table 6.5: Individual values of plasma angiotensin II 
concentrations in patients with diabetes at 
120 minutes in angiotensin n  infusion study.
Low dose ANG II = lng/kg/min. High dose ANG II = 5 ng/kg/min 
NR = not recorded.
Values expressed as pg/ml.
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ng/AI/min compared with 1.55 ± 1.08 ng/Al/min after the placebo infusion.
The acute rise in serum insulin was associated with a significant increase in 
plasma noradrenaline and adrenaline concentrations (p<0.01) (figure 6.10). 
Angiotensin II had no significant effect on the increase in plasma catecholamine 
concentrations during the clamp.
6.5. DISCUSSION.
This placebo-controlled study has shown that a 3-hour infusion of angiotensin 
II in healthy volunteers (producing plasma angiotensin II concentrations within the 
pathophysiological range), with or without an increase in blood pressure, has no effect 
on insulin-stim ulated uptake of glucose, potassium and triglycerides under 
euglycaemic hyperinsulinaemic conditions. However, in patients with NIDDM who 
were normotensive and had no evidence of microvascular complications, the results 
clearly demonstrate that under euglycaemic hyperinsulinaemic conditions both low 
and high dose angiotensin II infusions were associated with increases in whole-body 
insulin-stimulated glucose uptake of 28% and 14% respectively, while only the higher 
dose of angiotensin II increased blood pressure.
In both groups of subjects a reproducible insulin stimulus (within the 
physiological range) was obtained on each of the 3 study days; the intra-subject 
variation in plasma insulin concentrations during the last 60 minutes was less than 8% 
in the healthy subjects and 6% in the patients with NIDDM. There was no evidence of 
an effect of angiotensin II on insulin clearance in either group. As with most clamp 
studies, the glucose infusion rate, the critical determinant of glucose disposal, was 
adjusted manually (by myself) in response to frequent measurements of plasma 
glucose at the bedside. It is often recognised but seldom acknowledged that this can 
introduce subjective bias, even though glucose levels are maintained within reasonable
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limits of "euglycaemia". A notable feature of this study was that the investigator 
performing the clamp remained blind to angiotensin II administration. Blood pressure 
recordings were monitored automatically and then stored by the Datascope Accutorr 
semiautomatic sphygmomanometer [chapter 2.2.3], and the changes in arterial 
pressure with high dose angiotensin II were sufficiently small and variable that a 
pressor effect was not immediately obvious. The results in healthy subjects and 
patients with NIDDM will now be discussed independently.
(i) Results in healthy subjects
These observations in healthy subjects have recently been extended by other 
investigators who have reported the effects of various doses of angiotensin II on 
insulin sensitivity in lean, healthy male volunteers (Townsend et al, 1993; Buchanan et 
al, 1993; Townsend & DiPette 1993).
My study has used a placebo-controlled double blind design and has 
demonstrated that the higher dose of angiotensin II (5 ng/kg/min) produced a small, 
sustained increase in blood pressure (11/9 mmHg) but neither this dose nor 
lng/kg/min of ANG II affected glucose uptake under hyperinsulinaemic conditions.
Townsend and colleagues (1993a) in an uncontrolled study of 8 normotensive 
young men, also found that a 3 hour infusion of subpressor (0.3ng/kg/min and 
lng/kg/min) doses of angiotensin II had no effect on insulin sensitivity in normal 
subjects during a euglycaemic clamp. However, the same group using higher doses of 
angiotensin II (10-20 ng/kg/min) have more recently reported increases in glucose 
transport and oxidation in skeletal muscle in 8 healthy subjects which generally tended 
to parallel the associated increments in blood pressure (Townsend & DiPette 1993b). 
This study however was not placebo-controlled.
Buchanan and colleagues (1993), in a study of 7 healthy males, performed a 
270 minute euglycaemic hyperinsulinaemic clamp on 3 occasions each, one week
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apart. On each study day, for the final 90 minutes of the clamp, they infused one of 
three dose pairs of angiotensin II: 0.5 and 2.0, 2.5 and 10.0, 5.0 and 20 ng/kg/min. 
The lower of each pair was given for 30 minutes followed by the higher dose for 60 
minutes. Despite the fact that there was no placebo control in this study which would 
have confirmed that the clamp had indeed reached steady state prior to the angiotensin 
II infusion, they reported a convincing dose-related increase in insulin-mediated 
glucose disposal of 41% with the lOng/kg/min infusion and 72% with the 20ng/kg/min 
infusion (Buchanan et al, 1993). Thus, the available data suggest that in healthy 
subjects angiotensin II increases glucose disposal in a dose-dependent fashion.
(ii) Results in patients with NIDDM
To the best of my knowledge, the effects of angiotensin II on glucose and 
insulin metabolism in patients with NIDDM have not been previously reported. In 
comparison with the above studies in normal subjects, the data from the patients with 
NIDDM suggest that these patients are more sensitive to the metabolic as well as the 
haemodynamic effects of angiotensin n. Perhaps the most significant finding in this 
study is that the metabolic response to angiotensin II was completely independent of 
its effect on blood pressure. Both active infusions increased insulin sensitivity and 
the effect on glucose uptake tended to be greater with the low-dose infusion which had 
no effect on arterial pressure. This dissociation of the haemodynamic and metabolic 
effects of angiotensin II was not observed in healthy volunteers and is difficult to 
reconcile with the recently proposed mechanisms of angiotensin II-induced insulin 
sensitisation (Townsend & DiPette, 1993; Buchanan et al, 1993). In particular, my 
results suggest that a haemodynamic (i.e. vasoconstrictor) effect of angiotensin II, 
presumably involving redistribution of blood flow from the splanchnic and visceral 
(especially renal) circulation towards skeletal muscle, might not be the sole (or even 
principal) underlying mechanism in patients with NIDDM. Three specific features of
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the present data suggest, albeit indirectly, that mechanisms in addition to 
haemodynamic changes might be contributing to the observed increase in insulin 
sensitivity in patients with NIDDM:
(1) Although blood flow was not directly measured, it seems unlikely that the 
metabolic response to such a low dose of angiotensin II (1 ng/kg/min) could be 
entirely accounted for by an increase in blood flow through large conduit arteries, e.g. 
to the limbs, in the absence of an effect on blood pressure.
(2) Both Buchanan and colleagues (1993) and Townsend and DiPette (1993b) 
have shown that high doses of angiotensin II (10-20 ng/kg/min) significantly decrease 
insulin clearance due to a reduction in renal plasma flow. Since there was no evidence 
of this effect in the present study, it would appear that the 25% increase in glucose 
uptake occurred without evidence of significant vasoconstriction in renal tissues.
(3) If changes in muscle perfusion were solely responsible for the increase in 
glucose extraction, it seems somewhat surprising that there was not a similar increase 
in potassium and triglyceride disposal under euglycaemic hyperinsulinaemic 
conditions.
Thus several features of the my study suggest that in patients with NIDDM 
mechanisms in addition to haemodynamic changes and simple redistribution of cardiac 
output might be contributing to angiotensin-II induced insulin sensitisation.
These data would be consistent with a direct biochemical effect of angiotensin 
II and since diabetic individuals are more sensitive to both the endocrine (i.e. 
aldosterone) and cardiovascular effects of the peptide (Tuck et al, 1990; Christlieb 
1980) it is conceivable that such a response is much less evident in normal subjects. 
An additional mechanism that has not been considered relates to local vascular effects
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of angiotensin II within skeletal muscles. Buchanan and colleagues (1993) have 
postulated that the metabolic effects of angiotensin II are due to large vessel 
redistribution of blood flow away from relatively insulin-resistant tissues (particularly 
the kidney) towards muscular areas (e.g. the limbs), but it is also possible that 
angiotensin II produces significant vascular effects (independent of major changes in 
blood pressure) at the level of the microcirculation. This is consistent with recent 
observations that local generation of angiotensin peptides occurs in the microvascular 
network of skeletal muscles (Vicaut & Hou 1993) and this might serve a paracrine role 
in regulating the perfusion of muscle fibres of varying insulin sensitivity (James et al, 
1986). Thus, subpressor doses of angiotensin n, while having little effect on larger 
arterioles, might still redistribute blood flow within skeletal muscles of mixed 
fibre-type composition, producing a net increase in perfusion of more insulin-sensitive 
(type 1) fibres. Such an effect might also serve a useful function in "fight or flight" 
reactions, since angiotensin n  increases during the stress response.
The present study has not excluded an effect of angiotensin II on hepatic 
glucose production. However, it has been shown that angiotensin II has no effect on 
hepatic glucose production in normal subjects (Buchanan et al, 1993), and limited data 
from in vitro experiments suggest a tendency for angiotensin II to increase 
glycogenolysis and decrease gluconeogenesis (Kaley et al, 1967), which would have 
tended to give an opposite result.
(iii) General discussion
The results of this study contribute information on the role of neuroendocrine 
regulation in insulin resistant states. The insulin antagonist effects of catecholamines 
and cortisol are well established. Reflex activation of the sympathetic nervous system 
has been directly associated with the development of metabolic complications in 
cardiovascular disease. For example, peripheral and hepatic insulin resistance in
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patients with congestive heart failure is directly related to increased plasma 
concentrations of noradrenaline (Paolisso et al, 1991). Thus, sympathetic activation 
clearly worsens insulin sensitivity but in contrast the present data suggest that the 
vasoconstrictor angiotensin II increases peripheral insulin sensitivity. This is 
somewhat unexpected, especially in view of some in vitro evidence showing that 
angiotensin II might increase plasma glucose levels via increased glycogenolysis and 
decreased gluconeogenesis (Kaley et al, 1967).
These data are also relevant to the present debate concerning the metabolic 
effects of ACE inhibitors, and specifically the reports that ACE inhibitors improve 
various parameters of glycaemic control in both diabetic and non-diabetic subjects 
(Pollare et al, 1989; Prince et al, 1988) [chapters 1.3.2 and chapter 5]. In the past it has 
been suggested that removal of angiotensin II-mediated effects on potassium and 
glucose transport are important (Ferrannini et al, 1992) but, conversely, the present 
studies suggest that the metabolic effects of ACE inhibition are probably independent 
of angiotensin II. Indeed, if the purported effects of ACE inhibitors were mediated via 
an angiotensin II sparing effect, the present data would suggest that angiotensin 
converting enzyme inhibitors would exert a deleterious effect on insulin sensitivity. 
However, the results of this acute study may not necessarily reflect the long term 
metabolic effects of ACE inhibitors described in hypertensive and diabetic (insulin 
resistant) patients.
An interesting biochemical feature of this study is that plasma renin activity 
did not show the expected decrease during angiotensin II administration. This may be 
explained by an interaction with the clamp; previous studies have demonstrated that 
under euglycaemic conditions insulin induced hypokalaemia increases plasma renin 
activity (Trovatti et al, 1989). Furthermore, the lower dose of angiotensin II was only 
associated with a modest increase in aldosterone concentration; this is perhaps 
surprising since insulin has been shown to enhance angiotensin II induced aldosterone 
secretion (Rocchini et al, 1990). This may be related to hypokalaemia induced by the
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clamp, since the weight of evidence indicates that serum potassium concentration is 
the key determinant to the aldosterone response to other stimuli (Young et al, 1984).
Another interesting finding was the increase in plasma catecholamines 
observed at the end of the clamp in the diabetic patients. A possible explanation for 
this observation is that when plasma glucose is maintained at 5.2 mmol/L, these 
patients with NIDDM (who are accustomed to a fasting glucose concentration of 8.0 
to 12.0 mmol/L) experience "relative" hypoglycaemia which induces an adrenergic 
response.
In conclusion, acute administration of angiotensin II at physiological plasma 
concentrations did not alter whole-body insulin sensitivity in healthy subjects but 
increased whole-body insulin sensitivity in patients with NIDDM. In contrast to recent 
observations in healthy volunteers which report a dose-related increase in glucose 
disposal with higher doses of angiotensin II than used in this study, the metabolic 
effects of angiotensin II in patients with NIDDM were observed at lower doses of 
angiotensin II and were independent of changes in blood pressure. While angiotensin 
II-induced redistribution of blood flow is likely to be an important underlying 
mechanism, these data suggest that additional effects of angiotensin II (including 
biochemical and/or microvascular changes within skeletal muscle) might be 
contributing to the metabolic response in NIDDM.
189
CHAPTER 7
DETERMINANTS OF INSULIN SENSITIVITY IN HEALTH AND DISEASE
190
7.1. GENERAL INTRODUCTION
Despite attempts at standardisation, recent studies have demonstrated that the 
oral glucose tolerance test (OGTT) has poor reproducibility and therefore does not 
constitute a controlled physiological stimulus. This casts further doubt on the test’s 
validity not only in the clinical research setting but also in the accurate classification 
of glucose intolerance (Yudkin et al, 1990). In order to investigate the complex 
interplay of insulin secretion and insulin action in pathophysiological states, 
standardised experimental techniques have been devised to quantify pancreatic insulin 
secretion and the sensitivity of target tissues to insulin [chapter 1.2]. Thus, the 
euglycaemic hyperinsulinaemic clamp, the minimal model technique and the insulin 
suppression test were devised as reproducible methods of determining the sensitivity 
of insulin-mediated responses, whereas the hyperglycaemic clamp can be used to 
quantify pancreatic sensitivity to glucose-induced insulin secretion. Whilst these tests 
define specific aspects of glucoregulatory control, some authors claim they are 
"unphysiological" (Ng et al, 1988). Furthermore, because- these techniques are 
relatively labour intensive, expensive and generally impractical for large numbers of 
subjects, epidemiological studies have relied on the simpler OGTT to infer 
abnormalities in insulin secretion and insulin resistance. For example, many of the 
large population-based studies linking insulin resistance to hypertension (for example, 
Modan et al, 1985; Asch et al, 1991) [see chapter 1.1.2] used fasting plasma insulin 
concentrations as a surrogate marker of peripheral insulin resistance. The problem 
with this approach is that few, if any, previous studies have properly validated the 
OGTT (or indeed other morphometric or biochemical indices) against direct 
measurements of insulin sensitivity derived from the euglycaemic hyperinsulinaemic 
clamp, which is arguably the "gold standard" for determining insulin-stimulated 
responses.
Having evaluated the methodology of the euglycaemic hyperinsulinaemic 
clamp and characterised insulin sensitivity not only in hypertensive, diabetic and
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diabetic hypertensive patients but also in healthy subjects, analysis of the entire data 
base is suitable for identifying factors which may account for the large inter-subject 
variability in insulin sensitivity. Thus, the principal aim of this study was to determine 
which clinical measurements, e.g. body weight, BMI, blood pressure etc. were the 
major determinants of insulin sensitivity in both normal individuals and in a range of 
patients with hypertension, impaired glucose tolerance and NIDDM. The following 
biochemical and morphometric indices were included: basal plasma glucose and 
insulin concentrations, weight, BMI, blood pressure, sex, waist hip-ratio, fasting 
cholesterol and triglycerides.
7.2. PATIENTS AND METHODS
7.2.1. General Methods.
Four clinical research studies have been described in this thesis which, in total, 
include measurements of whole body insulin sensitivity by means of the euglycaemic 
hyperinsulinaemic clamp in 65 individuals. In addition, 10 patients who were screened 
but excluded from the trandolapril study [chapter 5] were also included for the purpose 
of the present analysis. These patients underwent an OGTT and had insulin sensitivity 
measured during the placebo run-in, but they failed to meet the entry criteria for the 
study; 7 had impaired glucose tolerance or NIDDM but were not hypertensive, and 3 
were hypertensive but not glucose intolerant. Thus, by including data from these 
subjects, OGTT’s and euglycaemic clamps were performed in a total of 75 
individuals.
Each subject underwent a standard 75g OGTT at screening [chapter 2.2.4]; 
blood samples were collected for serum insulin and plasma glucose profiles at baseline 
and at 30 minute intervals until 120 minutes. On at least one occasion thereafter (while 
on placebo therapy), each individual attended the CIRU when a euglycaemic 
hyperinsulinaemic clamp was performed using arterialised blood samples to derive the
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calculation of whole-body insulin sensitivity. The clinical protocol is described in 
detail in chapter 2.3, and the same method was used in all subjects to derive insulin 
sensitivity (M) in mg glucose/kg/min.
7.2.2. Statistical analysis
In each subject, a number of metabolic, demographic, morphometric, 
neuro-endocrine and biochemical variables which may influence insulin sensitivity 
were recorded. The measurement techniques are described in chapter 2.
(i) Metabolic variables
- Fasting serum insulin concentration.
- Fasting plasma glucose concentration.
(ii) Haemodynamic variables.
- Screening supine systolic blood pressure.
- Screening supine diastolic blood pressure.
- Screening supine mean arterial blood pressure.
(iii) Biochemical variables.
- Serum total cholesterol.
- Serum triglycerides.
- Serum potassium.
(iv) Demographic and morphometric variables.
-Age
- Body mass index
- Waist hip ratio
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(v) Neuro-endocrine variables
- Baseline noradrenaline concentrations.
- Baseline aldosterone concentrations.
- Baseline plasma renin activity.
Data from the OGTT were used to calculate the ratio of fasting insulin to 
fasting glucose and the ratio of the 120 minute postload insulin to the fasting insulin 
(Saad et al, 1988). The area under the insulin and glucose curves in the OGTT were 
calculated by the trapezoidal rule.
The relationship between one or more of these variables and insulin sensitivity 
(M) was investigated in two ways; firstly, the relationship of individual parameters to 
insulin sensitivity was assessed by simple correlation analysis of the form;
y = AX + Z
where X is the independent variable, e.g. BMI or fasting plasm a glucose 
concentration, and y is the dependent variable , i.e. insulin sensitivity in mg 
glucose/kg/min. All scatterplots were inspected to detect non-linear associations and 
outliers. Thus, a square array of each pair of variables was constructed and this 
correlation matrix was then used as a starting point for stepwise linear regression 
analysis.
Stepwise linear regression analysis was performed by fitting a hierarchy of 
linear models to the distribution of values for insulin sensitivity. Thus, M is defined as 
the dependent variable and the independent variables are modelled seperately and in 
all combinations with each other to find the best overall fit. The R2 value obtained for 
each model represents the percentage variability in insulin sensitivity which can be 
accounted for by the variable or variables in the model. One, 2, and 3 variable models 
were fitted sequentially to the data, e.g.:
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y = AXx + Z (1)
y = AXj + BX2 + Z (2) 
y = AXj + BX2 + CX3 + Z (3)
where y is the M value, X v X2 and X3 are the independent variables, e.g. BMI, fasting 
glucose, triglycerides, etc., and A, B, and C are the coefficients. A forward stepping 
selection procedure was utilised. Thus, one variable was selected and each remaining 
variable was considered individually; the one with the highest F-to-enter statistic was 
then included in the model. To guard against overfitting, the value of R2 for the best 
subset of each size was plotted against the size of the subset; and the "optimal" 
number of regressors was identified where the plot began to level off. Because of the 
large number of comparisons, only p values of less than 0.001 were taken to indicate 
statistical significance.
The correlation coefficients and multiple linear regression analyses were firstly 
performed for the group as a whole (n=75). Subsequently, sub-group analysis was 
performed for the "insulin resistant" patient group with impaired glucose tolerance or 
NIDDM (n=30).
In an attempt to evaluate which variables (either those that influence insulin 
sensitivity, e.g. BMI and blood pressure, or those variables that reflect insulin 
sensitivity, e.g. fasting insulin concentrations), were of the greatest value in the 
prediction of insulin sensitivity in an individual, 95% confidence intervals for 
predicted values of M and the prediction error were calculated.
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7.3. RESULTS
7.3.1. General
Table 7.1 shows the mean age, sex, BMI and blood pressure together with 
fasting and 2 hour post-load plasma glucose concentrations, in each of the subject 
categories. The healthy volunteers were all male, significantly younger, less heavy and 
had significantly lower blood pressures compared with the patient groups. Thus, direct 
comparison between the three groups (normal, hypertensive and glucose intolerant) 
was not feasible. On analysis of the group as a whole, there was a wide range in 
insulin sensitivity as derived from the euglycaemic hyperinsulinaemic clamp; whole 
body glucose uptake ranged from 1.1 mg/kg/min in the most insulin resistant 
individual to 16.2 mg/kg/min in the most insulin sensitive subject. The number of 
cigarette smokers (22%) in the whole group was too small to allow any formal 
statistical analysis.
7.3.2. Correlation analysis
(i) All subjects (n=75)
Table 7.2 shows the correlation coefficients for one-variable analysis of insulin 
sensitivity versus the various demographic, metabolic, haemodynamic and 
biochemical measurements for all 75 subjects. A number of measurements correlated 
with insulin sensitivity. Strongest negative correlations were for identified for age 
(r=-0.64), BMI (r--0 .68 ), fasting plasma glucose concentration (r=-0.68) and 
diastolic blood pressure (r--0.62), as shown in figure 7.1. There were also significant 
negative correlations with fasting insulin and total cholesterol concentrations, but there 
was no correlation with fasting triglycerides. Similarly, there was no significant 
correlation between serum aldosterone, serum potassium, plasma renin activity or 
plasma noradrenaline concentrations and insulin sensitivity.
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Healthy
Subjects
(n=36)
NIDDM or IGT 
Patients 
(n=30)
Hypertensive
Patients
(n=9)
Sex 36 males 27 males 
3 females
4 males
5 females
Age
(median)
26 years 
range 18-43
56 years 
range 33-73
50 years 
range 33-66
BMI
(kg/m2)
23.8 +/- 3.2 30.0+/-5.5 263 +/- 2.4
Blood pressure 
(mm/Hg)
118/65+/-11/8 157/89 +/- 21/11 174/93 +/-16/7
Fasting glucose 
(mmol/L)
5.0 +/- 0.4 7.9 +/- 23 5.1 +/- 0.8
120 min glucose 
(OGTT)
4.9+/-1.0 12.8+/-4.0 5.3 +/-1.1
Fasting insulin 
(uU/ml)
9.0 +/- 3.7 20.1 +/-13.4 8.1+/-4.3
120 min insulin 
(OGTT)
25.0 +/-13.1 90.1 +/- 66.0 48.7 +/-18.2
AUC glucose 
(OGTT)
810+/-128 1512+/-35.8 935 +/- 234
AUC insulin 
(OGTT)
5500 +/- 2957 8806 +/- 6297 8466+/-4211
Triglycerides
(mmol/L)
1.19+/-0.88 2.01+/-0.88 1.46+/-1.59
Cholesterol
(mmol/L)
4.41 +/-1.18 5.70+/-0.84 6.20 +/- 0.50
WHR 0.94 +/- 0.09 1.00+/-0.07 0.78 +/- 0.5
M Value 
(mg/kg/min)
10.4+/-2.3 4.5 +/-1.9 7.6 +/- 2.1
M value range 
(mg/kg/min)
6.2-16.2 0000tfHH 5.8 -10.0
Table 7.1: Demographic, metabolic and biochemical characteristics 
of normal subjects, glucose intolerant patients and hypertensive 
patients studied. Data shown are mean +/- S.D. unless otherwise stated 
IGT = impaired glucose tolerance, AUC = area under the curve 
BMI = body mass index.
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rvalue pvalue
Age -0.64 <0.001
Weight -0.50 <0.001
Height 0.32 N.S
BMI -0.68 <0.001
Systolic BP -0.50 <0.001
Diastolic BP -0.62 <0.001
Mean Arterial BP -0.59 <0.001
Fasting glucose -0.68 <0.001
Fasting insulin -0.58 <0.001
AUC glucose (OGTT) -0.67 <0.001
AUC insulin (OGTT) -0.38 N.S.
Triglycerides -0.25 N.S.
Cholesterol -0.54 <0.001
Noradrenaline -0.38 N.S.
Plasma renin activity -0.05 N.S.
Potassium -0.07 N.S.
Aldosterone -0.38 N.S.
Waist Hip Ratio -0.52 <0.001
Table 7.2: Correlation between demographic, metabolic and haemodynamic 
measurements and insulin sensitivity derived from the euglycaemic hyperinsulinaemic 
clamp in the 75 individual subjects studied.
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Figure 7.1: Correlations of body mass index (top panel), age (middle panel) and 
fasting plasma glucose (lower panel) to whole body insulin sensitivity in all 75 
subjects studied.
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(ii) Patients with impaired glucose tolerance or NIDDM (n=30)
Table 7.3 shows the correlations between insulin sensitivity and the various 
individual parameters for the 30 patients with either impaired glucose tolerance or 
NIDDM. In these subjects, the strongest negative correlations were with waist hip 
ratio (r=-0.81), BMI (r=-0.59), fasting insulin (r=-0.53) and the ratio of the 120 
minute post load insulin to the fasting insulin (r=0.60). These correlations are 
represented diagramatically in figure 7.2. There was also a significant correlation for 
fasting cholesterol and fasting triglyceride concentrations.
7.3.2. Multiple linear regression analysis
For the group as a whole and the subgroup of patients with impaired glucose 
tolerance or NIDDM, insulin sensitivity was modelled with independent variables 
using stepwise least squares linear regression analysis [section 7.2.2]. The results are 
summarised in table 7.4, which presents the R2 values for each of the one-variable 
analyses and the combination of variables that was most appropriate for predicting the 
inter-subject differences in insulin sensitivity in the 2 groups. Thus, for all subjects, 
BMI was singularly the best predictor of insulin sensitivity, accounting for 45% of the 
variability in M, while age and diastolic blood pressure accounted for 41% and 38% 
respectively (table 7.4). Incorporating additional variables in more complex models 
improved the correlation; for example, the 3 variable model shown below explained 
67% of the variability in insulin sensitivity:
M value = 36.4 - 0.254 BMI - 0.126 DBP - 12.7 WHR
The prediction error for this equation was 1.8+1.6 mg glucose kg/min. Using 
regression analysis, fasting insulin alone explained only 27% of the variability in M 
values observed. The prediction error was 2.8+2.0 mg glucose/kg/min.
200
r value gxalu£
Age
Weight
Height
BMI
Systolic BP 
Diastolic BP 
Mean Arterial BP 
Fasting glucose 
Fasting insulin 
AUC glucose (OGTT)
AUC insulin (OGTT)
Fast, glucose/fast, insulin
120 min insulin/fast insulin
30 min insulin/30 min glucose
Triglycerides
Cholesterol
Noradrenaline
Plasma renin activity
Potassium
Aldosterone
Waist Hip Ratio
-0.31 N.S.
-0.54 <0.001
-0.13 N.S.
-0.59 <0.001
-0.16 N.S.
0.06 N.S.
0.12 N.S.
-0.29 N.S.
-0.62 <0.001
-0.11 N.S.
-0.24 N.S.
-0.34 N.S.
0.60 <0.001
-0.21 N.S.
-0.54 <0.001
-0.54 <0.001
-0.38 N.S.
-0.19 N.S.
-0.17 N.S.
-0.24 N.S.
-0.81 <0.001
Table 7.3: Correlation between demographic, metabolic and haemodynamic 
measurements and insulin sensitivity derived from the euglycaemic 
hyperinsulinaemic clamp in the 30 patients with impaired glucose tolerance or 
NIDDM.
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For the patients with impaired glucose tolerance or NIDDM, waist hip ratio 
was singularly the best predictor of insulin sensitivity with a R2 value of 65%. 
However, the most appropriate model to describe the variability in insulin sensitivity 
was a 2 variable model incorporating waist hip ratio and BMI. This model accounted 
for 79% and was defined by the equation:
M value = 26.7 - 0.137 BMI -183  WHR
The prediction error for this equation was 1.1+1.4 mg glucose kg/min. Using 
regression analysis, fasting insulin alone explained only 24% of the variability in M 
values observed. The prediction error was 1.9±1.4 mg glucose/kg/min.
7.4. DISCUSSION
When studying insulin sensitivity it is necessary for the investigator to have a 
precise measure of quantifying glucose disposal in response to insulin. Many recent 
epidemiological studies have inferred the presence of insulin resistance from OGTT 
data but few studies have validated the OGTT against formal measurements of insulin 
sensitivity derived from the euglycaemic hyperinsulinaemic clamp. The purpose of 
this study was therefore to investigate which variables, if  any, are the best 
determinants of insulin sensitivity in an individual.
A number of haemodynamic, morphometric, metabolic and biochemical 
markers were examined in relation to insulin sensitivity; the results clearly indicate 
that insulin sensitivity is correlated with age independently of BMI or blood pressure. 
This is consistent with previous reports that insulin resistance is a characteristic feature 
of the normal ageing process (Rowe et al, 1983). Likewise, blood pressure was 
correlated with insulin insensitivity independently of age and BMI, and glucose 
tolerance. However, for the whole group, by far the most important determinants of 
insulin sensitivity as derived by the euglycaemic hyperinsulinaemic clamp was the 
BMI. Of the data derived from the OGTT, the fasting insulin concentration showed the
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best correlation with insulin sensitivity; more complex calculations of AUC’s of 
insulin or glucose profiles, or ratios of insulin and glucose concentrations conferred 
no advantage.
In the patients with NIDDM or impaired glucose tolerance, fasting insulin 
concentrations correlated with insulin sensitivity but better predictors of insulin 
sensitivity were BMI and waist hip ratio. The insulin and glucose responses to an 
OGTT were poor predictors of insulin sensitivity. A possible explanation for this is the 
well recognised "Starling’s curve of the pancreas" in patients with NIDDM, whereby, 
in normal weight individuals with impaired glucose tolerance and in mild diabetics, 
the plasma insulin response to ingested glucose increases progressively until the 
fasting glucose reaches approximately 6.8 mmol/L when progressive increases in 
plasma glucose levels are associated with a progressive decline in insulin secretion 
(DeFronzo, 1988). Another possible explanation of the poor correlation of plasma 
insulin profiles during an OGTT is the possible confounding effect of defective insulin 
processing or secretion in patients with established NIDDM tending to discrepant 
measurements of insulin in these subjects (Temple et al, 1991) [chapter 1.1.3]. This is 
supported by a recent report that fasting levels of split proinsulin correlated well with 
insulin sensitivity (as measured by an insulin tolerance test) in both healthy subjects 
and patients with impaired glucose tolerance or NIDDM (Phillips et al, 1994).
In summary, these data suggest good correlation between BMI, WHR and 
fasting insulin concentrations and derived measurements of insulin sensitivity. Thus, 
these variables may individually explain up to 50% of the inter-subject variability in 
the M value. Unfortunately however, when these variables are used individually, they 
are insufficiently robust to predict insulin sensitivity in an individual subject. This is 
demonstrated by the prediction errors of the regression equations [section 7.3.2]. For 
example, if an attempt is made to predict the M value of an individual [e.g. volunteer 
no.l of the lacidipine study] in whom the M value as determined by the euglycaemic 
hyperinsulinaemic clamp was 13.9 mg glucose/kg/min, the regression equation 
incorporating BMI, diastolic blood pressure and waist hip ratio [section 7.3.2] predicts
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an M value of 11.4 mg glucose/kg/min. The 95% confidence intervals of this 
prediction are wide (6.0,16.8 mg glucose kg/min). Thus, these variables are imprecise 
when used as predictors of insulin sensitivity in an individual as they may 
underestimate or overestimate the M value by up to 50%.
In conclusion, I have demonstrated that factors such as BMI, blood pressure 
and waist hip ratio may explain up to 50% of the observed inter-subject variability in 
M as determined by the euglycaemic hyperinsulinaemic clamp. It is evident, however, 
that these factors are of little value when used to predict the insulin sensitivity of an 
individual. Thus, an accurate measurement of insulin sensitivity requires a 
sophisticated technique such as the euglycaemic clamp; estimates of insulin resistance 
derived from OGTT and morphometric data in epidemiological studies of glucose 
tolerance should be viewed with caution.
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CHAPTER 8
GENERAL DISCUSSION
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8.1. DISCUSSION
Reports from epidemiological studies (Modan et al, 1985) that patients with 
essential hypertension are hyperinsulinaemic when compared with controls, and from 
glucose clamp studies demonstrating that hypertensive patients are resistant to insulin 
stimulated glucose uptake (Ferrannini et al, 1987; Pollare et al, 1990) have fuelled an 
increasing recognition that high blood pressure is only one facet of a metabolic 
syndrome that represents a cluster of risk factors for long-term development of 
cardiovascular disease. Thus, glucose intolerance, hyperinsulinaemia, altered cell 
membrane structure and function, hypertriglyceridaemia and altered concentrations of 
cholesterol subfractions are frequently found in patients with primary hypertension, 
and may contribute to the risk of atherosclerosis conferred by high blood pressure. 
Failure to address these metabolic aspects may partly explain the shortfall in the 
reduction in morbidity and mortality from coronary heart disease which might have 
been anticipated in several of the large studies of the treatment of mild-to-moderate 
hypertension. Thus, in terms of the treatment of hypertension, much recent research 
has focussed on the m etabolic as well as the haem odynam ic effects of 
pharmacological intervention.
This thesis is comprised of a series of studies which have utilised the 
euglycaemic hyperinsulinaemic clamp to measure insulin sensitivity in normal 
subjects, patients with hypertension and patients with impaired glucose tolerance or 
NIDDM.
(i) Evaluation of the euglycaemic hyperinsulinaemic clamp
A comprehensive understanding of the prevalence of insulin resistance and the 
ability to evaluate the effects of pharmacological and non-pharmacological 
interventions on insulin sensitivity is dependent upon a precise and reproducible 
technique to quantify the body’s response to insulin. The simplest, and perhaps the 
crudest, estimation of insulin sensitivity is provided by the OGTT. However,the 
resultant plasma insulin and glucose concentrations following an OGTT are the result
208
of insulin secretion as well as insulin action of an individual; thus, mean curves for a 
population are smooth but individual curves are notoriously erratic. Thus, techniques 
have been devised which provide a more accurate measurement of insulin action 
(euglycaemic hyperinsulinaemic clamp, IVGTT minimal model technique, CIGMA) 
and insulin secretion (hyperglycaemic technique and IVGTT).
It was recognised, however, that despite widespread use of the euglycaemic 
clamp in clinical research, key aspects of the technique remained to be validated. 
Thus, the intra- and inter- subject variability, the time for insulin mediated glucose 
disposal to reach steady state, the need to arterialise venous blood, and the 
haemodynamic and metabolic effects of hand warming were evaluated in 24 healthy 
male subjects and 6 patients with essential hypertension.
My data suggest that M values derived from clamps of 120 minute duration are 
10% less than those derived from 180 minute clamps. The intra-subject variability is 
less than 10% in both healthy subjects and patients with essential hypertension, 
whereas the inter subject variability is much greater at 20-30% even in a group of 
apparently homogeneous healthy subjects. Thus, the clamp lends itself to studies 
where subjects act as their own controls.
The haemodynamic and metabolic effects of a hand-warming box, an integral 
part of the clamp procedure designed to arterialise venous blood sampled from a 
dorsal hand vein, were evaluated in 12 healthy subjects. The box was shown to 
effectively arterialise venous blood with oxygen saturations of greater than 95%. Hand 
warming was associated with an increase in the derived measurement of insulin 
sensitivity, with an increase in heart rate and decrease in blood pressure. Thus, the 
hand warming device should be used with caution, as it may be associated with a 
confounding increase in the derived measurement of whole body insulin sensitivity 
from the euglycaemic hyperinsulinaemic clamp.
(ii) Anti hypertensive therapy and insulin sensitivity
The fact that blood pressure tends to increase, and glucose tolerance and
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insulin sensitivity decrease throughout the middle to late years of life even in the 
absence of anti hypertensive treatment (Skarsfors et al, 1991) renders uncontrolled 
studies and epidemiological observations ill suited for the evaluation of the effects of 
anti hypertensive drugs in causing insulin resistance, impaired glucose tolerance or 
NIDDM. On review of the literature, however, there are few controlled studies of the 
effects of anti hypertensive drugs on insulin sensitivity and few direct comparisons 
with placebo. Despite well publicised studies of anti hypertensive drugs improving 
insulin sensitivity (Pollare et al, 1989a), many conflicting reports have been published. 
This thesis has incorporated two studies which have evaluated the effects of two anti 
hypertensive drugs, the dihydropyridine calcium antagonist, lacidipine, and the ACE 
inhibitor, trandolapril, on insulin sensitivity using a randomised, double-blind 
placebo-controlled crossover design.
Despite indirect evidence of vasodilatation as reflected by an increase in supine 
heart rate, there was no significant effect of 2 weeks treatment with lacidipine on 
insulin sensitivity in neither healthy male subjects nor patients with essential 
hypertension; the confidence intervals excluded a 15% change in insulin sensitivity in 
the volunteer group. This is one of the first placebo-controlled crossover studies to 
evaluate the effects of a calcium antagonist on insulin sensitivity.
The second study evaluated the effects of 4 weeks treatment with trandolapril 
on insulin sensitivity in patients with at least 2 cardiovascular risk factors, namely, 
glucose intolerance and essential hypertension. The hypothesis under test was that 
ACE inhibition would increase insulin sensitivity via a vasodilatory mechanism and 
angiotensin II "sparing" effect. Despite evidence of 70% ACE inhibition and blood 
pressure lowering effects of trandolapril, there was no evidence that trandolapril 
altered insulin sensitivity when compared with placebo. Confidence intervals excluded 
a 12% increase in insulin sensitivity.
Thus, my results suggest that treatment (2 to 5 weeks) with either a calcium 
antagonist or an ACE inhibitor exert neutral effects on whole-body insulin sensitivity. 
These results contrast with previous reports from uncontrolled studies of
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heterogeneous patient groups.
Despite the theoretical concern that certain classes of antihypertensive agent 
are associated with the exacerbation of insulin resistance, the available data suggest 
that any such effect, at best, is modest especially when compared with the magnitude 
of the pre-existing insulin resistance observed in NIDDM, obesity and essential 
hypertension. The pivotal concern is therefore: "Do these adverse metabolic effects 
matter?" Only when there are data demonstrating that long-term anti hypertensive 
therapy with different drug classes is associated with differential effects on coronary 
events will we be able to assess the overall importance of biochemical abnormalities in 
the treatment of the individual hypertensive patient.
(iii) Effects of angiotensin II on insulin sensitivity
Having evaluated the effects of pharmacological removal of angiotensin II with 
trandolapril, the angiotensin II infusion study was performed to test the hypothesis that 
acute administration of the vasoconstrictor would reduce insulin sensitivity in healthy 
subjects and patients with NIDDM.
It has been proposed that changes in glucose and insulin metabolism might be 
secondary to hypertensive microvascular complications, and much discussion has 
focussed on the importance of skeletal muscle blood flow as a determinant of glucose 
disposal rate and the potential insulin-antagonist effects of neuroendocrine 
mechanisms involved in cardiovascular regulation. Although activation of the 
sympathetic nervous system (via release of catecholamines) is diabetogenic, the 
effects of other vasoactive hormones on glucose and lipid metabolism have been 
poorly documented.
Using doses that produced systemic angiotensin II concentrations within the 
pathophysiological range, (20 to 140 pg/ml), angiotensin II had no effect of insulin 
sensitivity in healthy subjects. When the identical experimental protocol was repeated 
in patients with NIDDM, angiotensin II significantly increased whole body insulin 
sensitivity. Other investigators (Buchanan et al, 1993; Townsend & DiPette, 1993),
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using much higher doses of the octapeptide in healthy subjects, have reported a 
dose-related increase in insulin sensitivity.
The dissociation of metabolic and blood pressure effects of angiotensin II 
suggests that haemodynamic alterations and redistribution of cardiac output might not 
be the sole (or principal) underlying mechanism explaining the observed increase in 
insulin mediated glucose uptake in patients with NIDDM.
(iv) Determinants of insulin sensitivity
Having evaluated the methodology of the euglycaemic hyperinsulinaemic 
clamp and characterised insulin sensitivity not only in hypertensive, diabetic and 
diabetic hypertensive patients but also in healthy subjects, analysis of the entire data 
base was performed to identify factors which may account for the large inter-subject 
variability in insulin sensitivity.
The most important determinant of insulin sensitivity as derived by the 
euglycaemic hyperinsulinaemic clamp was the BMI. Of the data derived from the 
OGTT, the fasting insulin concentration showed the best correlation with insulin 
sensitivity; more complex calculations of AUC’s of insulin or glucose profiles, or 
ratios of insulin and glucose concentrations conferred no advantage.
In patients with NIDDM or impaired glucose tolerance, the fasting insulin 
concentrations correlated with insulin sensitivity but the best predictors of insulin 
sensitivity were BMI and waist hip ratio. The insulin and glucose responses to an 
OGTT were poor predictors of insulin sensitivity.
Thus, my data suggest good correlation between BMI, WHR and fasting 
insulin concentrations and derived measurements of insulin sensitivity, and these 
variables may individually explain up to 50% of the inter-subject variability in the M 
value. When these variables are analysed on an individual basis, however, they are 
insufficiently robust to predict insulin sensitivity in an individual subject. Thus, 
estimates of insulin resistance derived from OGTT or morphometric data in 
epidemiological studies of glucose tolerance should be viewed with caution.
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(v) Summary
The last ten years has seen an increase in interest and research into the 
phenomenon of insulin resistance and hyperinsulinaemia and their importance in the 
pathogenesis of disease. Not only is insulin resistance and hyperinsulinaemia of 
primary importance in the development of NIDDM, it also occurs in other conditions, 
most notably obesity and essential hypertension.
This thesis has evaluated the euglycaemic clamp as a method of reproducibly 
measuring insulin-mediated metabolic responses. In two separate studies, two 
anti hypertensive agents have been shown to exert neutral effects on insulin-stimulated 
responses, casting further doubt on the importance of iatrogenic "worsening" of insulin 
sensitivity associated with the treatment of hypertension. The effects of angiotensin II 
on whole-body insulin sensitivity have been evaluated in both healthy subjects and 
patients with NIDDM. Contrary to general expectations, the vasoconstrictor increased 
insulin sensitivity in patients with NIDDM, suggesting a possible dissociation of 
haemodynamic and metabolic effects of angiotensin II. Lastly, using the entire 
database of all 75 subjects studied, major determinants of insulin sensitivity in man 
have been evaluated.
In conclusion, there is increasing recognition that high blood pressure is only 
one facet of a metabolic syndrome that represents a cluster of risk factors for 
long-term development of cardiovascular disease. The true impact of insulin resistance 
and hyperinsulinaemia on the promotion of an atherogenic lipid profile, elevation of 
blood pressure and acceleration of the atherosclerotic process remains to be clearly 
defined.
213
REFERENCES
Abramson, D.I., Tuck, S., Chu, L.S.W., Lee, S.W., Gibbon, C., Richardson, G. (1965) 
Indirect vasodilatation in thermotherapy. Archives o f Physiology and Medical 
Rehabilitation, 46,412-420.
Amery, A., Berthaux, R, Bulpitt, C., Deruyttere, M., de Schaepdryver, A., Dollery, 
C.T., Fagard, R., Forette, F., Lund-Johansen, J., Tuomilehto, J. (1978). Glucose 
intolerance during diuretic therapy: results of trial by the European Working Party on 
high blood pressure in the elderly. Lancet, 1,681-683.
Amiel,S. (1993) Amylin and diabetes. Lancet, 341,1249-1253.
Anderson E.A., Hoffman R.R, Babon T.W., Sinkey C.A., Mark A.L. (1991) 
Hyperinsulinaemia produces both sympathetic neural activation and vasodilation in 
normal humans. Journal o f Clinical Investigation, 87,2246-2252.
Andersson D.E.H., Rodjmark S. (1981) Modulation by verapamil of insulin and 
glucagon secretion in man. Acta Medica Scandinavia, 210,27-33.
Andres, R., Swerdloff, R., Pozefsky, T., Coleman, D. (1966) Manual feedback 
technique for the control of blood glucose concentration. In: Skeggs Jr, LT (ed). 
Automation in Analytical Chemistry, Medicaid Inc, New York, pp486-497.
Andrews, J., Klimes, I., Vasquez, B., Nagulesparan, M., Reaven, G.M. (1984) Can 
mixed venous blood be used to measure insulin action during the hyperinsulinaemic 
clamp? Hormone and Metabolic Research, 16,164-166.
Asch S., Wingard D.L., Barrett-Connor E.L. (1991) Are insulin and hypertension 
independently related? Annals of Epidemiology, 1,231-244.
Bak,J.F., Geides, L.U., Sorensen, N.S., Pedersen, O. (1992) Effects of perindopril on 
insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent 
diabetic patients. American Journal of Medicine, 92,69-72.
Banskota, N.K., Taub, R., Zellner, K., King, G.L. (1989) Insulin, insulin like growth 
factor-1 and PDGF interact additively in the induction of the proto-oncogene c-myc 
and cellular proliferation in cultured bovine aortic smooth muscle cells. Molecular 
Endocrinology, 3,1183-1190.
Barbieri, R.L., Smith, S., Ryan, K.J. (1988) The role of hyperinsulinaemia in the 
pathogenesis of ovarian hyperandrogenism. Fertility and Sterility, 50,197-212.
215
Barker, D.J., Gluckman, P.D., Godfrey, K.M., Harding, J.E., Owens, J.A., Robinson, 
J.S. (1993a) Foetal nutrition and cardiovascular disease in adult life. Lancet, 341, 
938-941.
Barker, D.J., Hales, C.N., Fall, C.H., Osmond, C., Phipps, K., Clark, P.M. (1993b) 
Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia 
(syndrome X): relation to reduced fetal growth. Diabetologia, 36,62-67.
Barnes, A.J., Garbien, K.J.T., Crowley, M.F., Bloom, A. (1974) Effects of short and 
long term chlorpropamide treatment on insulin release and blood glucose. Lancet, 2, 
69-72.
Baron, A.D., Laakso, M., Brechtel, G., Hoit, B., Watt, C., Edelman, S.V. (1990) 
Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in 
human obesity. Journal of Clinical Endocrinology and Metabolism,, 70,1525-1533.
Baron, A.D., Laakso, M., Brechtel, G., Edelman, S.V. (1991a) Reduced capacity and 
affinity of skeletal muscle for insulin mediated glucose uptake in non-insulin 
dependent diabetic subjects. Effects of insulin therapy. Journal o f Clinical 
Investigation, 87,1186-1194.
Baron, A.D., Laakso, M., Brechtel, G., Edelman, S.V. (1991b). Mechanism of insulin 
resistance in insulin-dependent diabetes mellitus: A major role for reduced skeletal 
muscle blood flow. Journal o f Clinical Endocrinology and Metabolism, 73,637-643.
Baron, A.D., Biechtel-Hook, G., Johnston, A., Hardin, D. (1993) Skeletal muscle 
blood flow: a possible link between insulin resistance and blood pressure. 
Hypertension, 21,129-135.
Baum, M. (1987) Insulin stimulates volume absorption in the proximal convoluted 
tubule. Journal o f Clinical Investigation, 56,335-340.
Beatty, O.L., Harper, R., Sheridan, B., Atkinson, A.B., Bell, P.M. (1993) Insulin 
resistance in offspring of hypertensive parents. British Medical Journal, 307,92-96.
Beck-Nielsen, H., Pedersen, O., Lindskov, H.O. (1979) Increased insulin sensitivity 
and cellular insulin binding in obese diabetics following treatment with gUbenclamide. 
Acta Endocrinologica, 90,451-462.
216
Beer, N.A., Jakubowicz, D.A., Beer, R.M., Arocha, I.R., Nestler, J.E. (1993) Effects 
of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone 
sulfate levels in insulin-resistant obese and hypertensive men. Journal of Clinical 
Endocrinology and Metabolism, 1 6 ,178-83.
Benediktsson, R., Lindsay, R.S., Noble, I., Seckl, J.R., Edwards, C.R.W. (1993) 
Glucocorticoid exposure in utero: new model for adult hypertension. Lancet, 341, 
339-341.
Bengston, C., Blohmd, G., Lapidus, L., Lindquist, O., Lundgren, H., Nystrom, E., 
Petersen, K., Sigurdsson, J.A. (1984) Do antihypertensive drugs precipitate diabetes? 
British Medical Journal, 298,1495-1497.
Beietta-Piccoli C„ Davies, D.L., Boddy, K., Brown, J.J., Cumming, A.M.M., East, 
B.W., Fraser, R., Lever, A.F., Padfield, PL., Semple, P.F., Robertson, J.I.S., 
Weidmann, P., Williams, E.D. (1982) Relation of arterial pressure with body sodium, 
body potassium and plasma potassium in essential hypertension. Clinical Science, 63, 
257-270.
Berglund, G., Larsson, B., Andersson, O., Larsson, O., Svardsudd, K., Bjomtoip, P., 
Wilhelmsen, L. (1976) Body composition and glucose metabolism in hypertensive 
middle-aged men. Acta Medica Scandinavia, 200,163-169.
Bergman, R.N., Prager, R., Volund, A., Olefsky, J.M. (1987) Equivalence of the 
insulin sensitivity index in man derived by the minimal model method and the 
euglycaemic glucose clamp. Journal of Clinical Investigation, 79,790-800.
Bergman, R.N., Hope, I.D., Yang, Y.J., Watanabe, R.M., Meador, M.A., Young, J.H., 
Ader, M. (1989) Assessment of insulin sensitivity in vivo: a critical review. 
DiabeteslMetabolism Reviews, 5,411-429.
Berne, C , Pollare, T., Lithell, H. (1991) Effects of antihypertensive treatment on 
insulin sensitivity. Diabetes Care, 14,25-29.
Bhathagar, S.K., Amin, M.M.A., Al-Yusuf, A.R. (1984). Diabetogenic effects of 
nifedipine (letter). British Medical Journal, 289,19.
Bland, M. (1987) An Introduction to Medical Statistics. Oxford University Press, 
Oxford. pp277-280.
217
Bogardus, C., Ravussin, E., Robbins, D.C., Wolfe, R.R., Horton, E.S., Sims, E.A.H. 
(1984) Effects of physical training and diet therapy on carbohydrate metabolism in 
patients with glucose intolerance and non-insulin dependent diabetes mellitus. 
Diabetes, 33,311-318.
Bogardus, C., Lillioja, S., Stone, K., Mott, D. (1987) Correlation between muscle 
glycogen synthase activity and in vivo insulin action in man. Journal of Clinical 
Investigation, 80,415-425.
Bonadonna, R.C., Groop, L.C., Kraemer, N., Ferrannini, E., Del-Prato, S., De Fronzo, 
R.A. (1990) Obesity and insulin resistance in humans: a dose-response study. 
Metabolism, 39,452-459.
Bonora, E., Bonadonna, R.C., Del-Prato, S., Gulli, G., Solini, A., Matsuda, M., 
DeFronzo, R.A. (1993) In-vivo glucose metabolism in obese and type II diabetic 
subjects with or without hypertension. Diabetes, 42,764-772.
Brands, M.W., Mizelle, H.L., Gaillard, D.A., Hildebrandt, D.A., Hall, J.E. (1991) The 
haemodynamic response to chronic hyperinsulinaemia in conscious dogs. American 
Journal of Hypertension, 4,164-168.
Bree, F., Nguyen, P., Tillement, J.P., Johnson, C., Tremblay, D. (1992) How do 
trandolapril, a new ACE inhibitor, and trandolaprilat, the major and active metabolite, 
bind to human blood constituents? (abstract) Journal of Hypertension, 10 (Suppl 4), 
188.
Bressler, R., Johnson, D. (1992) New pharmacological approaches to therapy of 
NIDDM. Diabetes Care, 15,792-805.
Brunner, D.B., Despond, G., Biollaz, J. (1981) Effect of a new angiotensin converting 
enzyme inhibitor, MK421, and its lysine analogue on the components of the renin 
angiotensin system in healthy subjects. British Journal of Clinical Pharmacology, 11, 
461-467.
Buchanan, T.A., Sipos, G.F., Gadalam, S., Yip, K.P., March, D.J., Hsueh, W. 
Bergman, R.N. (1991) Glucose tolerance and insulin action in rats with renovascular 
hypertension. Hypertension, 18,341-347.
218
Buchanan, T.A., Thawani, H., Kades, W., Modrall, J.G., Weaver, F.A., Laurel, C., 
Poppiti, R., Xiang, A., Hseuh, W. (1993) Angiotensin II increases glucose utilization 
during acute hyperinsulinaemia via a hemodynamic mechanism. Journal of Clinical 
Investigation, 92,720-726.
Bursztyn, M., Ben-Ishay, D., Gutman A. (1992) Insulin resistance in spontaneously 
hypertensive rats but not in DOCA-salt or renal vascular hypertension. Journal of 
Hypertension, 10,137-42.
Calle Pascual, A.L., Rodriguez, G , Martin Alvarez, P.J., Camacho, F., Calle, J.R., 
Yuste, E., Hildago, I., Diaz, R.J., Martin-Vaquero, P.,Santiago, M. (1991) Effect of 
weight loss on insulin sensitivity and cardiovascular risk factors in glucose tolerant 
and intolerant obese subjects. Diabetologia, 17,404-409.
Calver, A., Collier, J., Vallance, P. (1992) Inhibition and stimulation of nitic oxide 
synthesis in the human forearm arterial bed of patients with insulin-dependent 
diabetes. Journal of Clinical Investigation, 90,2548-2554.
Cambien, F., Warner, J-M., Eachwege, E., Jacqueson, A., Richard, J.L., Rosselin, G. 
(1987) Body mass, blood pressure, glucose and lipids: does plasma insulin explain 
their relationships? Arteriosclerosis, 7,197-202.
Canessa, M„ Adragna, N., Solomon, H.S., Connolly, T.M., Tosteson, D.C. (1980) 
Increased sodium-lithium countertransporter in red cells of patients with essential 
hypertension. New England Journal o f Medicine, 302,772-776.
Capaldo, B., Lembo, G., Napoli, R., Rendina, V., Albano, G., Sacca, L., Trimarco, B. 
(1991) Skeletal muscle metabolism is a primary site of insulin resistance in essential 
hypertension. Metabolism, 40,1320-1322.
Charles, S., Ketelslegers, J.M., Buysschaert, M., Lambert, A.E. (1981). 
Hyperglycaemic effect of nifedipine. British Medical Journal, 283,19-20.
Chellingsworth, M., Kendall, M., Wright, A., Sugh, B., Pasi, J. (1989) The effects of 
verapamil, diltiazem, nifedipine and isopranolol on metabolic control in hypertensives 
with non-insulin dependent diabetes mellitus. Journal of Human Hypertension, 3, 
35-39.
Chen, Y-D.I., Golay, A., Swislocki, A., Reaven, G.M. (1987) Resistance to insulin 
suppression of plasma free fatty acid concentration and insulin stimulation of glucose 
uptake in NIDDM. Journal o f Clinical Endocrinology and Metabolism, 64,17-21.
219
Chiariello, M. (1991) A double-blind comparison of the efficacy and safety of 
lacidipine and hydrochlorothiazide in essential hypertension. Journal of 
Cardiovascular Pharmacology, 17 (suppl 4), S35-S37.
Chiknas, S.G. (1979) Liquid chromatography assisted assay for angiotensin 
converting enzyme in serum. Clinical Chemistry, 25,1259-1262.
Christlieb, A.R. (1976) Vascular reactivity to angiotensin II and to norepinephrine in 
diabetic subjects. Diabetes, 25,268-274.
Colca, J.R., Morton, D.R. (1990) Antihyperglycaemic thiazolidinediones. In: 
Antidiabetic drugs, Eds: Bailey, C.J., Flatt, P.R. London, Smith-Gordon, p255-261.
Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N.H., Eberlein, K.H., 
Godwin, I., Qizilbach, N., Taylor, J.O., Hennekens, C.H. (1990) Blood pressure, 
stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: 
overview of randomised drug trials in their epidemiological context. Lancet, 335, 
827-838.
Collins, W.C.J., Cullen, M.J., Felly, J. (1986) The effect of therapy with 
dihydropyridine calcium channel blockers on glucose tolerance in non-insulin 
dependent diabetes. British Journal o f Clinical Pharmacology, 21,568.
Cooper, G.J.S., Leighton, B., Dimitriadis, G.D., Parry-Billings, M., Kowalchuk, J.M., 
Howland, K., Rothbard, J.B., Willis, A.C., Reid, K.B. (1988) Amylin found in amylin 
deposits in human type 2 diabetes may be a hormone that regulates glycogen 
metabolism in skeletal muscle. Proceedings of the National Academy of Science of 
America, 85,7763-7766.
CONSENSUS Trial Study Group. (1987) Report. New England Journal o f Medicine, 
316,1429-1435.
Conway, G.S., Clark, P.M.S., Wong, D. (1993) Hyperinsulinaemia in the polycystic 
ovary syndrome confirmed with a specific immunoradiometric assay for insulin. 
Clinical Endocrinology, 38,219-222.
Creager, M.A., Cooke, J.P., Mendehlson, M.D., Gallagher, S.G., Coleman, S.M., 
Loscalzo, J., Dzau, V.J. (1990) Impaired vasodilatation of forearm resistance vessels 
in hypercholesterolaemic humans. Journal of Clinical Investigation, 86,228-234.
220
Creager, M.A., Liang, C-S., Coffman, J.D. (1985) Beta adrenergic-mediated 
vasodilator response to insulin in the human forearm. Journal of Pharmacology and 
Experimental Therapeutics, 235,709-714.
Cullen, K., Stenhouse, N.S., Weame, K.L., Welbom, T.A. (1983) Multiple regression 
analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, 
Western Australia -13 year study. Journal o f Chronic Diseases, 36,371-377.
Czyzyk, A., Lawecki, J., Sadowski, J., Ponikowksa, I., Szczepanik, Z. (1968) Effect of 
biguanides on intestinal absorption of glucose. Diabetes, 17,492-498.
Daly, P.A., Landsberg, L. (1991) Hypertension in obesity and NIDDM: role of insulin 
and the sympathetic nervous system. Diabetes Care, 14,240-248.
da Prada, M., Zurcher, G. (1976). Simultaneous determination of plasma adrenaline, 
noradrenaline and dopamine in the femtomole range. Life Sciences, 19,1161.
Deedwania, P., Shah, J., Robison, J. (1984) Effects of nifedipine on glucose tolerance 
and insulin release in man. Journal of American College of Cardiology, 3,577.
DeFronzo, R.A., Cooke, C.R., Andres, R., Faloona, G.R., David, P.J. (1975) The 
effect of insulin on renal handling of sodium, potassium, calcium and phosphate in 
man. Journal o f Clinical Investigation, 55, 845-855.
DeFronzo, R.A., Tobin, J., Andres, R. (1979). Glucose clamp technique: a method 
for quantifying insulin secretion and resistance. American Journal o f Physiology, 237, 
E214-E223.
DeFronzo, R.A., Felig, P., Ferrannini, E., Wahren, J. (1980) Effect of graded doses of 
insulin on splanchnic and peripheral metabolism in man. American Journal of 
Physiology, 238, E421-E427.
DeFronzo, R.A. (1981) The effects of insulin on renal sodium metabolism. 
Diabetologia, 21,165-171.
DeFronzo, R.A., Sherwin, R.S., Kraemer, N. (1987) Effect of physical training on 
insulin action in obesity. Diabetes, 36,1379-1385.
DeFronzo, R.A., Barzilai, N., Simonson, D.C. (1991) Mechanism of metformin action 
in obese and lean non-insulin-dependent diabetic subjects. Journal o f Clinical 
Endocrinology and Metabolism, 73,1294-1301.
221
DeFronzo, R.A., Bonadonna, R.C., Ferrannini, E. (1992) Pathogenesis of NIDDM: a 
balanced overview. Diabetes Care, 15,318-368.
Deibert, D.C., DeFronzo, R. (1980) Epinephrine-induced insulin resistance in man. 
Journal of Clinical Investigation, 65,717-721.
De Marinis, L., Barbarino, A. (1980) Calcium antagonists and hormone release. 
Effects of verapamil on insulin release in normal subjects and patients with islet-cell 
tumours. Metabolism, 29,599-604.
De Ponti, F., Marelli, C., D’Angelo, L., Caravaggi, M., Bianco, L., Lecchini, S., Figo, 
G.M., Crema, A. (1991) Pharmacological activity and safety of trandolapril (RU 
44570) in healthy volunteers. European Journal o f Clinical Pharmacology, 40, 
149-153.
Derkx, F.H.M., Tan-Tjiong, H.L., Man in’t Veld, A.J., Schalekamp, M.P.A., 
Schalekamp, M.A.D.H. (1979). Activation of inactive plasma renin by renin and 
plasma kallikreins. Clinical Science, 57,351-357.
Despr6s, J.P., Mooijani, S., Lupien, P.J., Tremblay, A., Nadeau, A., Bouchard, C. 
(1990) Regional distribution of body fat, plasma lipoproteins and cardiovascular 
disease. Arteriosclerosis, 10.497-511.
Dietze, G. (1982) Modulation of the action of insulin in relation to the energy state in 
skeletal muscle. Possible involvement of kinins and prostaglandins. Molecular and 
Cellular Endocrinology, 25,127-149.
Dobeme, L., Greenfield, M.S., Schulz, B., Reaven, G.M. (1981) Enhanced glucose 
utilization during prolonged glucose clamp studies. Diabetes, 30, 829-835.
Dohm, G.L., Elton, C.W., Friedman, J.E., Pilch, P.F., Porles, W.J., Atkinson, S.M., 
Caro, J.F. (1991) Decreased expression of glucose transporter in muscle from insulin 
resistant patients. American Journal o f Physiology, 260, E459-E463.
Donnelly, T., Harrower, A.D.B. (1980) Effect of nifedipine on glucose tolerance and 
insulin secretion in diabetic and non-diabetic patients. Current Medical Research and 
Opinion, 6,690-693.
222
Donovan D.S., Solomon, C.G., Seely, E.W., Williams, G.H., Simonson, D.C. (1993) 
Effect of sodium intake on insulin sensitivity. American Journal of Physiology, 264, 
E730-E734.
Dowse, G.K., Collins, V.R., Alberti, K.G.M., Zimmet, P.Z., Tuomilehto, J., Chitson,
P., Gareeboo, H. (1993) Insulin and blood pressure levels are not independently 
related in Mauritians of Asian Indian, Creole or Chinese origin. Journal of 
Hypertension, 11,297-307.
Ducimetiere, P., Eschwege, E., Papoz, L., Richard, J.L., Claude, J.R., Roselin, G.
(1980) Relationship of plasma insulin levels to the incidence of myocardial infarction 
and coronary heart disease mortality in a middle-aged population. Diabetologia, 19, 
205-210.
Ducsterdieck, G., McElwee, G. (1971) Estimation of angiotensin II in human plasma 
by radioimmunoassay. Some applications to physiological and clinical states.
European Journal o f Clinical Investigation, 2 ,32-38.
Dulbecco, A., Albenga, C., Borretta, G., Vacca, G., Milanesi, G., Lavezzori, M.
(1989) Effect of acipimox on plasma glucose levels in patients with 
non-insulin-dependent diabetes mellitus. Current Therapeutic Research, 46,478-483.
Ebeling, P., Bourey, R., Koranyi, L., Tuominen, J.A., Groop, L.C., Henriksson, J., 
Mueckler, M., SovijSrvi, A., Koivisto, V.A. (1993) Mechanism of enhanced insulin 
sensitivity in athletes: increased blood flow, muscle glucose transport protein 
(GLUT-4) concentration and glycogen synthase activity. Journal of Clinical 
Investigation, 92,1623-1631.
Edwards, C.R.W., Benediktsson, R., Lindsay, R., Seckl, J.R. (1993) Dysfunction of 
placental glucocorticoid barrier: link between fetal environment and early 
hypertension? Lancet, 341,355-357.
Elliott, T.G., Cockcroft, J.R., Groop, P-H., Viberti, G-C., Ritter, J.M. (1993)
Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent 
diabetic patients: blunted vasoconstriction in patients with microalbuminauria.
Clinical Science, 85,687-693.
Eschwege, E., Richard, J.L., Thibult, N., Duciemetiere, P., Wamet, J.M., Claude, J.R., 
Rosselin, G.E. (1985) Coronary heart disease mortality in relation with diabetes, blood 
glucose and plasma insulin levels: the Paris Prospective study, ten years later. 
Hormone and Metabolic Research, 14,41-46.
223
Evans, D J., Hoffman, R.G., Kalkhoff, R.K., Kissebah, A.H. (1984) Relationship of 
body fat topography to insulin sensitivity and metabolic profiles in premenopausal 
women. Metabolism, 33,68-75.
Faberberg, B., Berglund, A., Holme, E., Wilhelmsen, L., Elmfeldt, D. (1990) 
Metabolic effects of controlled-release metoprolol in hypertensive men with impaired 
or diabetic glucose tolertance: a comparison with atenolol. Journal of Internal 
Medicine, 227,37-43.
Faberberg, B., Berglund, A., Andersson, O.K., Berglund, G. (1992) Weight reduction 
versus antihypertensive drug therapy in obese men with high blood pressure: effects 
upon plasma insulin levels and association with changes in blood pressure and serum 
lipids. Journal of Hypertension, 10,1053-1061.
Facchini, F.S., Hollenbeck, C.B., Jeppesen, J. Chen, Y-D.I., Reaven, G.M. (1992) 
Insulin resistance and cigarette smoking. Lancet, 339,1128-31.
Fantus, G.I., Brousseau, R. (1986) Mechanism of action of metformin: insulin receptor 
and postreceptor effects in vitro and in vivo. Journal of Clinical Endocrinology and 
Metabolism, 63, 898-905.
Feldman, J.M., Lebovitz, H.E. (1969) Appraisal of the extrapancreatic actions of 
sulphonylureas. Archives of Internal Medicine, 123,314-322. •
Ferlito, S., Fichera, C., Carr, G. (1980) Effect of nifedipine on blood sugar,insulin and 
glucagon levels after an oral glucose load.
Panminerva Medicus, 23,75-80.
Ferlito, S., Modica, L., Romano, F. (1982) Effect of verapamil on glucose insulin and 
glucagon levels after oral glucose load in normal and diabetic subjects.
Journal o f Internal Medicine, 24; 221-226.
Ferrannini E., Buzzicoli G„ Bonadonna R., Giorico, M.A., Oleggini, M., Graziadei,
L., Pedrinelli, R., Brandi, L., Bevilqacqua, S. (1987). Insulin resistance in essential 
hypertension. New England Journal of Medicine, 317,350-357.
Ferrannini, E. (1989) The theoretical basis for indirect calorimetry: a review. 
Metabolism, 37: 287-301.
224
Ferrannini, E., Haffner, A.M., Stem, M.P. (1990) Essential hypertension: an insulin 
resistant state. Journal of Cardiovascular Pharmacology 15 (suppl 5), 518-525.
Ferrannini, E., Galvan, A.Q., Santoro, D., Natali, A. (1992) Potassium as a link 
between insulin and the renin-angiotensin-aldosterone system. Journal of 
Hypertension, 10 (Suppl. 1), S5-S10.
Ferrara, L.A., Soro, S., Fasano, M.L. (1985) Effects of nitrendipine on glucose and 
serum lipid concentrations. Current Therapeutic Research, 37, 614-618.
Ferrari, P., Weidmann, P. (1990). Insulin, insulin sensitivity and hypertension. 
Journal of Hypertension, 8,491-500.
Ferrari, P., Weidmann, P., Shaw, S., Giachino, D., Riesen, W., Allemann, Y., Heynan, 
G. (1991a) Altered insulin sensitivity, hyperinsulinaemia and dyslipidaemia in 
individuals with a hypertensive parent. American Journal of Medicine, 91, 589-596.
Ferrari, P., Giachino, D., Weidmann, P., Shaw, S., Riesen, W., Neuner, N., Keller, U., 
Heynan, G. (1991b). Unaltered insulin sensitivity during calcium channel blockade 
with amlodipine. European Journal of Clinical Pharmacology, 41, 109-113.
Ferriere, M., Bringer, J., Richard, J., Rodier, M., Jaffiol, C., Mirouze, J. (1985) 
Captopril and insulin sensitivity. Annals of Internal Medicine, 102, 134-135.
Finegood, D.T., Bergman, R.N., Vranic, M. (1987) Estimation of endogenous glucose 
production during euglycaemic hyperinsulinaemic glucose clamps: comparison of 
unlabelled and labelled exogenous glucose infusates. Diabetes, 36, 914-924.
Foley, J.E. (1992) Rationale and application of fatty acid oxidation inhibitors in 
treatment of diabetes mellitus. Diabetes Care, 15, 773-784.
Fontbonne, A., Charles, M.A., Thibult, N., Richaer, J.L., Claude, J.R., Wamet, J.M., 
Rosselin, G.E., Eschwege, E. (1991) Hyperinsulinaemia as a predictor of coronary 
heart disease mortality in a healthy population: the Paris Prospective Study. 
Diabetologia, 34, 356-361.
Forster, H.V., Dempsey, J.A., Thompson, J., Vidruk, E., doPico, G.A. (1972) 
Estimation of arterial p02, pC02, pH and lactate from arterialised venous blood. 
Journal of Applied Physiology, 32, 134-137.
225
Frank, R., Rougier, R.F.I., Tonet, J.L., Harding, S., Bons, J., Fontaine, G., Grososeat, 
Y. (1990) Effect of the new once-daily calcium antagonist, lacidipine in controlling 
24-hour ambulatory blood pressure. American Journal of Cardiology, 66,1228-1230.
Fruncilo, R.J., Tomensch, H.H., Vlasses, P.H., Koplin, J.R., Monsell, K., Clementini, 
R.A., Fergusson, R.A. (1983) Effects of captopril and hydrochlorothiazide on the 
pressor responses to norepinephrine and angiotensin n  in hypertensives. Clinical 
Pharmacology and Therapeutics, 33,226-229.
Fuccella, L.M., Goldaniga, G., Lovisolo, P., Maggi, E., Musatti, L., Mandelli, V., 
Sirtori, C.R. (1980) Inhibition of lipolysis by nicotinic acid and acipimox. Clinical 
Pharmacology and Therapeutics, 28,790-795.
Fujita, N., Baba, T., Tomiyami, T., Kodama, T., Kako, N. (1992) Hyperinsulinaemia 
and blood pressure in patients with insulinoma. British Medical Journal, 304,1157.
Fukagawa, N.K., Anderson, J.W., Hageman, G., Young, V.R., Minaker, K.L. (1990) 
Low carbohydrate, high fiber diets increase peripheral insulin sensitivty in healthy 
young and old adults. American Journal o f Clinical Nutrition, 52,524-528.
Gallen, I.W., Macdonald, I. A. (1990) Effect of two methods of hand heating on body 
temerature, forearm blood flow, and deep venous oxygen saturation. American 
Journal o f Physiology, 259, E639-E643.
Galloway, J.A., Hooper, S.A., Spradlin, C.T., Howey, D.C., Frank, B.H., Bousher, 
R.R., Anderson, J.H. (1992) Biosynthetic human pro-insulin. Diabetes Care, 15, 
666-692.
Gans, R.O., Bilo, H.J.G., Maarschalkerweerd, W.W.A., Heine, R.J., Nauta, J.J.P., 
Donker, A.J.M. (1991a) Exogenous insulin augments in healthy volunteers the 
cardiovascular reactivity to noradrenaline but not to angiotensin n. Journal of 
Clinical Investigation, 88,512-518.
Gans, R.O.B., Bilo, H.J.G., Nauta, J.J.P., Popp-Snijders, C„ Heini, R.J., Donker, 
A.J.M. (1991b) The effect of angiotensin-I converting enzyme inhibition on insulin 
action in healthy volunteers. European Journal o f Clinical Investigation, 21, 
527-533.
Gill, J.S., Al-Hussary, N., Zezulka, A.Y., Pasi, K.J., Atkins, T.W., Beevers, D.G.
(1987). Effect of nifedipine on glucose tolerance, serum insulin and serum 
fructosamine in diabetic and nondiabetic subjects. Clinical Therapeutics, 9,304-310.
226
Gin, H., Messerchnitt, C., Brottier, E., Aubertin, J. (1983) Metformin improves 
insulin resistance in type I diabetes. Diabetologia, 24,351-354.
Giugliano, D., Torella, R., Cacciapuot, F., Gentile, S., Verza, M., Yarricchio, M.
(1980). Impairment of insulin secretion in man by nifedipine. European Journal of 
Clinical Pharmacology, 18,395-398.
Giugliano, D., Gentile, S., Verza, M. Passariello, N., Giannetti, G., Varricchio, M.
(1981) Modulation by verapamil of insulin and glucagon secretion in man. Acta 
Diabetologia, 18,163-171.
Gliemann, J., Sonne, O. (1978) Binding and receptor-mediated degradation of insulin 
in adipocytes. Journal of Biological Chemistry, 253,7857-7863.
Greenfield, M.S., Dobeme, L., Kraemer, F., Tobey, T., Reaven, G. (1981) Assessment 
of insulin resistance with the insulin suppression test and the euglycaemic clamp. 
Diabetes, 30,387-392.
Groop, L.C., Pelkonen, R. (1984) Treatment failures: a common problem in the 
management of patients with type II diabetes. Acta Endocrinologia, 105 (Suppl 262), 
131-135.
Grootenhuis, P.A., Mooy, J.M., Popp-Snijders, C., Bouter, L.M., Heine, R.J. (1993) 
Proinsulin like molecules in relation to blood lipids and blood pressure in a general 
Caucasian population, (abstract) Diabetologia, 36, A270.
Gupta, A.K., Clark, R.V., Kirchner, K.A. (1992) Effects of insulin on renal sodium 
excretion. Hypertension, 19 (suppl I), 167-171.
Haffner, S.M., Ferrannini, E., Hazuda, H.P., Stem. M.P. (1992) Clustering of 
cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension, 
20, 38-45.
Haffner, S.M. (1993) Insulin and blood pressure - fact and fantasy. Journal o f Clinical 
Endocrinology and Metabolism 76,541-543
Hale, P.J., Singh, B.M., Crase, J., Baddeley, R.M., Nattrass, M. (1988) Following 
weight loss in massively obese patients correction of the insulin resistance of fat 
metabolism is delayed relative to the improvement in carbohydrate metabolism. 
Metabolism, 37,411-417.
227
Halkin, H., Or, J., Fuchs, Z., Lusky, A., Chetrit, A., Modan M. (1989) Smoking 
accounts for the adverse effects of antihypertensive medication on plasma lipids: a 
population based study. Hypertension, 14,210-217.
Hall, J.E., Coleman, T.G., Mizelle, H.L., Smith, M.J. (1990) Chronic 
hyperinsulinaemia and blood pressure regulation. American Journal o f Physiology, 
258, F722-F731.
Hall, S.T., Harding, S.M., Evans, G.L., Pellegatti, M., Rizzini, P. (1991) Clinical 
pharmacology of lacidipine. Journal of Cardiovascular Pharmacology, 17 (suppl 4), 
S9-S13.
Harano, Y., Hidaka, H., Takatsuki, K. Ohgaku, S., Haneda, M., Motoi, S., Kawagoe, 
K., Shigeta, Y., Abe, H. (1978) Glucose, insulin and somatostatin infusion for the 
determination of insulin sensitivity in vivo. Metabolism, 27,1449-56.
Hardin, D., Dominguez, J.H., Garvey, W.T. (1993) Muscle group-specific regulation 
of GLUT 4 glucose transporters in control, diabetic and insulin-treated diabetic rats. 
Metabolism, 42,1310-1315.
Hargreaves, A.D., Logan, R.L., Elton, R.A., Buchanan, K.D., Oliver, M.F., 
Riermersma, R.A. (1992) Glucose tolerance, plasma insulin, HDL cholesterol and 
obesity: 12 year follow-up and development of coronary artery disease in Edinburgh 
men. Atherosclerosis, 94,61-69.
Harper, R., Ennis, C., Atkinson, B., Johnston, D„ Bell, P. (1993) Effect of low and 
conventional dose bendrofluazide on insulin action in essential hypertension (abstract) 
Diabetes, 42,165A.
Heath, G.W., Gavin, J.R.m., Hinderliter, J.M. (1983) Effects of exercise and lack of 
exercise on glucose tolerance and insulin sensitivity. Journal of Applied Physiology: 
Respiratory, Environmental and Exercise Physiology, 55,512-517.
Heber, M.E., Broadhurst, P.A., Brigden, G.S., Raftery, E.B. (1990) Effectiveness of 
the once-daily calcium antagonist, lacidipine, in controlling 24-hour ambulatory blood 
pressure. American Journal o f Physiology, 66,1228-1232.
Heding, L.G. (1977) Specific and direct radioimmunoassay for human proinsulin in 
serum. Diabetologia, 13,467-474
228
Hedner, T., Thulin, T., Gustaffson, S., Olsson, S.O. (1990) A comparison of diltiazem 
and metoprolol in hypertension. European Journal o f Clinical Pharmacology, 39, 
859-865.
Helgeland, A., Leren, P., Foss, O.P., Hjermann, I., Holme, I., Lund-Larsen, I. (1984) 
Serum glucose levels during long-term obsevation of treated and untreated men with 
mild hypertension: the Oslo study. American Journal of Medicine, 76, 802-805.
Helgeland, A., Strommen, R., Hagelund, C.H., Trett, S. (1986) Enalapril, atenolol and 
hydrochlorothiazide in mild-to-moderate hypertension, Lancet, 1, 872-876.
Helve, E., Tuominen, J.A., Koivisto, V.A. (1993) Captopril does not acutely enhance 
insulin sensitivity. Journal of Internal Medicine, 234,41-44.
Herbette, L.G., Gaviraghi, G., Tulenko, T., Mason, R.P. (1993) Molecular interaction 
between lacidipine and biological membranes. Journal o f Hypertension, 11 (suppl), 
S13-S19.
Himsworth, H.P. (1936) Diabetes mellitus; its differentiation into insulin-sensitive and 
insulin-insensitive types. Lancet, 1,127-130.
Himsworth, H.P., Kerr, R.B. (1939) Insulin-sensitive and insulin-insensitive types of 
diabetes mellitus. Clinical Science, 4,119-123.
Hodsman, G.P., Brown, J.J., Davies, D.L. (1982) Converting enzyme inhibitor 
enalapril in the treatment of hypertension with renal artery stenosis. British medical 
Journal, 285,1697-1699.
Hofmann, C.A., Lorenz, K., Colca, J.R. (1991) Glucose transport deficiency in 
diabetic animals is corrected by treatment with the oral antihyperglycaemic agent 
pioglitazone. Endocrinology, 129,1915-1925.
Hofmann, C.A., Colca, J.R. (1992) New oral thiazolidinedione antidiabetic agents act 
as insulin sensitisers. Diabetes Care, 15,1075-1078.
Hosker, J.P., Matthews, D.R., Rudenski, A.S., Burnett, M.A., Darling, P., Bown, E.G., 
Turner, R.C. (1985) Continuous infusion of glucose with model assessment: 
measurement of insulin resistance and 6-cell function in man. Diabetologia, 28, 
401-411.
229
Howes, L.G., Millar, S.K., Reid, J.L. (1985) The simultaneous assay of 3,4 
dihydroxyphenylethylene glycol and norepinephrine in human plasma by HPLC with 
electrochemical detection. Journal o f Chromatography, 338,401-403.
Hughes, T.A., Gwynne, J.T., Switzer, B.R., Herbst, C., White, G. (1984) Effects of 
caloric restriction and weight loss on glycaemic control, insulin release and resistance, 
and atherosclerotic risk in obese patients with type II diabetes mellitus. Kidney 
International, 77,7-17.
Hunt, S.C., Wu, L.L., Hopkins, P.N., Williams, R.R. (1989) Sodium-lithium 
countertransport and fasting insulin in patients with familial combined 
hyperlipidaemia and hypertension, (abstract) Hypertension, 14,345.
Hunt, S.C., Stephenson, S.H., Hopkins, P.N., Hasstedt, S.J., Williams, R.R. (1991) A 
prospective study of sodium-lithium countertransporter and hypertension in Utah. 
Hypertension, 17,1-7.
Hwang, I-S., Ho, H., Hoffman, B.B., Reaven, G.M. (1987) Fructose induced insulin 
resistance and hypertension in rats. Hypertension, 10,512-516.
Hypertension in Diabetes Study Group (1993). Hypertension in Diabetes Study 
(HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and 
the association with risk factors for cardiovascular and diabetic complications. Journal 
of Hypertension, 11,309-317.
Iversen, E., Jeppesen, D., Steensgard-Hansen F. (1990) Direct diabetogenic effects of 
diltiazem? Journal of Internal Medicine, 227,285-286.
Iwamoto, Y., Kuzuya, T., Matsuda, A. Awata, T., Kumakura, S., Inooka, G., Shiraishi, 
I. (1991) Effect of the new oral antidiabetic agent CS-045 on glucose tolerance and 
insulin secretion in patients with NIDDM. Diabetes Care, 14,1083-1086.
Jamerson, K.A., Julius, S., Gudbrandsson, T., Andersson, O., O’Brant, D. (1993) 
Reflex sympathetic activation induces acute insulin resistance in the human forearm. 
Hypertension, 21,618-623.
James, D.E., Burleigh, K.M., Storlien, L.H., Bennett, S.P., Kraegen, E.W. (1986) 
Heterogeneity of insulin action in muscle: influence of blood flow. American Journal 
of Physiology 251: E422-E430.
230
Jauch, K.W., Hartl, W., Guenther, B., Wicklmays, M., Rett, K., Dietze, G. (1987). 
Captopril enhances insulin responsiveness of forearm muscle tissue in 
non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation, 
17,448-454.
Jauch, K.W., Hard, W.H., Georgeieff, M., Wolfe, R.R., Dietze, G., Gunther, B.
(1988). Low-dose bradykinin infusion reduces endogenous glucose production in 
surgical patients. Metabolism, 37,185-190.
Jiang, X., Srinivasa, S.R., Bao, W., Berenson, G.S. (1993) Association of fasting 
insulin with longitudinal changes in blood pressure in children and adolescents. The 
Bogalusa Heart Study. American Journal o f Hypertension, 6,564-569.
Joffe, B.I., Lamprey, J.M., Shires, R., Baker, S., Viljoen, M., Seftel, H.C. (1983)
Lack of hormonal effects of a single dose of nifedipine in healthy young men.
Journal of Cardiovascular Pharmacology, 5,599-604.
Johlin-Dannfelt, A., Frisk-Holmberg, M., Karlsson, J., Tesch, P. (1979) Central and 
peripheral circulation in relation to muscle fibre type composition in normotensive and 
hypertensive man. Clinical Science, 56,335-340.
Johnson, C.I.J., Kerr, J.H. (1985) Automatic blood pressure recorders: a clinical 
evaluation of five models in adults. Anaesthesia, 40,471-478.
Julius, S., Gudbrandsson, T., Jamieson, K., Shabab, S.T., Andersson, O. (1991) The 
haemodynamic link between insulin resistance and hypertension. Journal of 
Hypertension, 9 ,983-986.
Junichi, K., Shigehiro, K., Kiyishi, T., Akira, I., Shyoji, K., Jun, I. (1991) Effects of 
captopril on glucose concentration: possible role of augmented postprandial forearm 
blood flow. Diabetes Care, 13,1109-1111.
Kadish, A.H., Little, R.L., Sternberg, J.C. (1968) A new and rapid method for the 
determination of glucose by measurement of rate of oxygen consumption. Clinical 
Chemistry, 14,116.
Kaley, G., Donshik, P.C., Schlissler, G.L. (1967) Metabolic effects of angiotensin. 
Federation Proceedings, 26,439-443.
Kannell, W.B., McGhee, D.L. (1979) Diabetes and cardiovascular risk factors: the 
Framingham Study. Circulation, 59, 8-13.
231
Kannell, W.B., Wolf, P.A., Castelli, W.P., D’Agostini, R.B. (1987) Fibrinogen and 
risk of cardiovascular disease. Journal of American Medical Association, 258, 
1183-1186.
Kannell, W.B., Wilson, P.W.F., Zhang, T-J. (1991) The epidemiology of impaired 
glucose tolerance and hypertension. American Heart Journal, 121,1268-1273.
Kashiwagi, A., Verso, M.A., Andrews, J., Vasquez, B., Reaven, G.M., Foley, J.E.
(1983) In vitro insulin resistance of human adipocytes isolated from subjects with 
non-insulin dependent diabetes mellitus. Journal of Clinical Investigation, 12, 
1246-1254.
Kendall, M.J., Lewis, H., Griffith, M., Barnett, A.H. (1988) Drug treatment of the 
hypertensive diabetic. Hypertension, 1,249-258.
Kjellstrom, T., Blychert, E., Lindgarde, F. Felodipine in the treatment of hypertensive 
type II diabetics: effect on glucose homeostasis. Journal o f Internal Medicine, 229, 
233-239.
Klauser, R., Prager, R„ Gaube, S., Gisinger, C., Schnack, C., Kuenburg, E., 
Schemthaner, G. (1991). Metabolic effects of isradipine versus hydrochlorothiazide in 
diabetes mellitus. Hypertension, 17,15-21.
Kneer, N.M., Lardy, H.A. (1983) Regulation of gluconeogenesis by norepinephrine, 
vasopressin and angiotensin II: a comparative study in the absence and presence of 
extracellular calcium. Archives of Biochemistry and Biophysiology, 225,187-195.
Kolterman, O.G., Gray, R.S., Shapiro, G., Scarlett, J.A., Griffin, J., Olefsky, J.M.
(1984) The acute and chronic effects of sulphonylurea therapy in type II diabetic 
subjects. Diabetes, 33,346-354.
Krone, W., Naegle, H., Behnke, B., Greten H. (1988) Opposite effects of insulin and 
catecholamines on LDL-receptor activity in human mononuclear leucocytes. Diabetes, 
37,1386-1391
Kuzuya, T., Iwamoto, Y., Kosaka, K., Takebe, K., Yamanouchi, T., Kasuga, M., 
Kajinuma, H., Akanuma, Y., Yoshida, S., Shigeta, Y. (1991) A pilot clinical trial of a 
new oral hypoglycaemic agent, CS-045, in patients with NIDDM. Diabetes Research 
and Clinical Practice, 11,147-153.
232
Landkin, K., Tengbom, L., Smith, U. (1990) Elevated fibrinogen and plasminogen 
activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for 
cardiovascular disease. Journal of Internal Medicine, 60,491-494.
Landmark, K. (1985) Antihypertensive and metabolic effects of long-term therapy 
with nifedipine slow-release tablets. Journal o f Cardiovascular Pharmacology, 7, 
12-17.
Lang, R., Klein, H.O., Shapiro, M.S., Kaplinsky, E. (1981) Verapamil therapy and 
blood glucose concentration. Archives o f Internal Medicine, 141,1724.
Lembo, G., Rendina, V., Iaccarino, G., Lamenza, F., Massimo, V., Trimarco, B.
(1993) Insulin reduces sympathetic vasoconstriction in healthy humans. Hypertension, 
21,1015-1019.
Leonetti, G. Fogari, R., Mazzola, C., Mangiameli, S., Castello, C. (1991a) Comparison 
of the effects on blood pressure and left ventricular hypertrophy of lacidipine and 
hydrochlorothiazide in hypertensive patients. Journal o f Hypertension, 9 (suppl 3), 
S29-S31.
Leonetti, G. (1991b) Comparative study of lacidipine and nifedipine SR in the 
treatment of hypertension: an Italian multicenter study. Journal of Cardiovascular 
Pharmacology, 17 (suppl 4), S31-S34.
Levy, J., Zemel, M.B., Sowers, J.R. (1989) Role of cellular calcium metabolism in 
abnormal glucose metabolism and diabetic hypertension. American Journal of 
Medicine, 87(suppl. 6A), 7S-16S.
Lichtenstein, M.J., Yamell, J.W.G.* Elwood, P.C., Beswick, A.D., Sweetnam, P.M., 
Marks, V., Teale, D., Riad-Fahmy, D. (1987) Sex hormones, insulin, lipids and 
prevalent ischaemic heart disease. American Journal of Epidemiology, 126,647-57.
Lillioja, S., Young, A.A., Culter, C.L., Ivy, J.L., Abbott, W.G., Zawadzki, J.K., 
Yki-Jarvinen, H., Christin, L., Secomb, T.W., Bogardus, C. (1987) Skeletal muscle 
capillary density and fibre type are possible determinants of in-vivo insulin resistance 
in man. Journal of Clinical Investigation, 80,415-425.
Lind, L., Lithell, H., Wide, L., Ljunghall, S. (1992) Metabolic cardiovascular risk 
factors and the renin-angiotensin-aldosterone system in essential hypertension. 
Journal of Human Hypertension, 6,27-29.
233
Liu, D., Moberg, E., Kollind, M., Lins, P-E., Adamson, W., MacDonald, LA. (1992). 
Arterial, arterialised venous, venous and capillary blood glucose measurements in 
normal man during hyperinsulinaemic euglycaemia and hypoglycaemia.
Diabetologica, 35,287-290.
Lund, S., Vestergaard, H., Andersen, P.H., Schmitz, O., Gotzsche, L.B.H., Pedersen,
O. (1993) GLUT-4 content in plasma membrane of muscle from patients with 
non-insulin dependent diabetes mellitus. American Journal o f Physiology, 265, 
E889-E897.
Lundgren, H., Bjorkman, L., Keiding, P., Lundmark, S., Bengtsson, C. (1988)
Diabetes in patients with hypertension receiving pharmacological treatment. British 
Medical Journal, 297,1512.
Lyons, D., Fowler, G., Webster, J., Hall, S.T., Petrie, J.C. (1994) An assessment of 
lacidipine and atenolol in mild to moderate hypertension. British Journal of Clinical 
Pharmacology, 37,45-51.
MacKenzie, J.K., Clements, J.A. (1974). Simplified radioimmunoassay for serum 
aldosterone utilising increased antibody specificity. Journal of Clinical Endocrinology 
and Metabolism, 38,622-627.
MacMahon, S.W., MacDonald, G.J., Blacket, R.B. (1985) Plasma lipoprotein levels in 
treated and untreated hypertensive men and women. Arteriosclerosis, 5, 391-396.
Mancia, G., De Cesaris, R., Fogari, R., Lattuada, S., Montemurro, G., Palombo, C., 
Porcellati, C., Ranieri, G., Tettamanti, F., Verdecchia, P. (1992) Evaluation of 
once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian 
Trandolapril Study Group. American Journal of Cardiology, 70 ,60D-66D.
Marigliano, A., Teddle, R., Sechi, L.A., Pala, A., Pisanu, G., Pacifico, A. (1990) 
Insulinaemia and blood pressure relationships in patiennts with primary and secondary 
hypertension, and with and without glucose metabolism impairment. American 
Journal of Hypertension, 3,521-526.
Marquie, G. (1978) Effect of insulin in the induction and regression of experimental 
cholesterol atherosclerosis in the rabbit. Postgraduate Medical Journal, 54,80-85.
Marrotta, T., Ferrara, L.A., Pasanisi, F., Rubba, P., Iovine, C., Mancini, M. (1989). 
Enhancement of exogenous triglyceride removal following calcium channel blockade. 
Artery, 16,312-326.
234
Matthews, D.R., Hosker, J.P., Rudenski, J.S., Naylor, B.A., Treacher, B.F., Turner, 
R.C. (1985) Homeostasis model assessment: insulin resistance and 6-cell function 
from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 
412-419.
Mattiasson, I., Bemtrop, K., Lindgarde, F. (1992) Sodium-lithium countertransport 
and platelet cytosolic free calcium concentration in relation to peripheral insulin 
sensitivity in postmenopausal women. Clinical Science, 83,319-324.
Mbanya, J.C., Thomas, T.H., Wilkinson, R., Alberti, K.G.M.M., Taylor, R. (1988) 
Hypertension and hyperinsulinaemia: a relation in diabetes but not in essential 
hypertension. Lancet, 1,733-744.
McGuire, E.A.H., Helderman, J.H., Tobin, R.D., Andres, R., Bergman, R. (1976) 
Effects of arterial versus venous sampling on analysis of glucose kinetics in man. 
Journal of Applied Physiology, 41,565-573.
McMurray, J., Fraser, D.M. (1986) Captopril, enalapril and blood glucose, (letter) 
Lancet, 1,1035.
McVeigh, G.E., Brennan, G.M., Johnston, G.D., McDermott, B.J., McGrath, L.T., 
Henry, W.R., Andrews, J.W., Hayes, J.R. (1992) Impaired endothelium-dependent 
vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. 
Diabetologia, 35,771-776.
Medical Research Council Working Party. (1985) MRC trial of treatment of mild 
hypertension: principal results. British Medical Journal, 291,97-104.
Meistas, M.T., Margolis, S., Kowarski, A.A. (1983) Hyperinsulinaemia of obesity is 
due to decreased clearance of insulin. American Journal o f Physiology, 245, 
E155-E159.
Minaker, K.L., Rowe, J.W., Tonino, R., Pallotta, J.A. (1982) Influence of age on 
clearance of insulin in man. Diabetes, 31, 851-855.
Mitchell, B.D., Stem, M.P., Haffner, S.M., Hazuda, H.P., Patterson, J.K. (1990) Risk 
factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites: 
the San Antonio Heart Study. American Journal o f Epidemiology, 131,423-433.
235
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., 
Fuchs, Z. (1985) Hyperinsulinaemia; A link between hypertension, obesity and 
glucose intolerance. Journal o f Clinical Investigation, 75,809-817.
Modan, M., Halkin, H. (1991) Hyperinsulinaemia or increased sympathetic drive as 
links for obesity and hypertension Diabetes Care, 14,470-487.
Moller, D.E., Flier, J.S. (1991) Insulin resistance - mechanisms, syndromes and 
implications. New England Journal o f Medicine, 325,938-948.
Moore, M.P., Elliott, T.W., Nicholls, M.G. (1988) Hormonal and metabolic effects of 
enalapril treatment in hypertensive subgroups with NIDDM. Diabetes Care, 11, 
397-401.
Morton, J.J., Webb, D.J. (1985) Measurement of plasma angiotensin n. Clinical 
Science, 68,483-484.
Multiple Risk Factor Intervention Research Group (1982) Multiple Risk Factor 
Intervention Trial: Risk factor changes and mortality results. Journal o f American 
Medical Association, 248,1465-1477.
Muiphy, M.B., Lewis, P.J., Kohner, E., Schumer, B., Dollery, C.T. (1982) Glucose 
intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. 
Lancet, 2,1293-1295.
Nakano, J., Kusakari, T. (1966) Effects of synthetic angiotensin on plasma FFA and 
blood glucose levels. Nature, 209,922-923.
Natali, A., Santoro, D., Palambo, C., Cerri, M., Ghione, S., Ferrannini, E. (1991). 
Impaired insulin action on skeletal muscle metabolism in essential hypertension. 
Hypertension, 17,170-178.
Neahring, J.M., Stepniakowski, K., Greene, A.S., Egan, B.M. (1993) Insulin does not 
reduce forearm alpha-vasoreactivity in obese hypertensive or lean normotensive men. 
Hypertension, 22,584-590.
Ng, L.L. (1988) Application of modelling techniques to the assessment of insulin 
sensitivity in man. Diabetic Medicine, 5,217-223.
236
Odigwe, C.O., McCulloch, C.J., Williams, D.O., Tunbridge, W.M. (1986). A trial of 
the calcium antagonist nisoldipine in hypertensive non-insulin diabetic patients. 
Diabetic Medicine, 3,463-467.
Oehman, K.P., Weiner, L., Schenck, K., Karlberg, B.E. (1985). Antihypertensive and 
metabolic effects of nifedipine and labetalol alone and in combination in primary 
hypertension. European Journal of Clinical Pharmacology, 29,149-154.
Ohno, Y., Suzuki, H., Yamakawa, H., Nakamura, M., Otsuka, K., Saruta, T. (1993) 
Impaired insulin sensitivity in young, lean normotensive offspring of essential 
hypertensives: possible role of disturbed calcium metabolism.
Journal o f Hypertension, 11,421-426.
O’Hare, J.A., Ferriss, J.B., Brady, D., Twomey, B., O’Sullivan, D.J. (1985) 
Exchangeable sodium and renin in hypertensive diabetic patients with and without 
nephropathy. Hypertension, 7 (suppl. II), H43-II48.
Olefsky, J., Reaven, G.M., Farquhar, J.W. (1974) Effects of weight reduction on 
obesity: studies of lipid and carbohydrate metabolism in normal and 
hyperlipoproteinaemic subjects. Journal o f Clinical Investigation, 53,64-76.
Oliver, F.J., De la Rubia, G., Feener, G., Feener, E.R, Lee, M.E., Loeken, M.R., 
Shiba, T., Quertermons, T., King, G.L. (1991) Stimulation of endothelin-1 gene 
expression by insulin in endothelial cells. Journal o f Biological Chemistry, 266, 
23251-23256.
Pandit, M.K., Burke, J., Gustafson, A.B., Minocha, A., Peiris, A.N. (1993) 
Drug-induced disorders of glucose tolerance. Annals o f Internal Medicine, 118, 
529-539.
Panza, J.A., Quyyumi, A.A., Brush, J.E., Epstein, S.E. (1990) Abnormal 
endothelium-dependent vascular relaxation in patients with essential hypertension. 
New England Journal of Medicine, 323,22-27.
Paolisso, G., De Riu, S., Marrazzo, G„ Verza, M., Vanicchio, M., D’Onofirio, F.
(1991) Insulin resistance and hyperinsulinaemia in patients with chronic congestive 
heart failure. Metabolism, 40,972-977.
Paolisso, G., Gambardella, A., Verza, M., D’Amore, A., Sgambato, S., Varricchio, M.
(1992) ACE inhibition improves insulin sensitivity in aged insulin resistant 
hypertensive patients. Journal of Human Hypertension, 6,175-179.
237
Parillo, M., Coulston, A., Hollenbeck, C., Reaven, G.M. (1988) Effect of a low fat diet 
on carbohydrate metabolism in patients with essential hypertension. Hypertension, 11, 
244-248.
Pasanisi, F., Ferrara, A.L., Iovine, C. (1986) Effects of nifedipine on insulin secretion 
and plasma lipids in hypertensive patients. Current Therapeutic Research, 39,
894-899.
Pasanisi F„ Marotta T., Ferrara A., Grasso A., Cortese G, Mancini M. (1988). Acute 
and chronic effects of dihydropyridines on triglycerides in humans. Journal of 
Cardiovascular Pharmacology, 12, S140-S141.
Peiris, A.N., Struve, M.F., Mueller, R.A., Lee, M.B., Kissebah, A.H. (1988) Glucose 
metabolism in obesity: influence of body fat distribution. Journal o f Clinical 
Endocrinology and Metabolism, 67,760-767.
Perelman, M. (1991) Selection of initial and maintenance dosages for lacidipine, a 
new once-daily calcium antagonist for the treatment of hypertension. Journal of 
Cardiovascular Pharmacology, 17, S14-S19.
Perez, G.O., Lespier, L., Jacobi, J. (1977) Hyporeninaemia and hypoaldosteronism in 
diabetes mellitus. Archives of Internal Medicine, 137,852-855.
Phillips, D.I.W., Clark, P.M., Hales, C.N., Osmond, C. (1994) Understanding oral 
glucose tolerance: comparison of glucose or insulin measurements during the oral 
glucose tolerance test with specific measurements of insulin resistance and insulin 
secretion. Diabetic Medicine, 11,293-298.
Pollare, T., Lithell, H., Selinus, I., Berne, C. (1988). Application of prazosin is 
associated with an increase of insulin sensitivity in obese patients with hypertension. 
Diabetologia, 31,415-420.
Pollare, T.G., Lithell, H., Berne, C. (1989a). A comparison of the effects of 
hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with 
hypertension. New England Journal o f Medicine, 321,686-673.
Pollare, T., Lithell, H., Hvarfner, A., Morlin, C., Prantare, H., Ljunghall, S. (1989b) 
Metabolic effects of diltiazem and atenolol: results from a randomised, double-blind 
study with parallel groups. Journal of Hypertension, 1 ,551-59.
238
Pollare, TG., Lithell, H., Selinus, I., Berne, C. (1989c). Sensitivity to insulin treatment 
with atenolol and metoprolol: a randomised, double-blind study of effects on 
carbohydrate and lipoprotein metabolism in hypertensive patients. British Medical 
Journal, 297,1147-1152.
Pollare, T.G., Lithell, H., Berne, C. (1990) Insulin resistance is a characteristic feature 
of primary hypertension independent of obesity. Metabolism, 39,167-174.
Pool, P.E., Seagren, S.C., Salel, A.F. (1985) Effects of diltiazem on serum lipids, 
exercise tolerance and blood pressure: randomised, double blind, placebo-controlled 
evaluation for systemic hypertension. American Journal of Cardiology, 56, 86H-91H.
Ponchner, M., Heine, R.J., Pemet, A., Hanning, I., Francis, A.J., Cook, D., Orskov, H., 
Alberti, K.G. (1984) A comparison of the artificial pancreas (glucose controlled 
insulin infusion system) and a manual technique for assessing insulin sensitivity 
during euglycaemic clamping. Diabetologia, 26,420-425.
Porte, D. (1967) A receptor mechanism for the inhibition of insulin release by 
epinephrine in man. Journal of Clinical Investigation, 46,86-91.
Poulter, N., Sever, P., Thom, S. (1990) Antihypertensive drugs and adverse 
biochemical effects of bendrofluazide. (letter) British Medical Journal, 300,1465.
Prince, M.J., Stuart, C.A., Padia, M., Bandi, Z., Holland, O.B. (1988) Metabolic 
effects of hydrochlorothiazide and enalapril during treatment of the hypertensive 
patient. Archives o f Internal Medicine, 148,1363-1368.
Pyolara, K. (1979) Relationships of glucose intolerance and plasma insulin to the 
incidence of coronary artery disease: results from two population studies in Finland. 
Diabetes Care, 2,131-141.
Randle„P.J., Hales, C.N., Garland, P.B., Newsholme, E.A. (1963) The glucose 
fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of 
diabetes mellitus. Lancet, i, 785-789.
Ratheiser, K., Schneeweiss, B., Waldhausl, W., Farching, P., Kom, A., Nowotny, P., 
Rohac, M., Wolf, H.P.O. (1991) Inhibition by etomoxir of CPT 1 reduces hepatic 
glucose production and plasma lipids in NIDDM. Metabolism, 40,1185-1190.
Reaven, G.M., Miller, R. (1968) Study of the relationship between glucose and 
insulin responses to an oral glucose load in man. Diabetes, 17,560-565.
239
Reaven, G.M. (1983) Insulin resistance in non-insulin dependent diabetes mellitus: 
Does it exist and can it be measured? American Journal of Medicine, 74,2-17.
Reaven, G.M. (1988a) Role of insulin resistance in human disease. Diabetes, 37, 
1495-1507.
Reaven, G.M., Moore, J., Greenfield, M. (1988b) Quantification of insulin secretion 
and in vivo insulin action in non-obese and moderately obese individuals with normal 
glucose tolerance. Diabetes, 32,600-604.
Reaven, G.M., Chang, H., Hoffman, B.B., Azhar, S. (1989a) Resistance to 
insulin-stimulated glucose uptake in adipocytes isolated from spontaneously 
hypertensive rats. Diabetes, 38,1155-1160.
Reaven, G.M., Ho, H., Hoffman, B.B. (1989b) Somatostatin inhibition of 
fructose-induced hypertension. Hypertension, 14,117-120.
Reaven, G.M., Twersky, J., Chang, H. (1991a) Abnormalities of carbohydrate and 
lipid metabolism in Dahl rats. Hypertension, 18,630-635.
Reaven, G.M., Chang, H. (1991b) Relationship between blood pressure, plasma 
insulin and triglyceride concentration, and insulin action in SHR and WKY rats. 
American Journal of Hypertension, 4,34-38.
Reaven, G.M., Chen, Y-D.I., Hollenbeck, C.B., Sheu, W.H.H., Ostrega, D., Polansky, 
K.S. (1993) Plasma insulin, C-peptide and proinsulin concentrations in obese and 
non-obese individuals with varying degrees of glucose tolerance. Journal of Clinical 
Endocrinology and Metabolism, 76,44-48.
Resnick, L.M. (1993) Ionic basis of hypertension, insulin resistance, vascular disease, 
and related disorders. The mechanism of "syndrome X". American Journal of 
Hypertension, 6 ,123S-134S.
Rett, K., Jauch, K.W., Wicklmayr, M., Dietze, G., Fink, E., Mehnert, H. (1986) 
Angiotensin converting enzyme inhibitors in diabetes: experimental and human 
experience. Postgraduate Medical Journal, 62 (Suppl. 1), 59-64.
Rett, K., Jauch, K.W., Wicklmayr, M. (1988) Hypoglycaemia in hypertensive diabetic 
patients treated with sulphonylureas, biguanides and captopril. New England Journal 
o f Medicine, 319,1609.
240
Richardson, J.M., Balon, T.W., Treadway, J.L., Pessin, J.E. (1991) Differential 
regulation of glucose transport activity and expression in red and white skeletal 
muscle. Journal o f Biological Chemistry, 266,12690-12694.
Rocchini, A.P., Moorehead, C., DeRemer, S., Bondie, D. (1989) Pathogenesis of 
weight related changes in blood pressure in the dog. Hypertension, 13,922-928.
Rocchini, A.P., Moorehead, C., DeRemer, S., Goodfriend, T.L., Ball, D.L. (1990) 
Hyperinsulinaemia and the aldosterone and pressor responses to angiotensin II 
Hypertension, 15, 861-866.
Roddie, I.C., Shepherd, J.T., Whelan, R.F. (1956) Evidence from venous oxygen 
saturation measurements that the increase in forearm blood flow during body heating 
is confined to the skin. Journal of Physiology, 134,444-450.
Rodjmark, S., Andersson, D.E.H., Hed, R. (1981) Does verapamil influence 
glucose-induced insulin release in man? Acta Medica Scandinavia, 210,501-505.
Rodjmark, S., Andersson, D.E.H., Hed, R. (1980) Effect of verapamil on glucose 
response to intravenous injection of glucagon and insulin in healthy subjects. 
Hormone and Metabolic Research, 12,285-300.
Rodnick, K.J., Haskell, W.L., Swislocki, A.L.M., Foley, J.E., Reaven, G.M. (1987) 
Improved insulin action in muscle, liver and adipose tissue in physically trained 
human subjects. American Journal o f Physiology 253, E489-E495.
Rogers, M.A., Yamamoto, C., King, D.S., Hagberg, J.M., Ehsani, A.A., Holloszy, J.O. 
(1988) Improvement in glucose tolerance after one week of exercise in patients with 
mild NIDDM. Diabetes Care, 11,613-618.
Ronnemaa, T., Laasko, M., Pyorala, K., Kallio, V., Puukka, P. (1991) High fasting 
plasma insulin is an indicator of coronary artery disease in non-insulin dependent 
diabetic patients and non-diabetic patients. Arteriosclerosis and Thrombosis, 11, 
80-90.
Rosenthal, M., Haskwell, W.L., Solomon, R., Widstrom, A., Reaven, G.M. (1983) 
Demonstration of a relationship between level of physical training and 
insulin-stimulated glucose utilization in normal humans. Diabetes, 32,408-411.
241
Rowe, J.W., Young, J.B., Mimaker, K.L., Stevens, A.L., Pallotta, J., Landsberg, L.
(1981) Effect of insulin and glucose infusions on sympathetic nervous system activity 
in normal man. Diabetes, 30,219-225.
Rowe, J.W., Minaker, K.L., Pallotta, J.A., Flier, J.S. (1983) Characterization of the 
insulin resistance of aging. Journal o f Clinical Investigation, 71,1523-1535.
Saad, M.F., knowler, W.C., Pettitt, D .J., Nelson, R.G., Mott, D.M., Bennett, P.H. 
(1988) The natural history of impaired glucose tolerance in the Pima Indians. New 
England Journal o f Medicine, 319,1500-1506.
Saad, M.F., Lillioja, S., Nyomba, B.L., Castillo, C., Ferraro, R., De Gregorio, M., 
Ravussin, M., Knowler, W.C., Bennett, P.H., Howard, B.V. (1991) Racial differences 
in the relation between blood pressure and insulin resistance. New England Journal of 
Medicine, 324,733-739.
Saito, I., Nishino, M., Kawabe, H., Wainai, H., Hasegawa, C„ Saruta, T., Nagano, S., 
Sekihara, T. (1992) Leisure time physical activity and insulin resistance in young 
obese students with hypertension. American Journal o f Hypertension, 5,915-918.
Sakai, K., Imaizumi, T., Masaki, H., Takeshita, A. (1993) Intra-arterial infusion of 
insulin attenuates vasoreactivity in the human forearm. Hypertension, 22, 67-73.
Salomaa, V.V., Strandberg, T.E., Vanhanen, H., Naukkarinen, V., Sama, S.,
Miettinen, T.A. (1991) Glucose tolerance and blood pressure: long term follow up in 
middle aged men. British Medical Journal, 302,493-496.
Sando, H., Katagiri, H., Okada, M. (1983) The effect of nifedipine and nicardipine on 
glucose tolerance, insulin and C-peptide. (abstract) Diabetes, 32 ,66A.
Santoro, D., Natali, A., Palomba, C., Brandi, L.S., Piatti, M., Ghione, S., Ferrannini, 
E. (1992) Effects of chronic angiotensin converting enzyme inhibition on glucose 
tolerance and insulin sensitivity in essential hypertension. Hypertension, 20,181-191.
Seefeldt, T., Orskov, L., Rasmussen, O., Pedersen, M.M., Moller, N., Christiansen, 
J.S., Schmitz, O. (1990) Lack of effects of angiotensin-converting enzyme inhibitors 
on glucose metabolism in insulin-dependent diabetes mellitus. Diabetic Medicine, 7, 
700-704.
242
Seghieri, G., Yin, W., Boni, C., Sanna, G., Anichini, R., Bartolmei, G., Ferrannini, E. 
(1992) Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in 
hypertensive type II diabetic patients. Diabetic Medicine, 9,732-738.
Shamiss, A., Carroll, J., Rosenthal, T. (1992) Insulin resistance in secondary 
hypertension. American Journal of Hypertension, 5,26-28.
Sharma, A.M., Ruland, K., Spies, K-R, Distler, A. (1991) Salt sensitivity in young 
normotensive subjects is associated with a hyperinsulinaemic response to oral glucose. 
Journal of Hypertension, 9,329-335.
Shen, D.C., Shieh, S.M., Fuh, M.T., Wu, D-A., Chen, Y-D.I., Reaven, G.M. (1988) 
Resistance to insulin stimulated glucose uptake in patients with hypertension. Journal 
of Clinical Endocrinology and Metabolism, 66,580-583.
SHEP Cooperative Research Group. (1991) Prevention of stroke by antihypertensive 
drug treatment in older patients with isolated systolic hypertension. Final results of the 
Systolic Hypertension in the Elderly Programme (SHEP). Journal o f the American 
Medical Association, 265,3255-3264.
Shieh, S-M., Shen, M., Fuh, M.M-T., Chen, Y-D.I., Reaven, G.M. (1987) Plasma lipid 
and lipoprotein concentrations in Chinese males with coronary artery disease, with and 
without hypertension. Atherosclerosis, 67,49-55.
_ * m i
Shultz, T.A., Lewis, S.B., Westbie, D.K., Wallin, j i ) .  (1977) Glucose delivery: a 
modulator of glucose uptake in contracting skeletal muscle. American Journal of 
Physiology, 2, E514-E518.
Simonson, D.C., Ferrannini, E., Bevilacqua, S., Smith, D., Barrett, E., Carlson, R., De 
Fronzo, R.A. (1984) Mechanism of improvement in glucose metabolism after chronic 
glyburide therapy. Diabetes, 33, 838-845.
Singer, P., Godicke, W., Voigt, S., Hajdu, I., Weiss, M. (1985) Post-prandial 
hyperinsulinaemia in patients with mild essential hypertension. Hypertension, 7, 
182-186.
Skarfors, E.T., Lithell, H.O., Selinus, I., Aberg, H. (1989) Do antihypertensive drugs 
precipitate diabetes in predisposed men? British Medical Journal, 298,1147-1152.
243
Skarsfors, E.T., Selinus, I., Lithell, H.O. (1991) Risk factors for developing 
non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. British 
Medical Journal, 303,493-496.
Spradlin, C.T., Galloway, J.A., Anderson, J.H. (1990) Apparent increase in coronary 
heart disease with human proinsulin (HPI) - randomisation failure or HPI effect? 
(abstract) Diabetologia, 33, A60.
Stacpoole, P.W., Moore, G.W., Komhauser, D.M. (1978) Metabolic effects of 
dichloroacetate in patients with diabetes mellitus and hyperlipoproteinaemia. New 
England Journal of Medicine, 298,526-530.
Stacpoole, P.W., Gonzalez, M.G., Vlasak, J., Oshiro, Y„ Bodor, N. (1987) 
Dichloroacetate derivatives: metabolic effects and pharmacodynamics in normal rats. 
Life Science, 41,2167-2176.
Stacpoole, P.W., Greene, Y.J. (1992) Dichloroacetate. Diabetes Care, 15,785-791.
Stamler, R., Stamler, J., Reidlinger, W.F., Algera, G., Roberts, R.H. (1978) Weight 
and blood pressure. Journal o f the American Medical Association, 240,1607-1610.
Stein, P.P., Black, H.R. (1991) Drug treatment of hypertension in patients with 
diabetes mellitus. Diabetes Care, 14,425-448.
Steiner, K.E., Lien, E.L. (1987) Hypoglycaemic agents which dp not release insulin. 
Progress in Medical Chemistry, 24,209-248.
Stem, M.P., Morales, P.A., Haffner, S.M., Valdez, R.A. (1992) Hyperdynamic 
circulation and the insulin resistance syndrome ("Syndrome X"). Hypertension, 20, 
802-808.
Stout, R.W. (1970) Development of arterial lesions in insulin treated animals fed a 
normal diet. British Medical Journal, 37,685-687.
Stout, R.W., Bierman, E.L., Ross, R. (1975) The effect of insulin on the proliferation 
of cultured primate arterial smooth muscle cells. Circulation Research, 36,319-327.
Stout, R.W. (1989). Insulin and atheroma. Diabetes Care, 13,631-654.
244
Strong, P., Anderson, R., Coates, J., Ellis, F., Evans, B., Gurden, M.F., Johnston, M., 
Kennedy, I., Martin, D.P. (1993) Suppression of non-esterified fatty acids and 
triacylglycerol in experimental animals by the adenosine analogue GR79236. Clinical 
Science, 84,663-669.
Struthers, A.D., Murphy, M.B., Dollery, C.T. (1985) Glucose tolerance during 
antihypertensive therapy in patients with diabetes mellitus. Hypertension, 7, 
II95-II101.
Suter, S.L., Nolan, J.J., Wallace, P., Gumbiner, B., Olefsky, J.M. (1992) Metabolic 
effects of the new oral hypoglycaemic agent CS-045 in NIDDM subjects. Diabetes 
Care, 15,193-203.
Swislocki, A.L., Hoffman, B.B., Reaven, G.M. (1989) Insulin resistance, glucose 
intolerance and hyperinsulinaemia in patients with hypertension. American Journal of 
Hypertension, 2,419-423.
Temple, R.C., Carrington, C.A., Luzio, S.D., Owens, D.R., Schneider, A.E., Sobey, 
W.J., Hales, C.N. (1989) Insulin deficiency in non-insulin dependent diabetes. Lancett 
i, 293-295.
Temple, R.C., Clark, P.M.S., Nagi, D.K., Schneider, A.E., Yudkin, J.S., Hales, C.N.
(1990) Radioimmunoassay may overestimate insulin in non-insulin dependent 
diabetes. Clinical Endocrinology, 32,689-693.
Tentoria, A., Ghilardi, G., Pedroncelli, A., Benco, R., Stroppa, S., Adib, S., Gianola, 
D., Pagani, G. (1989). Insulin secretion and glucose tolerance in non-insulin 
dependent diabetic patients after chronic nifedipine treatment European Journal of 
Clinical Pharmacology, 36,311-313.
Teuscher, A., Egger, M., Herman, J.B. (1989) Diabetes and hypertension. Blood 
pressure in clinical diabetic paients and a control population. Archives o f Internal 
Medicine, 149,1942-1945.
Torlone, E., Rambotti, A.M., Perriello, G., Botta, G., Santeusanio, F., Brunetti, P., 
Bolli, G.B. (1991) ACE-inhibition increases hepatic and extra-hepatic sensitivity to 
insulin in patients with type 2 (non-insulin dependent) diabetes mellitus and arterial 
hypertension. Diabetologia, 34,119-125.
245
Torlone, E., Britta, M., Rambotti, A.M., Perriello, G., Santeusanio, F., Brunetti, R, 
Bolli, G.B. (1993) Improved insulin action and glycaemic control after long-term 
angiotensin-converting enzyme inhibition in subjects with arterial hypertension and 
type II diabetes. Diabetes Care, 16,1347-1355.
Townsend, R.R., DiPette, D., Lieux, T.R., Wolfe, R.R. (1993) The role of the renin 
angiotensin system in insulin sensitivity in normotensive subjects. American Journal 
of Medical Sciences, 305,67-71.
Townsend, R.R., DiPette, D. (1993) Pressor doses of angiotensin II increase 
insulin-mediated glucose uptake in normotensive men. American Journal of 
Physiology 265, E362-E366.
Trost, B.N., Weidmann, P. (1984). Effects of nitrendipine and other calcium 
antagonists on glucose metabolism in man. Journal of Cardiovascular Pharmacology, 
6,986-995.
Trost, B.N., Weidmann, P. (1987) Nitrendipine in patients with hypertension and 
diabetes mellitus. Journal of Cardiovascular Pharmacology, 9 (suppl 4) S280-S285.
Trovatti, M., Massuco, P., Anfossi, G., Caralot, F., Mularoni, E., Mattiello, L., Rocca,
G., Emannuelli, G. (1989) Insulin influences the renin-angiotensin-aldosterone system 
in humans. Metabolism, 38,501-503.
Trujillo, A., Eggena, P., Barrett, J., Tuck, M. (1989) Renin regulation in type II 
diabetes mellitus: influence of dietary sodium. Hypertension, 13,200-205.
Tuck, M., Corry, D., Trujillo, A. (1990) Salt-sensitive blood pressure and exaggerated 
vascular reactivity in the hypertension of diabetes mellitus. American Journal of 
Medicine, 88,210-216.
Turner, R.C., Holman, R.R., Matthews, D.R., Hockaday, T.D.R., Peto, J. (1979) 
Insulin deficiency and insulin resistance interaction in diabetes: estimation of their 
relative contribution by feedback analysis from basal insulin and glucose 
concentrations. Metabolism, 28,1086-1096.
Uehara, M., Kishikawa, H., Isami, S., Kisanuki, K., Ohkubo, Y., Miyamura, N., 
Miyata, T., Yano, T., Shichiri, M. (1994) Effect on insulin sensitivity of angiotensin 
converting enzyme inhibitors with or without a sulphydryl group: bradykinin may 
improve insulin resistance in dogs and humans. Diabetologia, 37,300-307.
246
United Kingdom Lacidipine study Group. (1991) A double-blind comparison of the 
efficacy and safety of lacidipine with atenolol in the treatment of essential 
hypertension. Journal of Cardiovascular Pharmacology, 17 (suppl 4), S27-S30.
Vicaut, E., Hou, X. (1993) Arteriolar constriction and local renin-angiotensin system 
in rat microcirculation. Hypertension, 21,491-497.
Vierhapper, H., Waldhausl, W., Nowotny, P. (1983) The effect of insulin on the rise 
in blood pressure and plasma aldosterone after angiotensin n  infusion in normal man. 
Clinical Science, 64,383-386.
Wada, S., Makayama, M., Masaki, K. (1982) Effects of diltiazem hydrochloride on 
serum lipids: comparison with beta-blockers. Clinical Therapeutics, 5,163-173.
Wahab, P.J., Rijnsburger, A.W.E., Oolbekkink, M., Heine, R.J. (1992) Venous versus 
arterialised blood for assessment of blood glucose levels during glucose clamping: 
comparison in healthy men. Hormone and Metabolic Research, 24,576-579.
Watt, G.C.M., Harrap, S.B., Foy, C .J.W., Holton, D.W., Edwards, H.V., Davidson,
H.R., Connor, J.M., Lever, A.F., Fraser, R. (1992) Abnormalities of glucocorticoid 
metabolism and the renin-angiotensin system: a four comer approach to the 
identification of genetic determinants of blood pressure. Journal of Hypertension, 10, 
473-482.
Weaver, J.U., Hitman, G.A., Kopelman, P.G. (1992) An association between a BaCI 
restriction fragment length polymorphism of the glucocorticoid receptor locus and 
hyperinsulinaemia in obese women. Journal of Molecular Endocrinology, 9,295-300.
Weidmann P., Feirarri P. (1991) Central role of sodium in hypertension in diabetic 
subjects. Diabetes Care, 14,220-32.
Welbom, T.A., Breckenridge, A., Dollery, C.T., Rubinstein, A.H., Russell Fraser, T. 
(1966) Serum insulin in essential hypertension and in peripheral vascular disease. 
Lancet, 1,1336-1337.
Welin, L., Eriksson, H., Larsson, B., Ohlson, L.O., Svardsudd, K., Tobblin, G. (1992) 
Hyperinsulinaemia is not a major coronary risk factor in elderly men: the study of men 
bom in 1913. Diabetologia, 35,766-770.
247
Whitcroft, I., Thomas, J., Davies, I.B. (1986) Calcium antagonists do not impair 
long-term glucose control in hypertensive non-insulin dependent diabetic patients, 
(abstract) British Journal of Clinical Pharmacology, 22 ,208P.
Widen, E., Blomqvist, A-C., Eriksson, J., Groop, L. (1991) Effect of glibenclamide 
on clearance of insulin in type II diabetes, (abstract) Acta Endocrinology, 124 
(Suppl 3), 40.
Widen, E.I.M., Eriksson, J.G., Groop, L.C. (1992) Metformin normalises 
non-oxidative glucose metabolism in insulin resistant normoglycaemic first-degree 
relatives of patients with NIDDM. Diabetes, 41,354-358.
Winocour, P.H., Gordon, C., Waldek, C., Anderson, D.C. (1986) The effect of 
nifedipine on glucose tolerance and insulin secretion in insulin-treated diabetics with 
varying endogeneous insulin reserve, (abstract) European Journal o f Clinical 
Investigation, 16, A23.
Wolf, H.P.O. (1990) Aryl-substituted 2-oxirane carboxylic acids: a new group of 
antidiabetic compounds. In: New Antidiabetic Drugs, Bailey, C.J., Flatt, P.R. (Eds), 
London, p217-229.
Wollen, N., Bailey, C.J. (1988) Inhibition of hepatic gluconeogenesis by metformin. 
Biochemical Pharmacology, 37,4353-4358.
Wolpert, H.A., Steen, S.N., Istfan, N.W., Simonson, D.C. (1993) Insulin modulates 
circulating endothelin levels in humans. Metabolism, 42,1027-1030.
WHO Study Group (1987). Diabetes Mellitus: Report of a WHO Technical Reports, 
727,1-113.
Yagi, S., Takata, S., Kiyokawa, H., Yamamoto, M., Noto, Y., Ikeda, T., Hattori, N.
(1988) Effects of insulin on vasoconstrictive responses to norepinephrine and 
angiotensin II in rabbit femoral artery and vein. Diabetes, 37,1064-1067.
Yamamoto, M., Asayama, K., Kanai, M., Sugimoto, T., Yagi, S., Takata, S., Ikeda, T., 
Hattori, N. (1990) Effects of insulin on vasoconstrictor responses to alpha agonist and 
tilting. Angiology, 41,394-400.
248
Yang, Y.J., John, J.H., Bergman, R.N. (1987) Modified protocols improve insulin 
sensitivity estimation using the minimal model. American Journal o f Physiology, 16, 
E595-E602.
Yip, J., Mattock, M.B., Morocutti, A., Sethi, M., Trevisan, R., Viberti, G-C. (1993) 
Insulin resistance in insulin-dependent patients with microalbuminuria. Lancet, 342, 
883-887.
Young, D.B., Smith, M.J., Jackson, T.E., Scott. R.E. (1984) Multiplicative interaction 
between angiotensin II and potassium concentration in stimulation of aldosterone. 
American Journal of Physiology, 247, E328-E335.
Yoshioka, S., Nishino, H., Shiraki, T., Ikeda, K., Koike, H., Okuno, A., Wada, M., 
Fujiwara, T., Horikoshi, H. (1993) Antihypertensive effects of CS-045 treatment in 
obese Zucker rats. Metabolism, 42,75-80.
Yudkin, J.S., Alberti, K.G.M.M., McLarty, D.G., Swai, A.B.M. (1990) Impaired 
glucose tolerance. Is it a risk factor for diabetes or a diagnostic ratbag? British Medical 
Journal, 301,397-402.
Yudkin, J.S. (1991) Hypertension and non-insulin dependent diabetes. British Medical 
Journal, 303,730-731.
Zavaroni, I., Mazza, S., DalFAglio, E., Gasparini, R, Passeri, M., Reaven, G.M.
(1992) Prevalence of hyperinsulinaemia in patients with high blood pressure. Journal 
of Internal Medicine 231,235-40.
Zemel, M.B., Johnston, B.A., Ambrozy, S.A. (1992) Insulin stimulated vascular 
relaxation: role of Ca2+-ATPase. American Journal of Hypertension, 40,2111-2125.
Zimmermann, S., Phillips, R.A., Dunaif, A., Finegood, D.T., Wilkenfeld, C., Ardeljan, 
M., Gorlin, R., Krakoff, L.R. (1992) Polycystic ovary syndrome: lack of hypertension 
despite profound insulin resistance. Journal o f Clinical Endocrinology and 
Metabolism, 75,508-513.
249
GLASGOW
tJN'^SITY
U £i;^Y
